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Introduction: Percutaneous intervention (PCI) is complicated by restenosis, stent thrombosis and delayed
endothelial recovery at the PCI site. One approach to reduce these complications is to deliver potent agents directly
to the PCI site. This local drug delivery can be achieved by absorbing drugs into a polymer coating applied to the
stent itself. Vascular Endothelial Growth Factor (VEGF) has been shown to accelerate the recovery of endothelium
over a stent, reducing intimal hyperplasia and thrombosis. It has not previously been delivered bound onto the stent
itself. VEGF-eluting stents were tested in vitro and in a rabbit model.
Original Hypothesis: Polymer coated stents may absorb and gradually release Vascular Endothelial Growth Factor.
This released VEGF may reduce the stent complications of thrombosis and neointimal hyperplasia, primarily by
accelerating the recovery of denuded endothelium. This was tested in vitro and in an animal model.
Methods: Studies were performed to determine optimum stent loading with VEGF, which was radiolabelled.
Loaded stents were perfused and the drug release kinetics measured. VEGF's potential to stimulate growth was
assessed in endothelial cell culture. The VEGF-eluting stents were placed in rabbit iliac arteries and their effects on
flow through the artery and acute platelet deposition were determined. Other animals were used to show longer-term
effects on endothelial recovery and stent thrombosis (at 7 days) and intimal hyperplasia (at 28 days).
Results: 21,7pg of VEGF was absorbed. This was released with a bi-exponential release curve with 20% remaining
at 9 days. In arterial tissue, 11% of the VEGF was detectable in the tissue at 24hr. VEGF-eluting stents stimulated
endothelial cell growth by 11% over 5 days, with effects that were sustained beyond the initial rapid VEGF release.
The animal studies showed a trend (p=0.07) towards reduced platelet deposition early after PCI, with reduced
thrombus formation at 7 days (Omg in VEGF stents vs. 12.5mg in controls). No benefit of VEGF stents was seen on
the re-endothelialisation process or on intimal hyperplasia.
Conclusions: VEGF can be delivered by polymer-coated stents. Prolonged drug release to the injured vessel wall
can be shown. However, VEGF did not fulfil the potential suggested by previous work and by the cell culture
experiments when tested in vivo. It did appear to reduce thrombus formation and so may have potential benefits in
clinical practice as a stent-based therapy.
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Chapter 1.
Introduction to the use of VEGF-eluting stents.
1.1 Thesis introduction overview.
Coronary artery disease is commonly treated by interventional means, often meaning the use
of a coronary stent to maximally open a stenosed, atherosclerotic vessel. After four to six
months, a proportion of patients undergoing stenting suffer from restenosis. This is the re-
narrowing of the artery, often with important adverse clinical consequences.
This thesis examines the use of polymer-coated coronary stents as a means of delivering a
drug locally to the site of the intervention. The agent selected, vascular endothelial growth
factor (VEGF), has been shown to reduce restenosis and thrombosis in animal models when
delivered by other means.
In this introduction the clinical importance of restenosis is discussed. The causes and
mechanisms underlying restenosis are explained. The use of stents and modification to their
design is considered. The use of stents as a local delivery device is compared to other
existing local drug delivery methods. The properties and clinical uses of VEGF are reviewed.
Finally, the main target of VEGF, the endothelium, is considered in relation to stent
restenosis.
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1.2 Introduction - Restenosis and coronary heart disease.
Ischaemic Heart Disease is the greatest single contributor to death in the industrialised
world, including the United Kingdom. These deaths are often at a relatively early age,
accounting for about a third of all deaths in men and one fifth of all deaths in women aged
under 65 years in the UK (Our Healthier Nation, 1998). In Scotland, 1 in 1,000 men under
65 will die every year of the disease1. 11,914 Scottish people died of IHD in 2001. As well
as causing a high mortality, IHD places a heavy burden of morbidity on the country. 20% of
the Scottish population aged between 65 and 74 report symptomatic angina1. The prevalence
of IHD continues to rise as the population ages. Angina resulting from IHD leads to a large
number of hospital admissions. Over 10% of acute hospital admissions are for chest pain1.
Chronic illness leads to early retirement from the workplace.
Angina is caused by atherosclerosis in the coronary blood vessels. Atherosclerosis is a
progressive disease thought to be provoked initially by damage to the vascular endothelium,
e.g. from oxidised LDL, hypertension or smoking. This is the "response to injury
hypothesis". The response of the vessel is complex but essentially involves a thickening of
the wall with cells and extracellular material. This can encroach into the vessel lumen, often
to the extent where it causes significant haemodynamic compromise. Poor bloodflow distal
to this point may cause relative ischaemia to part of the myocardium, which manifests as
angina.
Although coronary artery bypass surgery is suitable in many cases as a treatment that will
overcome this ischaemia, it is an invasive procedure with significant morbidity and
mortality. In 1979 Gruentzig et al reported the first use of percutaneous transluminal
coronary angioplasty (PTCA) as a minimally invasive alternative to bypass surgery. This
treatment has very rapidly become the main choice of therapy for patients in whom
pharmacological treatment has been insufficient to control symptoms of angina. It is also
used in the context of acute myocardial infarction - so-called primary angioplasty.
23,700 PTCA procedures were performed in 2000/2001 in the NHS in England, 3370 in
2001/2002 in Scotland (NHS Hospital Episode Statistics, Information and statistics division,
NHS Scotland.). Although initially seen as an extremely successful treatment, PTCA has a
high complication rate. In the RITA 2 trial, which compared angioplasty with medical
treatment alone, more patients needed bypass surgery in the PTCA group, often as an acute
complication of the procedure. At 2.7-year average follow-up a higher incidence of
death/non-fatal infarction was found2. The problem with analysing these sorts of data is that
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the pace of change in interventional cardiology is fast. The techniques, equipment and
adjunctive therapies used now are very different to those in RITA-2 or similar trials and the
presumption is that PTCA is becoming safer, especially with growing operator experience.
Despite its drawbacks, PTCA remains at the forefront of treatments for all but the mildest
cases of angina. This is because it compares favourably with the current alternative, bypass
grafting. Both techniques have similar complication rates, but PTCA is less invasive, is
cheaper and can be more easily repeated.
1.2.1 Intra-coronary stents
This development in interventional therapy forms much of the core of this research and stent
developments and modifications are discussed later (section 1.5).
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1.3 Restenosis.
Restenosis is the process of re-narrowing of a vessel after initially successful dilation with an
interventional procedure, typically angioplasty.
1.3.1 Clinical importance of restenosis.
Despite the advent of intra-coronary stenting, restenosis remains the most common
complication following coronary intervention. Approximately a third of patients undergoing
PTCA will show angiographic evidence of restenosis. There is some difficulty in reaching an
exact estimate, since angiographic follow-up in clinical trials is incomplete (fig.l).
Furthermore, the definition of angiographic restenosis is varaible. The calculation of
restenosis is derived from the relationship between the luminal diameter and the dimater of
the refernece vessel. Unfortunately, the reference vessel can be measured before, within or
after the restenotic lesion, which will change the resulting %restenosis. The usual binary
cutoff is a >50% narrowing. The incidence of angiographic restenosis in several of the major
trials of PTCA and stenting is shown below (fig. 1.1).
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Angiographic Angiographic Vessel
Study Name/ Year Variables Follow-up in-stent occlusion/




BENESTENT' 1994 >3mm vessels 93 22 1
STRESS4 1994 >3mm vessels 88 31.6 1.5
Kastrati et at 1997 DM, multiple or
small stents.
80 16-59 NA
STRESS6 1998 2.7mm±0.2 88 34 3.6
substudy vessels
BENESTENT II7 1996 >3mm vessels 92 13 0
Van Belle et al8 1997 DM NA 27 NA
Non-DM 25 NA
Lau et al? 1997 >2.5mm vessels NA 33 0
<2.5mm vessels 47 0
Figure 1.1. The extent of restenosis in various stent trials. Note
that in trials dealing with non - 'Benestent' lesions, stent
restenosis rates may be considerably higher (DM=diabetics.
NA=not assessed or not available).
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More than 500,000 angioplasties are performed annually in the US, a quarter of them are for
patients with restenosis following previous PTCA or stenting. This is estimated to cost
around $3 billion in the US alone10. Of course these re-do procedures are not without risk to
the patients that have them. An estimate of approximately 1-2% mortality or other major
adverse event is commonly accepted. These figures are likely to rise year upon year as the
use of PTCA has steadily grown in Europe and the US.
However the processes that underlie this process are complex. Angiographic measures of
restenosis, the most common means to quantify the problem, differ greatly in clinical trials to
the clinical results. The variable correlation between angiographic and clinical results in a
few trials is shown below (fig. 1.2):
Trial
Difference between




Control % Treatment %
CAVEAT-I" 0.11 30 28 (p=NS)
STRESS4 0.20 27 22 (p>0.05)
BENESTENT' 0.12 33 23 (p<0.05)
Angiopeptin 2 0.01 30 22 (p<0.05)
Figure 1.2: Differences in angiographic and clinical outcomes of restenosis
trials (Adapted from Topol et at13).
Angiography is, by virtue of its worldwide familiarity and daily use, the present standard by
which interventions to alter restenosis are judged. However, this does not necessarily mean it
is a gold standard giving accurate assessments of restenosis. It has a poor correlation with
clinical outcome, due to technical failings of a system that gives two-dimensional
representations of the lumen of arteries affected by atherosclerosis. It has difficulty with
distinguishing features smaller than about 0.2mm with even the best resolution. Intravascular
ultrasound overcomes many of these failings and may well be much closer to giving a true
representation of the extent or otherwise of restenosis, but is not commonly performed.
Interestingly, the correlation between these techniques is as low as 0.30°.
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1.3.2 Factors affecting restenosis rates.
1.3.2.1 Patient characteristics
Angiographic restenosis post-angioplasty occurs approximately 1.3 times more commonly in
patients with diabetes14 although this effect has not always been seen in stented patients8.
Angioplasty and stenting of restenotic lesions, as compared to de novo lesions, carries an
even greater risk of re-restenosis.
The importance of genetic influences has not yet been fully established. That there are
genetic influences seems certain. For example, there is an association between high TGFfl
production secondary to a TGF(3 gene polymorphism and a higher incidence of restenosis15.
1.3.2.2 Angiographic variables.
Angioplasty of the left anterior descending artery has been shown in one study to have a
tendency to restenose more frequently than other angioplastied arteries14. This may be
because of anatomical differences in the vessel e.g. its course in the interventricular septum.
It is also suggested that the large territory at risk if the LAD is lost may make interventionists
slightly less aggressive in their attempts to open fully a stenosis at this location. Restenosis
would thereby be made more likely because of an initially sub-optimal result14. Restenosis is
also more common in patients who are stented for chronic or subtotal occlusions and in
stenosed or obstructed vein grafts16'17. Longer initial lesions tend to occur in more diseased
arteries. The revascularisation process is more difficult and restenosis appears to be more
common"'. Multiple interventions, either PTCA or stenting, in a single procedure are also
associated with a higher restenosis rate18, although this does not correlate exactly with
clinical recurrence of symptoms. As seen above (fig. 1.1), the size of the target vessel is
closely related to the incidence of restenosis in both angioplasty and stenting, as is the
diameter of the residual stenosis following angioplasty. This latter variable, the mean
luminal diameter (MLD), is the strongest single predictor of restenosis.
Stent and balloon design is thought by many to be influential in the incidence of restenosis.
This is discussed elsewhere (section 1.5).
To understand more fully why a patient might develop restenosis after an interventional
procedure, it is important to examine the processes that underlie the phenomenon at a
cellular level.
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1.3.3 Cellular mechanisms - the pathophysiology of restenosis.
Coronary stenoses are due to atherosclerotic plaques, complex structures that contain both
cellular and acellular components. Angioplasty means the application of force to this
structure and this injury to the vascular wall and plaque is the stimulus to restenosis.
This process begins early after injury, since the natural healing process will also lead to
restenosis if it continues in a poorly controlled fashion. This is part of the "response to
injury" theory. Angioplasty relieves the initial narrowing of a blood vessel by forcibly
fissuring or dissecting the fibrous cap over the atherosclerotic plaque. Most of these
dissections are not of clinical significance19. After the angioplasty balloon has successfully
dilated the site of a plaque and has been withdrawn, a fissured plaque is left, largely denuded
of its endothelial covering. The severity of the injury may be directly related to the extent of
restenosis seen. This has been modelled in pigs where an injury score at angioplasty was
related to the resulting hyperplasia seen at one month20.
Restenosis of a vessel at the site of this fissured plaque is thought to be due to different
mechanisms interacting, including:
1. Elastic recoil of the vessel wall after stretching




Angioplasty relieves the obstruction partly by stretching the healthier, relatively normal parts
of the vessel wall. After angioplasty, much of the apparent gain in luminal diameter is lost as
the stretched vessel recoils. Stenting overcomes this recoil. Rodriguez et al showed that in
patients with significant angiographic recoil at 24hrs post-procedure, stent insertion changed
the restenosis rate from 76% to 21%21.
1.3.3.2 Remodelling
Remodelling is a term orginally applied to changes in vessel size caused by atherosclerosis.
In some cases, a diseased artery will slowly increase its overall external diameter. This
partially compensates for the reduction in luminal diameter due to the atherosclerotic plaque.
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Unfortunately, following angioplasty the opposite process often occurs. This negative
remodelling causes a gradual reduction in the diameter of the vessel, compromising the
luminal cross-sectional area. Mintz et al have looked at this process using serial intravascular
ultrasound studies. Of patients with restenosis, about 75% of the reduction in lumen was due
to remodelling the rest attributed to growth of plaque or to intimal hyperplasia22.
It is believed that stent insertion also prevents this shrinkage of the vessel by negative
remodelling.
1.3.3.3 Intimal hyperplasia
Intimal hyperplasia is the growth of material into the potential space created by the
angioplasty. This material is a complex mix of components, but includes vascular smooth
muscle cells (SMCs) and extracellular matrix.
1.3.3.3.1 The vascular smooth muscle cell
The SMCs in restenotic lesions are thought to originate in the media or adventitia of the
vessel, particularly in stented vessels21. Normally these cells are of a contractile nature, have
a low rate of replication and do not tend to secrete large amounts of cytokines. Following
injury to the vessel wall, the phenotype of these cells changes to a more proliferative or
secretory one. Cells with the secretory phenotype have lost their contractility, but have
gained the ability to migrate, under the influence of chemotactic factors, to the sites of vessel
injury. Here they proliferate and produce their own cytokines. Other cell types contribute to
the restenotic area. Deep injury can rupture right through the vessel wall and allow the
migration of cells from outside the vessel into the area. These include macrophages,
fibroblasts and capillary endothelial or lymphatic cells. All of these cells and SMCs may
differentiate to form the "restenosis cell"24.
1.3.3.3.2 The extracellular matrix and matrix metalloproteinases (MMPs).
SMCs in the intima of the restenotic lesion may have migrated from outside the injured part
of the artery. To do this the extracellular matrix has to be broken down. This occurs under
the influence of a large family of proteinases, the matrix metalloproteinases. Secretory
phenotype SMCs synthesise and release MMPs to facilitate their own migration25. Up-
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regulation of MMPs has been identified following angioplasty injury to a vessel within 24
hours26.
Intimal hyperplasia, as well as depending on the presence of active SMCs, involves non-
cellular material. In a restenotic lesion as much as 80% of the tissue will be of extracellular
material, particularly collagen, as well as proteoglycans27. The turnover of this collagen is
regulated by the activity of MMPs that both degrade and promote the synthesis of collagen.
Strauss et al showed reduced collagen in restenotic lesions by inhibition of MMPs in the
rabbit iliac model28. Adenovirus-mediated transfection of the gene for TIMP-1 (an inhibitor
of MMPs) resulted in a reduction in neointimal hyperplasia in a saphenous vein organ
culture model29.
1.3.3.3.3 The endothelium
In a manner analogous to the different forms of SMCs, endothelial cells also appear to have
two phenotypes - "normal" or "dysfunctional"24. The effect of the endothelium on the
underlying tissues has been much studied, including when processes such as angioplasty
cause endothelial damage or denudation. Endothelial removal had been thought to be the sole
requirement for the stimulation of intimal hyperplasia. In work using the rat aorta however,
careful experiments showed that gentle denudation of the endothelium did not lead to intimal
thickening. There was evidence of SMC proliferation nevertheless30. During angioplasty, the
endothelium is stripped away, but this effect is combined with the extensive damage to the
deeper tissues already discussed. Loss of endothelium in rabbit aorta organ culture did not
cause intimal thickening. With the addition of pressure from a Teflon rod pressed onto the
culture however, intimal proliferation did occur1'. Experimental work suggests that injured
intimal areas that are re-covered by an endothelial layer have less intimal thickening than
bare areas. This has been seen in rat thoracic aorta'2. This hypothesis is not uniformly
supported by the data available. In atherosclerotic micropigs endothelial damage (and the
extent of inflammation) after angioplasty seemed to have no relationship with the negative
remodelling that contributes to restenosis33. Studies in a rabbit aorta model showed worse
intimal thickening in the areas covered by endothelium than adjacent bare areas.
Furthermore, the function of the new endothelial cells was affected. When the rabbits were
fed either high or low lipid diets, they all showed increased lipid accumulation in the re-
endothelialised areas'4. To some extent this may be because the cells that regenerate are
dysfunctional.
Dysfunctional endothelium may contribute to intimal hyperplasia. Endothelial cells are
capable of producing growth factors themselves24 and endothelial dysfunction is seen after
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angioplasty. In the case of stenting, dysfunctional endothelium has been demonstrated in
stented porcine arteries up to three months after the initial procedure. It has been suggested
that this endothelial dysfunction may contribute to the intimal hyperplasia that is seen,
especially after stent use35. "Normal" ECs produce heparan sulphate and NO36. Cell culture
studies of endothelial cells have shown that cerivastatin, an HMG CoA reductase inhibitor,
increases endothelial cell NO production and inhibits smooth muscle cell growth17.
1.3.3.3.4 The macrophage/inflammation
Cells of the monocyte/macrophage line are found in atherosclerotic plaques as foam cells.
Inflammation, involving such cells, is found within 24 hours of angioplasty in rats38 and
there is a correlation between hyperplasia and macrophage infiltration in the rat carotid38.
Post-mortem studies of patients with restenotic lesions post-stenting also show abundant
macrophages at the restenosis site39. Treatment options aimed at reducing the inflammation
process have shown some promise. Hypercholesterolaemic rabbits underwent PTCA/stenting
and were given systemic IL-10, a deactivator of monocyte cells. Reduced inflammation and
reduced neointimal growth were noted40.
1.3.3.3.5 The adventitia/fibroblasts
In a rat carotid model of restenosis after angioplasty it has been shown that part of the
restenotic tissue is due to the migration of fibroblasts from the adventitia inwards to the
neointimal layers41.
1.3.3.4 Thrombus formation and restenosis.
Angioplasty and stenting produce a situation where all of Virchow's triad exists, i.e.
abnormal flow, intimal injury and hypercoagulability. After angioplasty/stenting, the fissured
plaque presents a highly thrombogenic surface to the constituents of the blood. Intimal injury
causes the loss of the endothelium, so the antithrombotic effects of the endothelial cells are
lost as well. These cells naturally produce compounds such as tissue plasminogen activator
and prostacyclin that inhibit thrombus formation and propagation.
Hypercoagulability can be attributed to the presence of exposed tissue factor in the vessel
wall activating the extrinsic coagulation cascade. The exposed underlying tissues contain
molecules, including von Willebrand Factor and collagen, that act as ligands for the
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receptors on platelets that allow them to adhere to surfaces. Blockade of platelet adherence
with recombinant leech antiplatelet protein has been shown, in the rat carotid model, to
reduce intimal hyperplasia42.
A formed clot is potentially of haemodynamic significance as a partial obstruction in the
vessel lumen, causing by its presence an element of restenosis. Its physical presence also
provides a scaffold for the migration of other cells that produce the fibrocellular matrix that
causes restenosis. The formed clot is an active structure, since the cells within it continue to
exert influence over the surrounding microenvironment.
Activated platelets produce many bioactive molecules including serotonin, ADP, basic
fibroblast growth factor, TGF-(3 or PDGF and thromboxane A2. All of these products are
known to be mitogenic42.
1.3.3.5 Apoptosis in the restenotic process.
Apoptosis, or programmed cell death, is a particular form of cell death. Unlike necrotic cell
death, cells which undergo apoptosis do not usually excite an inflammatory reaction44. Malik
et al have shown that, in a porcine coronary angioplasty model, apoptosis and cell
proliferation are both stimulated in comparison to quiescent, undamaged vessel45. Apoptosis
affected all cellular layers of the artery, but the time course amongst different layers varied.
In all, however, apoptosis occurred before cell proliferation. Atherectomy specimens taken
from patients with atherosclerosis and, particularly, with restenosis, have shown
immunological evidence of apoptosis46. It seems reasonable, therefore, to see the restenotic
process as a combination of cell proliferation and cell death, mediated by apoptosis. In
concept, being able to tilt the balance in favour of apoptosis for proliferating smooth muscle
cells, and against it for endothelium, might be beneficial both in influencing the course of
atheroma and in controlling post angioplasty restenosis. Steg et al, using the atherosclerotic
rabbit model, locally delivered gene therapy using an adenoviral vector. Systemic
gancyclovir was given. The gene synthesised an enzyme that activated gancyclovir to a toxic
metabolite. This caused the cells transfected with the gene to undergo apoptotic cell death.
Restenosis was reduced at the target site47.
1.3.3.6 Allergy as a contributor to in-stent restenosis
An interesting small study has investigated the hypothesis that differences between the
allergic responses to the metals in coronary stents may determine which patients develop
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restenosis. In a retrospective study, patch testing for nickel allergy was strongly correlated to
restenosis. All patients with nickel sensitivity (9/131) developed restenosis angiographically
48
at six months .
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1.4 Models of restenosis.
Various models have been developed to investigate the problem of restenosis. These all have
strengths and weaknesses of their own. The transfer of results in animals of various
treatments to clinical trials has often been disappointing. Despite their shortcomings it is
accepted that animal studies are the gold standard in testing the safety of agents of proposed
use in clinical trials. It may be the animal models themselves that gave the unreliable results
and differences between species stop animal results being applicable to humans. For
example, cyclosporin A, an immunosuppressant, showed reduction of neointima formation in
rats but not rabbits49. All animal models fall short of modeling complex coronary disease. In
humans this occurs over years or even decades, giving an organized, fibrous and even
calcified, atherosclerotic plaque. Laboratory animals are young and healthy, with completely
normal blood vessels. Several animal models have been used to model restenosis.
1.4.1 Animal models of stent restenosis.
1.4.1.1 Canine coronary artery.
Folts et al50 describe a model using coronary vessels. It involves the placing of constricting
rings around the dogs" coronaries and has been used to study thrombus and restenosis.
However, for the evaluation of stent-related complications it is not ideal. First, deployment
of balloon expandable stents is associated with deep vessel injury, in particular disruption of
the internal elastic lamina and penetration of stent wires into the deep media as has been
confirmed in human necropsy specimens51. Constricting rings may cause a stenosis, but do
not reproduce the deep vessel injury. Second, the stent itself should be well expanded to
correspond to clinical practice, so use of a plastic constrictor to produce a stenosis within the
stented area of the vessel is inappropriate. Third, on a practical level, use of dogs for research
purposes is increasingly difficult in this country because of public antipathy and
correspondingly tight regulatory controls.
1.4.1.2 Rabbit iliac model.
A rabbit iliac model was described by More et al52. Balloon angioplasty injury was produced
in the common iliac artery via the superficial femoral artery. This produced a deep arterial
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injury. The superficial femoral artery ligated. The effects on thrombosis and restenosis
following angioplasty were studied up to three months later. Reliable intimal thickening
caused by myointimal hyperplasia was seen with gradual re-endothelialisation over 14 days.
This model was relatively simple to perform and rabbits are easily kept. Many other groups
have used similar rabbit models with or without hypercholesterolaemic diets40'53 37.
1.4.1.3 Rat carotid artery model.
This model was initially developed to study plaque formation rather than restenosis. Its
strength lies in the comprehensive knowledge of rat cellular biology available. Rats are easy
to keep and inexpensive. However, neointimal formation following balloon angioplasty in
the rat is compensated for by increases in vessel diameter, i.e. remodelling, so functional
stenosis does not occur. Significant thrombosis does not occur in this model58.
1.4.1.4 Porcine coronary vessels
Coronary vessels differ from other vessels. They fill in diastole; they are not elastic arteries
like carotid or iliac arteries; in pigs, functionally important restenosis occurs, which is
similar to that seen in humans59. However, the animals are still young and the lesions formed
are produced in healthy arteries over a period of days rather than years. The animals are
difficult and costly to look after. A separate animal licence is required for their use in Britain.
Positive studies in pigs have not always translated into a reduction of restenosis in humans12'
60. Conversely, porcine models of the use of sirolimus to reduce restenosis significantly
underestimated the efficacy in human trials61'62.
1.4.2 Power calculations in clinical trials of restenosis.
Unless adequate numbers of similar patients are recruited a trial may be underpowered and
fail to demonstrate small but significant reductions in restenosis rates with a certain agent i.e.
type II error. When 57 restenosis trials were examined for this fault, only five were powered
sufficiently to be 80% confident that there was no type II error61. These trials all reported
negative results. It is possible that useful agents with clinical benefit have already been found
and erroneously discarded.
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1.4.3 Summary of agents targeted at the restenosis process.
The many different mechanisms that play a role in the proliferative response after
angioplasty have been reviewed. From an understanding of the underlying mechanisms,
many researchers have attempted to reduce the response therapeutically. The table below
summarises the systemic agents used and their effects in various models of intimal
hyperplasia (fig. 1.3).
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Agent Model used Result
Antibiotics
Rapamycin64 in vitro Inhibited growth
Lipid lowering agents
Fluvastatin - FLARE study65 Human No benefit




Human No clinical benefit
Cytokines and hormones
Il-lO40 Rabbit Inhibited stent restenosis.
Prostaglandin El68 Human Reduced neointimal hyperplasia
Prostacyclin69 Human No benefit
Oestradiol70 Rabbit Reduced neointimal hyperplasia
Activin71 Mice Reduced neointimal hyperplasia
Angiopeptin ~ Pig Reduced neointimal hyperplasia
Angiotensin II/ACE inhibitors
Losartan73 Pig Reduced neointimal hyperplasia
Cilazopril74 Human No benefit
Calcium antagonists
Verapamil 5 Human Reduced neointimal hyperplasia
(Peripheral vessels)
Amlodipine-CAPARES trial76 Human No reduction in restenosis
Y-27632 (Rho-Kinase
inhibitor)77
Rat Reduced neointimal hyperplasia
Antiallergens
Tranilast - TREAT study78 Human Reduced neointimal hyperplasia
Permirolast79 Human Reduced neointimal hyperplasia
Tyrosine kinase inhibitors
PP1/AGL187280 In vitro Reduced neointimal hyperplasia
Anticoagulants
Q 1
Enoxaparin - ERA trial Human No benefit
Anti-thrombin III /heparin82 Pig Borderline benefit
Clivarine/PEG hirudin8. Pig Reduced neointimal hyperplasia
Heparin84 Human No benefit
Hirudin - HELVETICA trial85 Human No benefit
Warfarin86 Human Mixed results
Antiplatelets, anti-PDGF & TXA2 antagonists
Trapidil /STARC study85; 87 Human No benefit/Reduced stenosis
Cilostazol88 Human Reduced neointimal hyperplasia
compared to aspirin




CV-415190 Human No benefit
Abciximab - ERASER trial91 Human No benefit
Metalloproteinase inhibitors
Bat i mas tat9 Pig Reduced neointimal hyperplasia
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Non-specific
Suramin'1 Rabbit Reduced neointimal hyperplasia
U-86983'™ Rat Reduced neointimal hyperplasia
Fatty Acids




ABT14762795 Pig Reduced neointimal hyperplasia
Antioxidants
Probucol-MVP trial91' Human Reduced neointimal hyperplasia
IRFI 04297 Rat Reduced neointimal hyperplasia
Inhibitors of DIN A synthesis
Mithramycin98 Rat Reduced neointimal hyperplasia
Others
Octreotide99 Human No benefit
Carvedilol100 Human No benefit in atherectomy patients
Colchicine101 Human No benefit
Methylprednisolone Human No benefit
ATF.BPTI102 Rat Reduced neointimal hyperplasia
Figure 1.3. Table of systemic agents used for restenosis
1.5 Local drug delivery for restenosis
In the search for suitable agents to prevent the problem of restenosis post-angioplasty, a
number of promising animal trials have led to disappointing results in humans. Clinical trials
of cilazipril, enoxaparin, angiopeptin and trapidil - all promising in animal studies - had
negative results12,74'1 3"104. It is suggested that part of the reason that these and other agents
have failed to translate to human studies is that they used relatively low doses of the drug
under trial compared to the animal work. This is usually because of concerns about the likely
side effects of high doses systemically. In the cilazipril trials the dose given had a high
incidence of postural hypotension, despite the fact that the dose was roughly 70 times lower
per kilogram than the doses used in animal work. Thus it may be that the ideal agent(s) for
the prevention of restenosis has already been found but that at systemic doses its side-effect
profile in humans makes it useless.
It seems reasonable to find a way to minimise the dose of the drug given, yet retain its
efficacy at the point where it is needed; the angioplasty site. This is the rationale behind the
concept of local drug delivery (LDD). By finding a way to deliver small doses of the drug to
where it is needed, the drug could achieve very high local concentration. Even if a drug is
normally inactivated in vivo by, for example, first pass metabolism in the liver, it will remain
an effective local treatment as it bypasses this biological inactivation. Less drug is required,
saving money. One approach has been to combine the angioplasty procedure with a LDD
technique, using modified angioplasty balloons:
1.5.1 Delivery balloons
The double-balloon catheter has a balloon at the tip of the catheter and one several
centimetres more proximally. In between there are holes through which drug solution can be
expressed, after both balloons have been inflated to prevent blood flow. Long periods of
instillation with vessel occlusion are required103, which precludes their use in coronary
arteries. The small holes of local delivery balloons cause the fluid instilled to form fluid jets,
which cause local trauma to the vessel itself103. As little as 1%' 5 of the drug instilled remains
in the vessel wall, the remainder is released into the bloodstream, further downstream in the
coronary circulation and even systemically. Local trauma can be quite significant as the
angioplasty balloon has to be inflated to allow the drug to be delivered. Infusion pressure
seems to be related to development of intimal hyperplasia106.
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Several modifications of the basic balloon design have been made. These include the
Transport, Wolinsky, Despatch, Channel and hydrogel balloons. The advantages and
drawbacks of these local delivery balloons can be illustrated briefly. Antisense
oligonucleotides to c-myb, a proto-oncogene expressed after angioplasty injury in vessels,
were infused locally with the Transport catheter. Neointimal growth was reduced. The
authors note exacerbated intimal hyperplasia in the control group, reflecting the trauma
caused by the local instillation of fluid107. In a small (ten patient) study, locally delivered
urokinase was very succesful in lysing intra-coronary thrombus following complicated
angioplasty. The authors note that only 0.4% of the urokinase was delivered to the vessel
wall in their animal model108. These balloon catheters have similar weaknesses. They rely on
the instillation of large volumes of fluid compared to the volume of space available in the
wall, causing trauma. Nevertheless, an enormous number of agents have been used in
various animal models to test local drag delivery by one or other balloon type (fig. 1.4).
Various adaptations have been made to the basic balloon principle to try and improve on
either delivery or retention of drags. These include adenoviruses containing DNA coding for
the desired agent, microparticle suspensions, liposomes and targeted drug therapy. These are
briefly discussed.
1.5.1.1 Adenoviruses.
Although DNA can be transfected into cells using various vectors, adenoviruses tend to
prove the most efficient method10'1. They carry the risk of severe hypersensitivity reactions
being provoked by their use and of transfecting cells accidentally with rogue viral DNA.
Adenoviruses have been used to deliver endothelial nitric oxide synthase in stented porcine
arteries, with equivocal results. Angiography failed to show a benefit, despite reduced
intimal hyperplasia. GAX (growth-arrest specific homeobox) transcription factor has been
shown to be an inhibitor of SMC proliferation and furthermore stimulates SMC apoptosis.
Adenoviral transfection delivered by channel balloon to overexpress GAX in stented porcine
arteries produced encouraging reductions in instent restenosis110.
1.5.1.2 Microparticles
To overcome the loss of liquid drag away from where it was intended, Wilensky et al
showed that agents might be injected into the vessel wall in a suspension of 5pm diameter
microparticles. These, when injected into the femoral arteries of atherosclerotic rabbits, were
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retained locally up to 14 days later111. These biodegradable microparticles can carry drugs
and keep them in the area where they are needed.
1.5.1.3 Liposomes
Liposomes containing agents felt to be beneficial in limiting the restenosis process have been
infused into the angioplastied vessel through a delivery balloon. Using liposomes as a
vehicle, oestradiol reduced neointimal hyperplasia in a rat carotid model"2.
1.5.1.4 Targeting
A refinement of the use of local drug delivery balloons has been the use of targeted agents to
aid retention at the intended target site. Targeting means the fusion of the active moiety of an
agent with a suitable agent that binds to structures in the target site, for example the injured
arterial wall after angioplasty. Hogrefe et al showed that a bi-specific antibody fragment
could be produced combining the binding sites for the Gp Ilb/IIIa receptor and for tissue
factor. This bi-specific antibody showed increased affinity for the angioplasty site because of
the exposed tissue factor there. In vivo, a trend towards reduced thrombus formation at the
site was observed over that seen with either agent alone"1.
1.5.2 Polymeric Endoluminal Gel Paving
Slepian et al approached local drug delivery using a different concept. They have
experimental polymers that can be moulded onto the interior surface of an angioplastied
vessel. The polymers acted as a barrier between the exposed intima and the bloodstream, as
wall supports and as depots for LDD. Initially, thermoplastic polymers were used to
reinforce the wall of the artery. Their work also tested hydrogels. These are not suitable for
supporting the vessel wall but will act as a barrier and as a vehicle for drug delivery. They
delivered the gel to the vessel and moulded it onto the surface by heating the gel with the
catheter. The gels biodegraded over weeks and released drug slowly. These studies, in rabbit
carotid models, showed favourable reductions in neointimal growth. In pigs, a similar
hydrogel containing radiolabeled heparin was used. The technique proved technically
successful and unlike some of the techniques described for LDD, no downstream delivery of
drug was seen. However, after only four hours, only 3% of the heparin remained in the
coronary vessel wall114.
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Agent Model used Result
Local Photodynamic therapy
Photofrin115. Pig Reduced neointimal hyperplasia
Anticoagulants and antiplatelets
Enoxaparin5 Human Reduced restenosis
Reviparin116 Rabbit No benefit
Urokinase117 Pig No benefit
Heparin118 Human No benefit
Dipyridamole119 Rabbit Reduced neointimal hyperplasia
Argatroban120 Rabbit Reduced neointimal hyperplasia
Antisense oligonucleotides
To MAPK121 Pig Reduced neointimal hyperplasia
To c-mybluv Pig Reduced neointimal hyperplasia
r-T". 122: 122To c-myc Rabbit/Human Reduced neointimal
hyperplasia/No benefit
Anti-proliferatives
Doxorubicin124 Rabbit No benefit
Mitomycin C124 Rabbit No benefit
Methotrexate125 Pig No benefit
Paclitaxel126 Rabbit Reduced neointimal hyperplasia
Green tea catechins127 Rat Reduced neointimal hyperplasia
Hormones and cytokines
Lipoxygenase inhibition1 8 Rat Reduced neointimal hyperplasia
Oestradiol 112 Rat Reduced neointimal hyperplasia
vegf127vegf 150 Rat/
Human
Successful /no benefit (not
stented)
Hepatocyte Growth Factor131 Rabbit Reduced neointimal hyperplasia
Angiopeptin132 Rabbit Reduced neointimal hyperplasia
I-kappa-B133 Rabbit Reduced re-occlusion
Proteasome/Tyrosine/Protein Kinase inhibitors
ST 638134 Pig Reduced stenosis arteries. Given
drug from outside
MG132135 Rat Reduced neointimal hyperplasia
Antioxidants
HA1077124 Rat Reduced neointimal hyperplasia
Gene therapy
Ac enovirus/Retrovirus
gax"°. Pig Reduced neointimal hyperplasia
Antisense cyclin Gl136 Rat Reduced neointimal hyperplasia
Rb137 Rat Reduced neointimal hyperplasia
Tk124 Rabbit Reduced neointimal hyperplasia
Protein Kinase G1,8 Rat Reduced neointimal hyperplasia
Plasmid
VEGF57 Rabbit Reduced neointimal hyperplasia
Others
Suramin139 Mouse Reduced neointimal hyperplasia
Chimeric ribozymes140 Pig Reduced neointimal hyperplasia
Ethanol141 Pig Reduced neointimal hyperplasia
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Dexamethasone124 Rabbit Reduced neointimal hyperplasia
Apolipoprotein A-Imilano142 Rabbit Reduced neointimal hyperplasia
AtRA144 Rabbit Reduced neointimal hyperplasia
Thrombospondin blockade144 Rat Reduced neointimal hyperplasia
Figure 1.4 Table of drugs administered locally to try and reduce restenosis.
This is not an exhaustive list but illustrates the very wide range of agents
used to try and treat the restenosis process.
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1.5.3 Local Photodynamic therapy in stented arteries
Photodynamic therapy (PDT) involves the systemic administration of a light-excitable
photosensitiser that is taken up preferentially by rapidly proliferating cells. During laser
irradiation, light energy is transferred from the photosensitiser to oxygen generating the
highly reactive oxygen radical. This causes severe cellular damage to the proliferating tissue.
Several different photosensitisers, for example photofrin"5, have been used with success in
reducing restenosis in both animal and human models.
1.5.4 Stents as local drug delivery devices.
Since stenting and local drug delivery by stent is the main focus of this MD thesis, stents and
their variations are now discussed in depth.
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1.6 Stenting and stent modifications
Since coronary angioplasty was introduced by Gruentzig145 in the late 1970s, it has been
apparent that although successful at relieving the symptoms of angina, it has some
complications. Intra-coronary stents are supportive devices that are placed inside the lumen
of a vessel to prevent collapse or elastic recoil of a dilated arterial segment after angioplasty.
Intra-coronary stents were first used in humans in the mid 1980s by Sigwart et al who used
them, initially, for bailout after an intimal dissection had been caused by balloon
angioplasty146.
1.6.1 In-stent restenosis
Two major trials have established the effectiveness of intra-coronary stents as a means of
reducing restenosis, at least in patients with low-risk, so-called "BENESTENT" type
lesions3'4. Despite these encouraging findings, there remains a considerable minority of
patients who suffer a major adverse cardiac event (MACE) or require subsequent target
lesion revascularisation. Studies suggest that restenosis occurs in up to 15-20% of cases. This
figure is higher in patients with diabetes, multiple stents and in stented, small, non-
BENESTENT vessels where restenosis rates approaching 45% have been documented (see
fig 1.1). Restenosis in stented vessels has proven difficult to treat. Current therapies include
the use of irradiation (brachytherapy), transluminal rotablation and atherectomy (cutting
balloon), to increase lumen diameter.
1.6.2 In stent thrombosis
Stents, which do appear to reduce the incidence of restenosis, may also have adverse effects.
In-stent thrombosis, although rare in BENESTENT lesions, has been reported in 2-3% in
small vessels147. Some of the incidence of instent subacute thrombosis can be attributed to
suboptimal stent deployment. Colombo et al demonstrated, using intravascular ultrasound,
that even when good angiographic deployment was seen, there was often poor apposition of
parts of the stent to the vessel wall. They showed that the use of antiplatelet rather than
anticoagulant treatment was effective in reducing thrombosis rates if the stent was fully
deployed to begin with148. This often meant repeated, high-pressure balloon inflations,
although more recent stents are more deformable, improving apposition.
29
Thrombosis is currently reduced also by the prescription of antiplatelet therapies including
aspirin and ADP receptor antagonists like ticlopidine or clopidogrel. In addition to their
natural thrombogenicity, stents appear also to cause other problems. One study in a porcine
model has found that stents adversely affect endothelial function as assessed by vascular
permeability and cell morphology, compared to angioplasty alone3'1.
It is postulated that both the thrombogenic potential and the stimulus to intimal hyperplasia
from a stent are secondary to the defect in the endothelium at the stent site. Until the vascular
endothelium fully regenerates therefore, the risks of these complications remain present149.
1.6.3 Modifications to intravascular stents.
The growing recognition that stents were not without complications led to the search for
modifications to the original concept that might reduce the incidence of problems. The
physical properties of stents have been examined to determine which of these is of
importance in the generation of complications of either thrombosis or restenosis. Stents are
generally stainless steel, tantalum or nitinol (a nickel-titanium alloy). There do not seem to
be great differences in the complication rates amongst these different metals'50. They have
different structural designs although typically can be classed as either a self-expanding stent
(e.g. Wallstent) or balloon-expandable stents, which are further divided into coiled wire (e.g.
Wiktor) type or a slotted tube (e.g. Palmaz-Schatz). In some animal models there are
suggestions that the greater the degree of coverage of the vessel wall by the stent - or the
greater the number of struts it has - the less restenosis is seen11'. In contrast, another group
suggest that closed stents, i.e. those without gaps between struts, have a worse restenosis
rate. In other words, they show that the less metal in contact with the vessel, the better'12.
Furthermore, the stents without gaps also, unsurprisingly, had an increased rate of side-
branch occlusion'11. Other factors including stent geometry and the uniformity of tension
within a stent have also had claims made as to the importance they have on the incidence of
restenosis154. Confusing the issue also is the extent to which qualities of the balloon used
may affect vessel wall injury and restenosis. The compliance of the balloon and the extent to
which it is inflated do seem to have some impact on these events151.
There is no clear picture as to whether there are important differences in clinical terms
amongst the many different stents on the market. It is difficult to demonstrate any difference
between stents because of the number of similar patients needed to power a study to show a
small difference in outcome. In ostial LAD stenoses, one very small study (55 patients)
suggested an advantage of the slotted tube style over coil stents. However, only 80-85% of
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patients in the trial returned for six month angiography156. It does not seem reasonable to
base major decisions as to stent selection on trials as small and as selective as this.
1.6.3.1 Stent surface characteristics
The roughness of the stent surface may determine the extent of early thrombus deposition.
Irregularities as small as 1pm have shown increased thrombogenic potential in a study of
stainless steel rings implanted into the inferior vena cava of experimental dogs157. In this
same work, the impact of surface charge was also assessed. Negatively charged surfaces
might repel the predominantly negatively charged proteins that form blood clots and so be
antithrombogenic. However, no such relationship was seen in this study. Irregularities can
easily be seen in the surface of stents under scanning electron microscopy. This is
demonstrated using the polymer-coated stents used in this work (fig. 7.5).
1.6.3.2 Coated stents
Attempts have been made to coat the surface of stents with different materials that make
them more biocompatible.
1.6.3.2.1 Plating stents with other metals.
Experimental models using stents coated with platinum, copper or gold initially suggested
that these might prove to have less adverse effects on the blood vessels into which they were
placed. The effect of ion charge of the metals was not found to be an indicator of extent of
intimal hyperplasia or thrombus formation158. A randomised control trial of gold-plated intra-
coronary stents proved disappointing however, with a higher rate of complications than the
control group159. Iridium Oxide stent coatings have been shown in vitro to reduce the
concentration of Reactive Oxygen Species in the vicinity of a stent to which leucocytes had
been adhered. This is thought to be due to a catalase-like ability of the coating to reduce
these free radicals. In theory, such stents would reduce the amount of inflammation related to
stent insertion. In a porcine model, reduced restenosis has been seen160. Titanium-nitride-
oxide (TiNOX) has been shown to resist platelet adhesion and stainless steel stents coated
with this alloy have been tested in a porcine model. At six weeks, a 44% reduction in
neointimal area was seen (p<0.02) compared to plain, stainless steel stents161.
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Figure 1.5. Scanning electron micrographs of the surface of the
polymer-coated Supra G stent. This shows the surface
irregularities present on this type of stent. The white line at the
foot of each picture indicates the scale. Irregularities larger than
1jum have been shown to be thrombogenic in vivo.
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1.6.3.2.2 Covered stents.
Stents covered with an artificial membrane have been promoted as they hold the potential to
reduce restenosis simply by acting as a barrier to ingrowth of SMCs. The Jomed, which is
covered with PTFE, has been used for patients with aneurysms or perforations of the
coronaries. No controlled trial of their use exists. Animal studies of covered stents have
shown that they inhibit the recovery of the endothelium, not surprisingly, compared to bare
metal stents162. A different clinical trial in a small number (9) of patients with femoral artery
stenosis, showed an increased stenosis rate with Dacron covered nitinol stents163.
1.6.3.2.3 Tissue coated/covered stents.
The use of endothelial cells bound onto stents is discussed elsewhere (1.6.1.1) as it is
relevant to the concept of re-endothelialisation. Stefanadis et a/164'165 have published reports
of using stents covered with sections of either vein or artery derived from the patient. All
these reports show promise but represent a handful of cases, in an uncontrolled trial, with no
published long-term results.
1.6.3.2.4 Semiconductor-coated stents.
A semiconductor coating of Silicon Carbide has shown promise as an inhibitor of thrombus
formation on stents in high-risk patients'66. Semiconductors are thought to deter the
adherence of platelets and fibrinogen. In rabbit studies, these stents showed a reduced
incidence of intimal hyperplasia and complete re-endothelialisation167.
1.6.3.2.5 Diamond-like coating.
Diamond-like carbon films, including Dylyn™, have been tested for their biocompatibilty as
a stent coating in a porcine model. In this study, two variations of the coating were tested
against identical, uncoated stents. Both coated groups showed reduced thrombus formation at




Vascular brachytherapy (VBT) is the local delivery of radiation to the coronary arteries to
prevent complications post-angioplasty, particularly restenosis due to intimal hyperplasia.
Two approaches to this have been taken. Radiation can be delivered post-angioplasty by
passing a radioactive wire that emits either beta or gamma irradiation. Human trials, with
small numbers of patients, have shown promising results when used to treat de novo1 or
restenotic lesions170. Alternatively, stents themselves can be made radioactive. In humans,
the IRIS trial of beta-emitting stents has been reported. Restenosis at six months was 31%171.
Both approaches to delivering radiation seem to have unwanted effects in the longer term
with reports of an "edge effect" complicating outcome in several patients. This is the finding
of good patency and continued inhibition of hyperplasia where the radiation is delivered, but
stimulated hyperplasia and consequent stenosis in sections of artery that immediately abut
it1Furthermore, several case reports have highlighted a phenomenon of late thrombosis in
patients receiving VBT. Across all reported VBT trials, 9.1% of patients have suffered acute
occlusion of the treated area, 40% of these with resultant myocardial infarction, as long as
nine months post-treatment17 \ This concern has led to prolonged use of antiplatelet agents
such as clopidogrel for up to a year post brachytherapy.
1.6.3.4 Bioabsorbable stents.
Concerns about the long-term effects of intra-coronary metal stents have been voiced174.
These concerns included the potential risk that the persistent presence of a stent might itself
be the stimulus to ongoing intimal hyperplasia. A permanent stent was thought to be a
potential focus for infection. Mechanical failings were anticipated that might cause trauma to
the vessel wall sufficient to cause aneurysm or vessel perforation. As a result of these
concerns, some researchers have explored the use of temporary, biodegradable or
bioresorbable stents. These stents would ideally also be of a material that as it degraded
released a bioactive drug i.e. the biodegradable stent would be a local drug delivery device.
The Duke bioabsorbable stent was pioneered in the early 1980s. Stents degraded over
approximately 18 months. The Igaki-Tamai stent, made of Poly-l-Lactic Acid (PLLA), has
been introduced into early clinical practice. At six months, a restenosis (and target vessel
revascularisation) rate of 10.5% was seen in a non-randomised series17'\ Ye and colleagues176
have also reported the use of biodegradable stents in a rabbit carotid model as a delivery
device for gene therapy. An adenovirus carrying a reporter gene was successfully transfected
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into the vessel wall. Magnesium alloy stents have been developed that in an uncontrolled
porcine study showed low thrombosis and restenosis rates177. Technical difficulties
concerning the structural characteristics (e.g. radial strength), radio-opacity and delivery of
biodegradable stents, have proven almost insurmountable. Furthermore, although metallic
stents do have complications, these all tend to be early after implantation. Late complications
like aneurysm formation or infection are not common. Therefore there is not a need to have
stents with a short lifespan, merely that they should be biocompatible quickly.
1.6.3.5 Polymer coated stents.
An ideal polymer would be biocompatible and non-thrombogenic. The extent to which a
polymer is hydrophilic is inversely related to the extent to which it attracts fibrin'78. Fibrin
deposition is an early stage in thrombus formation. In vivo assessment is essential, as the
polymer may interact with the components of the blood or coagulation cascades. The idea of
a hybrid stent, combining the proven mechanical benefits and long term success rate of metal
stents with the biocompatibility of polymers, has been proposed. The development of such a
stent has not proven easy. Many different polymers have been applied to stents with mixed
success. The thrombogenicity of polyurethane-coated, tantalum stents was examined in an ex
vivo porcine model using stented polytetrafluoroethylene grafts. A reduction in
thrombogenicity was seen179. In separate work, five different polymers were used to coat
stents in porcine arteries. These were a mixture of both biodegradable and non-biodegradable
polymers, including polyurethane. All polymers had previously shown evidence that they
were biocompatible in vitro. All induced a significant inflammatory response followed by
neointimal hyperplasia180. This study is disappointing, although technical aspects of it that
may have contributed to the negative results have been identified181. The layers of polymer
used were not applied uniformly, which would stimulate more turbulent flow over the
surface and encourage the deposition of activated platelets. Furthermore, the coating in each
case was relatively thick and other workers have reported more favourable results with
thinner coatings. Finally, stents used were not sterilised prior to implantation and therefore
could have been contaminated with pyrogenic organisms.
Phosphorylcholine (PC) is a phospholipid that is naturally found as part of the cell
membrane bilayer. PC-coated stents proved to be biologically neutral in rabbits and pigs, but
showed no reduction in restenosis at six months5'1. Other polymer coatings have shown more
promise, not just in vitro but in vivo, including in clinical trials. Canine studies of fluorine-
acryl-styrene-urethane-silicone coated stents implanted in iliac veins did show both a
reduction in thrombus formation and, at four weeks, reduced neointimal hyperplasia182. A
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polyamine/dextran sulphate trilayer stent has been studied in porcine arteries and shown to
have a reduced incidence of thrombosis when covalently bound to heparin183. Heparin-
adsorbed polymer surfaces have long been known to reduce the adhesion of platelets184. This
same heparin-bound polymer coated stent was used clinically in the BENESTENT II trial7.
Although this study was not a randomised control trial, the results using this stent were at
least as favourable as historical comparisons. The Cook GRII stent used a cellulose polymer
coating. In a randomised, controlled trial against uncoated Palmaz-Schatz stents, poor results
were obtained in the GR II group with higher incidences of both target vessel
revascularisation and MACE183. The authors defend this disappointing result on the basis of
poor deployment of the GR II and differences between lesions treated. Nevertheless, this
stent is no longer being marketed.
1.6.3.6 Fibrin-coated stents.
Fibrin is the natural end-product of enzymatic cleavage of fibrinogen in the coagulation
cascade. It can be polymerised in vitro with thrombin. This biopolymer has been coated onto
stents to form a kind of synthetic film of thrombus on the metal. This synthetic thrombus was
relatively inert and protected the stent from the components of the coagulation cascade. It
may also act as a framework onto which endothelial cells can regrow, encouraging the
passivation of the stent. Schwartz et al have used these stents in a porcine model
successfully. A reduction in both stent thrombosis and restenosis was seen186. In addition, the
fibrin coating was biodegradable and could be combined with drugs to act as a local delivery
method.
1.6.4 Polymer-coated stents as drug delivery devices.
The development of polymer-coated stents has been driven not only by the concept that they
might be intrinsically more biocompatible than bare metal, but also to provide an opportunity
to act as a reservoir of drugs or molecules that are released into the local microenvironment.
This is the concept of the stent as a local delivery device.
The advantages of this concept are that:
• The drug is delivered specifically to the area where it is required.
• High local concentrations can be achieved.
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• A sustained delivery of drug can be achieved, dependent on the pharmacokinetics of the
individual drug and polymer used.
• Less systemic side effects can be anticipated as the total amount of drug delivered will
be much less than that required for a clinical effect when administered systemically.
• The lower amount of drug required will substantially reduce the cost of administering it.
This may well allow more widespread use of newer, more expensive agents in a cash-
constrained health service.
There are disadvantages as well:
• All stents that deliver a drug loosely bound to its surface will lose a considerable
proportion of the drug as soon as the stent is exposed to the blood flowing in the target
vessel.
• Transiently, a small amount of drug will wash off the stent in a very short period of time,
creating high local concentrations. This is the "bolus effect".
• It is therefore important to ascertain that the drug used will not have any adverse effects
if relatively high concentration of it will be delivered into the coronary circulation, albeit
for very short periods.
• Stents because of their small surface area can only carry small quantities of an agent, so
to be effective it must be very potent.
• Similarly, the stent does not completely cover the intimal surface of an artery, so agents
delivered must be able to diffuse around the area covered by the stent to be uniformly
effective187. Stents cover only 5 -12% of the arterial surface area, so drug transfer into
the disrupted area is unlikely to be uniform since diffusion of the drug over a relatively
large distance may be necessary10'.
• The polymer coating used to deliver the drug may produce adverse effects.
The practicality of using stents as a local drug delivery device experimentally is supported
by the existence in other fields of cardiology of devices that fulfil this same role.
Diphosphonates have been successfully bound to polymeric matrices on bioprosthetic heart
valves in vitro and shown to reduce the extent of calcification on the valve188.
Various groups have exploited this potential use for stents (see fig. 1.6).
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Drugs delivered using Reduction in Reduction in intimal
coated stents Model thrombosis rate hyperplasia
Heparins183'189 Pig Y N
Rabbit Y N
Methotrexate1"'1 Pig NA N
Dexamethasone190 191 Dog N Y
Pig N N
Pig NA N
Methylprednisolone192 Pig NA Y
1 Ql
DNA Pig NA NA
Forskolin194 Rabbit Y NA
Argatroban191 Pig Y NA
Angiopeptin117 Pig NA N
NO donors196 Pig Y Y
Urokinase170 In vitro Y NA
Prostacyclin analogues19' In vitro Y NA
PEG-Hirudin197 In vitro Y NA
Activated Protein C198 Rabbit Y NA
VEGF plasmid199 Rabbit NA Y
ST638 (tyr. Kinase Pig NA Y
inhibitor)200
Paclitaxel117 Rat NA Y
201; 202 Rabbit NA Y
Pig NA Y
QP-2203 Rabbit NA NA
Sirolimus204 Pig NA Y
Gllb/IIIa blockers205'- 206 Rabbit Y NA
Dog Y NA




Strecker et alm) used stents coated in a biodegradable polymer membrane containing
dexamethasone in a canine model of restenosis. With small numbers they were able to show
reduced rates of restenosis at follow-up. 4 out of 14 dogs developed in-stent thrombosis.
Similar work in pigs191 showed a marked inflammatory response with the polymer coating
used to deliver dexamethasone. No beneficial effect was seen on intimal hyperplasia in the
treated group, despite high levels of the drug locally.
Methylprednisolone-eluting, polymer-coated stents were implanted in pigs and a reduced
amount of stenosis recorded. 96% of the drug had eluted from the stent within 24 hours192.
1.6.4.2 Sirolimus (Rapamycin)
Rapamycin, a macrocyclic lactone antibiotic, has shown immunosuppressive properties in
animal studies, acting via inhibition of cell cycle-dependent kinases64. It has shown a
reduction in intimal hyperplasia when delivered using a stent implanted in porcine
204
coronanes .
1.6.4.3 Trapidil, valsartan, ibuprofen, methylprednisolone
Fluorinated polymethacrylate polymer coated stents (PFM-P75) were used in a series of
porcine coronary experiments. All four of the above agents were impregnated into the
polymer prior to it being spraycoated onto the stent207. Ibuprofen, trapidil and valsartan had
no beneficial effect. Methylprednisolone did produce reduced neointimal hyperplasia, at the
highest dose used.
1.6.4.4 DNA
Stents coated with a biodegradable volatile polymer emulsion mixed with DNA for a marker
protein, have been implanted into porcine coronaries. A transfection rate of ~\% was seen193.
DNA oligonucleotides have also been loaded onto PC-coated stents in vitro208.
39
1.6.4.5 Forskolin
Forskolin is an adenylate cyclase activator with vasodilatory and anti-platelet effects. In
rabbit carotids194, this drug was delivered using a novel, removable stent. This showed that
the drug could be applied in high concentrations to the tissues adjacent to the stent, with
biological effects measured by increases in bloodflow through the stented vessels. Prolonged
time before the onset of cyclical flow variability was seen, suggesting less intraluminal
thrombus formation194. The effects on restenosis were not assessed. 95% of the drug had
eluted within 24hrs. The influence of the thermoplastic stent itself, requiring to be heated to
55°C, was not discussed.
1.6.4.6 Tyrosine Kinase inhibitors
Growth factors tend to exert their proliferative effects via tyrosine kinase receptors. ST638
causes blockade of these receptors and PLLA polymer stents coated with ST 638 have been
implanted into porcine coronaries. Reduced intimal proliferation was seen at three weeks
post-procedure200.
1.6.4.7 Paclitaxel
Paclitaxel is a diterpenoid compound, which polymerises the tubulin components of a cell's
microtubules into defective structures. Without normal microtubule function, cells cannot
divide or migrate. Paclitaxel has been shown to inhibit smooth muscle cell proliferation and
migration in vitro and in vivo after angioplasty in the rat209. Locally delivered paclitaxel in
the rabbit carotid artery angioplasty model resulted in reduced neointima formation"10.
Heldman et al placed paclitaxel-eluting stents in minipigs. Stents with 90pg paclitaxel
resulted in significant reduction in the angiographic lumen loss index and histological
neointima area after four weeks211.
1.6.4.8 QP-2
QP-2, an alternative microtubular inhibitor, has also been delivered via a polymer sleeve




This directly-acting, antithrombin drug was loaded onto polymer-coated stents in the porcine
coronary model and an inhibition of platelet deposition was seen1 5. This was a fairly short
study and so no data are available as to any effect on the restenotic process. It has been used
in humans both as an adjunct for thrombolysis and as an alternative to heparin during stent
placement in patients with thrombocytopaenia.
1.6.4.10 NO donors
Nitric Oxide (NO), which naturally is a product of the intact endothelium, is known to
inhibit, in vitro, the growth of vascular smooth muscle cells212. The delivery of exogenous
nitric oxide to the area of artery at risk of developing intimal hyperplasia might well be
beneficial. This has been achieved by modifying bovine albumin to carry covalently bound
S-NO groups. This polynitrosated albumin has been applied to angioplasty-damaged rabbit
arteries both alone, or loaded onto stents. The stents coated with this compound showed
antithrombotic effects, above and beyond that attributable to the albumin alone213.




Heparin-coated stents have been developed that show reduced incidence of thrombosis, but
not restenosis, in animals189. Use of the low molecular weight heparin reviparin delivered
using the Dispatch catheter has not shown effectiveness in rabbits116.
1.6.4.12 Glycoprotein Ilb/IIIa receptor antagonists.
In the rabbit iliac artery, stent delivery of an abciximab analogue led to a reduction in
thrombosis205. An analogue of tirofiban, L-703081, has been tested in a canine model. When




Activated Protein C loaded stents198 reduced fibrinogen deposition by 96% and flow was
increased tenfold compared to controls. Urokinase, a thrombolytic agent, has been absorbed
successfully to stents214. PEG-hirudin and prostaglandin analogues have both demonstrated
an antithrombotic effect in vitro when bound to polylactic acid coated stents197.
1.6.5 Clinical trials of drug-eluting stents
1.6.5.1 Clinical trials of anti-thrombotic stents.
1.6.5.1.1 Heparin.
Whilst heparin-coated stents have been used in large clinical trials, heparin delivery was not
itself under study in a randomised fashion. A heparin-bound polymer coated stent was used
clinically in the BENESTENT II7. Although this study was not a randomised control trial,
the results using this stent were at least as favourable as historical comparisons.
1.6.5.1.2 GHb/IIIa antagonists.
Abciximab-coated stents have been used in a small group of patients (Dr G. Roubin,
personal communication). The GRII stent was used to deliver abciximab, without
complications. This stent was withdrawn from the market because of high restenosis rates in
patients receiving the uncoated, drug-free stent. No clinical trial has been done with an
alternative stent for an abciximab-eluting stent, or indeed with any other Gllb/IIIa antagonist.
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Drug Study name Trial Comments Results
Immunosuppressant antibiotics
Sirolimus FIM Reg.
Ravel 2 year results 97.5% vs 86% EFS
Sirius RPB TVF 21% vs. 8.6%
E-Sirius RPB 9 month, allows direct
stenting
92% vs. 77% EFS
C-Sirius RPB High risk lesions 9
month results
18% vs. 4% MACE
Everolimus Future I 6 month results 9.1% vs. 0%
restenosis
Future II
Vision-E Not yet started
Tacrolimus PRESENT III
ABT578 Endeavor In progress
Actinomycin-D ACTION Trial abandoned high restenosis
Paclitaxel/c erivative
Paclitaxel Aspect R.PB 6 month 4% v 27%
Elutes RPB 12 month 5% v 16%
Taxus I RPB 6 month 11% v0%
restenosis
Taxus II R.P 6 month results 19.5 vs 8.5 MACE
Taxus III ISR trial 30 day benefit








Deliver P 9 month results No benefit
Simple-1 Reg 6 month, small vessels 4.4% restenosis





Dexamethasone STRIDE Reg 6 month 3.3% restenosis
Dexamethasone Emperor
Others
Mycophenolic acid IMPACT RP Six month results No benefit
Heparin BENESTENT -II Reg
Heparin Jostent trial RPB 6 month No benefit.
CD-34 antibody Case reports No adverse events
Batimastat BRILLIANT Reg Trial abandoned Poor restenosis
rates
Abciximab Series No adverse events
Angiopeptin Trial in progress
Oestrogen EASTER Reg 12 month results 90% EFS
Figure 1.7 Drug-eluting stent trials. EVF - Event-free survival MACE - Major
adverse cardiac event. TVF- Target vessel failure RPB - Randomised,
Placebo-controlled, blinded study Reg - Registry ISR In stent restenosis trial
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1.6.5.2 Clinical trials of anti-restenosis stents.
1.6.5.2.1 Sirolimus
The RAVEL (Randomized study with the sirolimus coated BX Velocity balloon-expandable
stent in the treatment of patients with de novo native coronary artery lesions) study
randomised 120 patients to the sirolimus-coated stent and 118 patients to the bare, non-
coated stent.0% restenosis was seen in the sirolimus group vs. a 26% restenosis rate in the
control arm (p<0.0001). No "edge effect" was detected (Morice el al. Presented at the XXIII
Congress of the European Society of Cardiology. Sep 4, 2001). The large-scale SIRIUS
clinical trial was reported in 2002. A 2% rate of angiographic in-stent restenosis was seen,
9E% less than that seen in the control arm.
1.6.5.2.2 Paclitaxel
ASPECT (ASian Paclitaxel-Eluting Stent Clinical Trial). The stent was coated with
paclitaxel using a process which does not involve a polymeric layer, i.e. bare metal. QCA
results at six-month showed a dose-dependent reduction in binary restenosis (4% vs. 12% vs.
27%, p<0.001). (Park S-J et al. Presented at the Transcatheter Cardiovascular Therapeutics
2001 meeting. Sep 12, 2001).
TAXUS-I enrolled 61 patients with de novo lesions <12mm in length and 3.0mm in
diameter. Thirty-one patients were randomised to the NIRx stent, coated with paclitaxel and
thirty to the NIR uncoated stent. At six months the binary restenosis rate was higher in the
control than the paclitaxel treated arms (11% vs. 0% (respectively), p=0.1062) (Grube et al).
A further trial (TAXUS-III) with the same stent in restenosis patients was reported at the
American Heart Association meeting in 2001 (Grube et al) with favourable results at 30 day
follow-up (7%MACE),
The ELUTES (Evaluation of the paclitaxel-eluting stent) trial evaluated the safety and
effectiveness of the Cook Inc. paclitaxel-coated, V-Flex coronary stent to reduce in-stent
restenosis. The study was a dose-finding study and 192 patients with single type A/Bl de
novo lesions less than 15mm long were randomised to receive stents coated with one of four
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doses of the drug or to a placebo stent arm. At 12 months, patients who received the highest
dose of stent-borne paclitaxel experienced a TLR rate of 5%, compared to 16% in the
patients treated with the non-drug-coated stent (Gershlick, A. et al, presented 2002 Paris
Course on Revascularization.)
1.6.5.2.3 QP-2.
Studies with the Quanam drug-delivery stent used QP-2, similar in structure to paclitaxel.
The SCORE trial has been suspended after completing only 275/400 patient randomisations.
The results were presented at TCT 2001 by G.W. Stone. Binary restenosis rate was
significantly lower in the Taxane group (36.9 vs. 6.4%, p<0.001). However, high stent
thrombosis rates 9.4% vs. 0%, including five deaths, caused the early termination of the trial.
1.6.5.2.4 Heparin
The BENESTENT II trial showed apparent benefits of the use of a stent with heparin
covalently bound to it. However this trial did not compare heparin-coated stents with bare
metal stents. Wohrle et a/215 reported a clinical study of 277 patients with 306 stented
lesions. Heparin-coated or bare Jostents were implanted in a blinded fashion. No differences
were seen at six-month follow-up in clinical endpoints, subacute stent thrombosis or
angiographic restenosis between the two groups. Very small doses of heparin, were bound
onto the surface of the stent.
1.6.5.2.5 Dexamethasone
The STRIDE (STudy of anti-Restenosis with the BiodivYsio Dexamethasone Eluting stent)
trial is a small 60 patient registry, rather than a randomised trial. Results reported by de
Scheerder at the ACC in 2002 showed a 3.3% MACE at six months. A larger trial is planned.
1.6.5.2.6 Oestrogen.
Oestradiol may have multiple modes of action in the vasculature. It is known to inhibit SMC
migration and proliferation and promotes re-endothelialistion of vessel wall after injury. It
also inhibits adventitial fibroblast cell migration, a process involved in negative
remodeling-The EASTER (Estrogen And Stents To Eliminate Restenosis) trial is a 90
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patient trial of oestrogen-coated stents in de novo lesions. The primary endpoint is binary
restenosis, secondary endpoint are MACE and IVUS measures of restenosis.
1.6.5.2.7 Batimastat
The MMP inhibitor batimastat has been selected as a stent-delivered agent because it is
active at nanomolar concentrations. The BRILLIANT (Batimastat anti-Restenosis trlaL
utiLizIng the BiodivYsio locAl drug Delivery PC-steNT) study was abandoned in March
2002, because of poor restenosis rates, although these have not been published.
1.6.5.2.8 Actinomycin-D.
Actinomycin-D, an antibiotic with known pro-apoptotic properties was tested as a stent-
delivered agent in the. ACTION trial. This was abandoned in March 2002 due to poor
results, which have not been made public.
1.6.5.2.9 Angiopeptin
A small (50pts) trial of an angiopeptin-eluting trial is planned in Hong Kong. Six month
angiographic and IVUS follow-up will be performed. The primary endpoint is binary
restenosis, secondary endpoint are MACE and IVUS measures of restenosis.
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1.7 Re-endothelialisation.
The concept of re-endothelialisation is central to this thesis. The importance of the
endothelium in the response to injury is discussed above (1.3.3.3.3). At the time of PCI, the
endothelium covering the stenotic area of artery is severely disrupted or even destroyed. In
animal models of stent placement, re-endothelialisation begins to occur in the first two to
seven days post placement. Full endothelialisation can take at least three or four weeks216. It
is thought that a similar or slightly longer time-course occurs in humans, although this has
been difficult to quantify from the rarity of available autopsy specimens from patients post
stent insertion217. Radiation causes endothelial dysfunction even six months after
exposure218. Groups working with radioactive stents have showed either delayed or
Tin- 900 • T71 . . . .
incomplete endothelial regrowth over the stent" ' ~ . Late thrombosis' in patients receiving
brachytherapy is felt to be due to adverse effects of radiation on the re-endothelialisation
process.
Over time endothelium will grow back over the PCI site. When this occurs over a stent, this
has been called "stent passivation". Several approaches have been tried to improve re-
endothelialisation.
1.7.1 Exogenous endothelial cell seeding to promote re-endothelialisation
In a rabbit hindlimb model"22, endothelial cell (EC) suspension was seeded onto an
angioplasty site. Platelet deposition, a marker of endothelial integrity, was significantly
reduced at thirty minutes. This demonstrated the feasibility of introducing ECs onto a
denuded site. In vitro, human umbilical vein endothelial cells (HUVECs) were attached to
stainless steel stents. The ECs continued to grow after stent expansion until a complete
endothelial coating was seen222. In porcine stented arteries, the stents grew an endothelial
coat within six days of implantation, with no evidence of thrombus formation. In a later
refinement of this work, ECs were genetically modified to deliver t-PA"4. Genetically
modified, immortalised ECs have been coated onto a stent. Vascular endothelial growth
factor (VEGF) has been used as the agent produced by genetically-engineered ECs seeded
onto a stent. No report has been made as to the effectiveness of such stents in reducing stent
complications227. Cell seeding has several disadvantages. It requires delicate handling and
would require harvesting and culturing ECs from the patient in advance of the stent
placement. The use of cultured cells raises the possibility of introducing infection e.g. of a
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fungal species into the coronary circulation. It is not clear how these cells could be
adequately sterilised for human use without damaging them. It is unclear to what extent
endothelial cells will remain on a stent in vivo or how long they will remain viable. The
long-term effects of genetically altered cells are unknown, raising concerns that these cells
may not function normally, even if they express the protein that they were modified to
produce. The use of cell seeding is not currently practical in human trials.
1.7.1.1 Cytokines and hormonal manipulation to promote re-endothelialisation.
Rather than directly administering ECs, agents that promote EC growth and recovery have
been tested in models of angioplasty.
1.7.1.1.1 Prostacyclin synthase (PCS).
PCS gene transfer has been performed using a balloon delivery to stented rabbit iliac arteries.
This led to more rapid stent endothelialisation and reduced neointimal area"6. VEGF was
found to be expressed more in the PCS treated arteries, suggesting that this gene treatment
acts through up-regulation of VEGF.
1.7.1.1.2 Hepatocyte Growth Factor (HGF).
HGF is a heterodimeric protein, which also belongs to a group of highly specific endothelial
cell mitogens. As well as promoting endothelial cell growth it promotes angiogenesis and
wound healing. It suppresses apoptosis. Systemic delivery of HGF failed to demonstrate
reduced intimal hyperplasia in a rat carotid artery model of restenosis. However, in the rabbit
iliac model, increased re-endothelialisation and reduced intimal thickness was seen when the
drug was delivered locally with a delivery balloon111.
1.7.1.1.3 TNF-alpha blockade.
Krasinski et al227 have shown that TNFa induces apoptosis in human endothelial cells.
Blockade of TNFa might be expected to favour the growth and recovery of endothelial cells
post-angioplasty. This has been demonstrated in the rat carotid model with systemic
administration of soluble TNF receptor molecules that block TNFa. At one week,
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endothelialisation was improved significantly in the treated group. Intimal hyperplasia was
not studied in this experiment.
1.7.1.1.4 Oestrogen.
Women suffer atheroclerotic narrowing of the coronary arteries at later age than men. This
difference may be related to differences in the effects of oestrogens on the vessel wall.
Oestradiol has been shown to inhibit myointimal hyperplasia and it is suggested that this is
due to its protective effect on endothelial regrowth228. In rats, a dose-dependent increase in
re-endothelialisation was seen with systemic oestradiol administration post-angioplasty229.
1.7.1.1.5 Thrombospondin blockade.
Thrombospondin is a matrix glycoprotein secreted by activated platelets and known to
stimulate vascular SMCs whilst inhibiting endothelial cell growth and migration. An
antibody to this glycoprotein, when delivered locally to the angioplastied rat carotid artery
shows significantly increased re-endothelialisation associated with decreased neointimal
hyperplasia144.
1.7.1.1.6 IRFI042.
This vitamin E-like antioxidant has been given systemically to rats with angioplastied carotid
arteries. Less intimal hyperplasia was seen compared to controls in conjunction with
improved endothelial function97.
1.7.1.1.7 C-type Natriuretic Peptide (CNP)
CNP is known to inhibit smooth muscle cell growth. Work with rabbit jugular vein grafts
dipped in solutions containing adenovirus coding for CNP has shown that this peptide leads





VEGF-C is a member of the VEGF family, which particularly affects the lymphatic system.
However, it has shown beneficial effects on re-endothelialisation when given locally to
balloon angioplastied rabbit aortae231. The resulting reductions in neointima formation were
not statistically significant.
1.7.1.1.9 Vascular Endothelial Growth Factor (VEGF).
The structure and function of this cytokine, which is the focus of this MD thesis, with
particular regard to the effects on re-endothelialisation, will now be reviewed.
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1.8 Vascular Endothelial Growth Factor (VEGF)
VEGF is a protein initially identified as Vascular Permeability Factor232 (VPF) or
Vasculotropin211. It appears to be essential to the growth, maintenance and repair of vascular
structures. Initially, the relevance of this protein to clinical medicine lay in its role in the
progression of cancers. It also appears crucial to our understanding of the repair or
regeneration of blood vessels in ischaemic tissues. It has also been recognised as important
in other clinical diseases.
1.8.1 Structure of VEGF.
VEGF is a heparin-binding, endogenous 46kD homo-dimeric peptide. It is one of a family of
peptides (VEGF-A to E). The VEGF (i.e. VEGF-A) form is by far the most thoroughly
studied. It occurs in five isoforms of 121, 145, 165, 189 and 206 amino acids, which are
formed by alternative splicing. VEGF121 and 165 are diffusible in the extracellular medium,
whilst VEGF 189 and VEGF 206 bind heparin more avidly, and tend to be more tightly
bound to proteoglycans in the extracellular matrix. All the isoforms are preceded by a 26
amino acid residue signal-protein that allows the protein to be secreted from cells. All also
possess an N-terminal glycosylation site and so the protein in vivo is found as a glycoprotein,
although removal of the carbohydrate moiety does not appear to alter its physiological
effects. VEGF is synthesised in smooth muscle cells and macrophages (amongst others). It is
almost exclusively bound by endothelial cells. Importantly however, both key receptors for
VEGF have been detected in human atherosclerotic artery tissue"34. This suggests that VEGF
is not solely active on the endothelial cell and may have effects on other cells within the
vascular wall.
1.8.2 Receptors for VEGF
Three different receptors have been isolated for VEGF:
The fit-1 receptor (VEGFR-1) is a tyrosine kinase trans-membrane receptor. It has high
affinity for VEGF235. The flk-1 (VEGFR-2) receptor is another of the tyrosine kinase
family21'1. It stimulates the Protein Kinase C and Map kinase pathways for protein
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synthesis237. The flt-4 (VEGFR-3) receptor has a similar structure to the other VEGF
receptors. It does not bind VEGF, but does however actively bind VEGF-C and D~ '" .
In addition to these receptor proteins, a subset of co-receptors has been identified that
selectively bind the VEGF-165 isoform240. These are Neuropilin 1 and 2. Neuropilins are
proteins originally identified as being involved in neuronal cell guidance. It is thought that
binding to these receptors modulates the effect of VEGF when bound to the VEGFR-2
receptor. To varying degrees, VEGF binds to heparan-sulphate proteoglycans on the cell
membrane. This is thought to affect its bioavailability. The interactions of these receptors
and their ligands are shown below (fig.1.8)
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Figure 1.8: The VEGF receptor family and their specific ligands. HIV-1/tat is a
protein produced by HIV infection. It may be that this is the mechanism
whereby HIV produces the lesions seen in Kaposi's sarcoma. PIGF is
Placental Growth Factor, see below (1.8.13.6). (adapted from Neufeld et al
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1.8.3 VEGF and nitric oxide (NO).
Adequate endothelial function, via the nitric oxide synthase release of NO (EDRF) is
essential for the action of VEGF242. In mice the effects of VEGF can be abolished where the
animal is deficient in nitric oxide synthase and its effects replicated by dietary augmentation
with L-Arginine, which increases NO synthesis242. NO may act in a negative feedback
system to reduce the production of VEGF241. The actions of VEGF can be abolished by
removing calcium from models of the action of the protein or by adding NO Synthase
inhibitors such as N-monomethyl-L-arginine244. Intimal hyperplasia caused by a silicone
collar around the carotids was attenuated by local VEGF delivery in an NO-dependent
245
manner .
1.8.4 VEGF and thrombosis.
NO and PGI2, which are both produced in endothelial cell cultures by VEGF, inhibit platelet
aggregation. As well as stimulating these factors, VEGF increases the expression and
activation of the serine proteases, urokinase and tissue-type plasminogen activator, which
cleave plasminogen to generate the key thrombolytic enzyme, plasmin246. VEGF is released
by aggregating platelets247 and increased levels of VEGF have been found within clots in
humans. Conversely, VEGF induces von Willebrand factor (vWF) and tissue factor in
endothelial cells. vWF promotes platelet adhesion to subendothelial collagen, whilst tissue
factor expression and activation are essential for the extrinsic pathway of coagulation and
clot formation246. In vivo, reduced clot formation has been seen on stents implanted in rabbit
iliac arteries when washed with VEGF by a channel balloon system67.
1.8.5 Actions of VEGF.
The actions of VEGF are summarised below (fig. 1.9.)
> It is essential for normal embryonic development. It is an integral agent for
vasculogenesis, the development of a normal vasculature during embryonic life.
Deletion of even one allele for VEGF has proven to be uniformly fatal in animal
studies248.
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> It is implicated in the process of angiogenesis. It has mitogenic activity that is
specific for vascular endothelium249.
> It also appears to have a role in the neovascularisation seen in diabetic retinopathy.
Although many growth factors have been identified in patients with this sight-
threatening condition, VEGF is the most closely correlated factor to it2'50.
> It causes an increase in vascular permeability mediated via the VEGFR-1 receptor251
and by increasing Platelet Activating Factor252. It seems likely that its proven effect
of increasing vascular permeability is an integral part of the process of angiogenesis.
As plasma proteins exude into the extracellular matrix, they may form the core
around which migrating endothelial cells develop into new vessels. It is also found in
the permeable membranes of the islets of Langerhans, suggesting a role in the
control of insulin production253.
> It upregulates the expression of receptors for similar growth factors including basic
Fibroblast Growth Factor and for endothelin-1 mRNA254.
> It causes vasodilatation05. This effect is likely to be due to the release of NO/EDRF,
mediated by the VEGFR-2 receptor256.
> Via VEGFR-1241, it is chemoattractant for monocytes257, which when activated to
become macrophages themselves produce VEGF.
> Like other angiogenic growth factors258, it has been linked to haematopoiesis.
VEGFR-2 deficient mice fail to form blood islands, the progenitors of the
haematopoietic system259.
> It modulates the function of endothelial cells, promoting the release of the
endothelial cell products plasminogen and PAI-1260. VEGF upregulates the
expression of endothelin-1 mRNA254.
> It improves endothelial function when the vessels are damaged"61 or in new
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Figure 1.9 Diagram of the main actions of VEGF in vivo.
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1.8.6 Regulation of VEGF.
The release of VEGF from cells is under the influence of a number of humoral, chemical and
physical factors. Cytokines and hormones including IL-6264, IGF-1265, Endothelin-1266, FGF-
4267, TGF-p208, PDGF269 and angiotensin-II have all been shown to up-regulate the
expression of VEGF. bFGF270 and TNFa271 up-regulate not the protein itself, but the
VEGFR-2 protein. Conversely TGFp has been shown to down-regulate VEGFR-1 and 2,
reducing the levels of mRNA for these proteins in a dose-dependent fashion"72.
Chemical conditions, in vitro at least, have shown effects on VEGF production in cardiac
myocytes as well. Hypoxia appears to be of importance in the stimulation of VEGF
production. VEGF is often found in the relatively ischaemic and hypoxic microenvironment
of the interior of a solid tumour. In vitro, hypoxia induces endothelial cells to produce
VEGF273. A transcription promoter for the VEGF gene has been identified that upregulates
VEGF synthesis in response to hypoxia-inducible factor (HIF-1)274. HIF-1 is also responsible
for the upregulation of erythropoietin, emphasising the close functional similarities between
the angiogenic and haematopoietic growth factors.
Other stimulatory factors for VEGF production include phorbol (a stimulator of protein
Kinase C), glucose275, veratridine (a promoter of calcium influx) and the transition metals
27/: # 277 • • ->70 .cobalt and manganese" . Reactive oxygen species" and oxidised-LDL" , which promote
the progression of atherosclerotic plaques, both potentiate the production of VEGF.
Electrical stimulation of skeletal muscle, either directly279, or via chronic motor nerve
stimulation280 both demonstrate increased VEGF production that led to angiogenesis in vivo.
Mechanical stimulation, via cyclical mechanical strain, also produces VEGF281. Such stretch-
induced VEGF release seems likely to be mediated by the release of TGF-(3 and resulting
protein kinase C activation"82.
1.8.7 VEGF in oncology.
For a tumour to grow it requires a rich blood supply and this entails angiogenesis. Tumour
cell lines release VEGF and VEGF over-expression has been identified in almost all human
tumours281. The richness of expression has been linked to the aggressive nature of these
tumours. In the case of both breast and stomach cancers, VEGF-rich tumours had the worst
prognosis284. Attention has been paid to the potential to inhibit the effects of VEGF in
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tumours in an attempt to stop their growth. Selective loss of new blood vessels by apoptosis
is seen in even established tumours following removal of VEGF2 5.
1.8.8 VEGF in re-endothelialisation.
1.8.8.1 Experimental work using VEGF to stimulate re-endothelialisation.
Endogenous VEGF and VEGFR-2 receptors begin to be expressed in increasing amounts
within 48 hours of an angioplasty injury in a minipig model"86. Exogenous VEGF has been
reported to accelerate re-endothelialisation of damaged rat carotid artery129. In this study, a
30-minute infusion of VEGF was given directly into the carotid artery at the site of balloon
denudation of the endothelium. Not only did the group report superior re-endothelialisation
in the treated group of rats, but also that intimal hyperplasia at this site had been attenuated.
Antibodies against VEGF seemed to inhibit this effect on re-endothelialisation243. When vein
grafts were dipped in VEGF prior to implantation in rabbit carotid arteries, EDRF-dependent
relaxation was seen to occur, whereas controls showed no relaxation. This study also found a
decreased incidence of intimal hyperplasia287. As well as a direct effect on local endothelial
cells, VEGF appears to stimulate the activity of circulating endothelial progenitor cells
(EPCs). In the mouse hindlimb ischaemia model, EPCs transfected with the VEGF gene
were adminstered and showed an improvement in neovascularisation"88.
Other groups have not replicated these results, however. Six-hour infusions of VEGF into the
aortic arch of rats with denuded endothelium in the carotid artery or aorta showed no
evidence of endothelial regrowth, nor indeed the presence of any VEGFR-2 receptors in
large vessels289. These include the carotid vessel that Asahara et a/129 had reported as
demonstrating endothelial recovery. These data were replicated in rats given either two or six
week infusions of VEGF. Furthermore, in the porcine restenosis model bolus, delivery of
1 mg of VEGF as a local infusion into the coronary arteries failed to demonstrate any
inhibition of restenosis, raising the possibility that different species had different responses
to the same method of administering VEGF290. In this study the total dose of VEGF given
was small especially in a fairly large animal and was not given for longer than five minutes
and it may be that a more sustained delivery is required. One study has been reported that
suggests a deleterious effect of VEGF administration on the progression of atherosclerotic
lesions (rather than restenotic ones), albeit in grafts rather than native vessels291. Indeed, this
study reported that blockade of the effect of VEGF led to reduced intimal thickening. A
mechanism for this effect is suggested by Zhao et al292 who reported that L-NAME, which
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induces inflammation through NO inhibition, depended for its action on the VEGF-1
receptor. This suggested that VEGF is required for the inflammatory reaction that led to
murine atherosclerosis.
VEGF protein was also used, by Van Belle et al, in a rabbit hind-limb model of endothelial
damage. In this study direct transfer of recombinant VEGF was performed with a channel
balloon catheter. At the same site a metallic stent similar to those used on human coronary
artery disease was implanted, causing endothelial damage. The rate of endothelialisation of
this stent was compared to controls without VEGF administration. A clear increase in the
rate of re-endothelialisation was shown29"1 (see fig. 1.10). In a further study, naked plasmid
DNA coding for VEGF was used in place of VEGF itself and administered locally using a
hydrogel-coated balloon. Stent "passivation" occurred quickly and completely in the rabbits
given VEGF DNA. This effect was associated with a decreased incidence of both intimal
hyperplasia and thrombus formation on the stent". A further study using the same techniques
showed that not only was the endothelial integrity restored, but also that the regenerated
endothelium was functional, at least as far as restoring vasomotor responsiveness and
thromboresistance261.
VEGF plasmid has been delivered bound to the stent and appeared to reduce intimal
hyperplasia, (29+/-18% reduction in intimal thickness (p<0.016)) in a rabbit iliac model)
although this study did not examine the speed with which the stent was covered by the
endothelium199. This group gave the rabbits in both cohorts a low molecular weight heparin
throughout the experiment. As has been discussed elsewhere, these are under investigation
for their own possible effects on reducing intimal hyperplasia.
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Figure 1.10a Micrograph of the surface of a partially endothelialised stent.



























Figure 1.10b Quantification of stent endothelialisation after local delivery of
VEGF or PBS (control). From Van belle et al.
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1.8.9 VEGF and angiogenesis.
VEGF in vitro and in vivo has been shown to have mitogenic effects on the vascular
endothelium. The VEGFR-2 receptor appears to mediate this effect217. As well as direct
effects on the endothelial cell, VEGF promotes the process of angiogenesis indirectly
through the production of matrix metalloproteinases such as interstitial collagenase. In vitro,
VEGF has been shown to stimulate this enzyme's production from HUVECs294. Breakdown
of the interstitial matrix will facilitate angiogenesis. Neovascularisation/angiogenesis is
influenced by the cqp, anda^P, integrins, collagen receptors. Blockade of these receptors by
antibodies has largely abolished the angiogenic effects of VEGF295.
VEGF in normal arteries is not expressed in detectable quantities. In angioplastied vessels, it
is expressed and correlates with the adventitial angiogenesis that causes the growth of vasa
vasorum296. These new vessels may be of importance in the repair of the damaged vessel. It
is also detectable in coronary sinus blood samples from patients with complete coronary
artery occlusions. VEGF levels in patients with severe stenosis are much lower. It is felt that
this may represent the natural angiogenic response to an ischaemic stimulus in the total
occlusion group"97. Similarly, VEGF may have a role in the neovascularisation of
atherosclerotic plaques298. This raises the possibility that VEGF, including exogenously
delivered VEGF, may contribute to an accelerated atherosclerotic process.
VEGF may have a beneficial role in improving the blood supply to ischaemic areas of the
myocardium. VEGF may stimulate the growth into these ischaemic territories of new
collateral vessels. A single intra-arterial bolus of 500-1000pg has been shown to promote
collateral growth and improve ankle-brachial blood pressure in rabbit hindlimb ischaemia299.
The increased number of collaterals was associated with physiological benefits in that
significantly higher bloodflow was seen in rabbits given the VEGF bolus500. These initial
results have been confirmed using a rabbit model, in which severe ischaemia was created by
ligation of the femoral artery and all its branches. After ischaemia had been established in the
hindlimb, VEGF was infused over a 28-day period using an osmotic pump into the iliac
artery101, improving neovascularisation. Gene therapy with VEGF increased collateral
growth and increased blood flow in the rabbit hindlimgbmodel when delivered locally on a
hydrogel balloon302.
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After ameroid constrictor placement to the left circumflex artery (LCx) 2pg VEGF was
administered extraluminally. VEGF animals showed higher bloodflow in the LCx
territory101. Separately, 2mg VEGF was instilled into the left coronary ostium 28 days after
ameroid constrictor placed around LCx. Half of these animals died due to extreme
hypotension. The survivors showed improved perfusion l04. Yorkshire pigs underwent
placement of an ameroid occluder to LCx. Three weeks later the animals were randomised to
with either VEGF (20pg) via an intracoronary delivery system, intracoronary bolus infusion,
epicardial implantation of an osmotic delivery system, or intracoronary saline. Three weeks
later, the animals were tested for myocardial perfusion and ventricular function. All three
VEGF treatment groups, but not the control animals, demonstrated a significant increase in
collaterals and myocardial bloodflow101. Intracoronary VEGF in pigs produced a dose-
dependent increase in coronary blood flow in the absence of significant changes in epicardial
artery diameter106.
In a canine307 models of chronic coronary ischaemia, VEGF showed enhanced collateral
vessel density and blood flow when delivered as a local infusion, although not when
administered systemically"20. VEGF has been implicated in the angiogenic proliferation seen
following transmyocardial laser revascularisation (TMR). The effects of TMR are
augmented by the addition of VEGF in ischaemic pig hearts308. Studies have suggested that
the effect of collateral growth may be most marked when VEGF is co-administered with
309 310 • •••..bFGF both in vitro and in vivo . VEGF has been delivered injecting it directly into
ischaemic muscle. VEGF protein injected daily for ten days in high doses showed a dose-
dependent improvement of collateral growth in the rabbit model1". Intramuscular injections
for the plasmid encoding for VEGF show successful transfection of the DNA into striated
muscle cells. Synthesis of VEGF was demonstrated for up to two weeks following the
procedure despite only 2% of cells having incorporated the plasmid112. Conflicting with these
results is the finding that injection of an entirely unrelated gene into the myocardium of pigs
also shows an upregulation of VEGF expression313. It may not be that gene therapy using
VEGF DNA is occurring but merely that the trauma of injection is itself a stimulus for
VEGF production, undermining the scientific rationale for performing the treatment. Other
workers have tried to replicate the results obtained in the rabbit hindlimb model of ischaemia
and have found that while VEGF plasmid injection did seem to be correlated with increased
angiogenesis, no actual VEGF could be detected in the tissues314. Angiogenesis due to VEGF
has been seen in relation to interventional treatments of restenosis. VEGF expression was
highest in vessels where the vasa vasorum were proliferating following earlier injury in a
porcine model296.
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1.8.10 VEGF in apoptosis.
VEGF inhibits apoptosis by the upregulation of apoptosis inhibitors including survivin315,
Bcl-2 and Al316. In a tumour model of immature blood vessels, removal of VEGF led to
selective apoptosis of endothelial cells forming immature blood vessels. More mature
vessels, with a layer of periendothelial cells did not undergo apoptosis285.
1.8.11 VEGF in other diseases.
VEGF expression has been identified in several human conditions that are characterised by
vascular growth or permeability. Synovial fluid in rheumatoid arthritis, where a highly
vascularised pannus erodes the joint surfaces, contains VEGF317. The lesions associated with
some skin conditions, including psoriasis, pemphigoid and dermatitis herpetiformis, all
express VEGF. Elevated levels of VEGF are found in peritoneal fluid of patients suffering
from endometriosis. Graves' disease, which tends to produce a highly vascular goitre,
stimulates VEGF production28'.
1.8.12 Clinical trials of VEGF.
A small study of plasmid-derived VEGF showed collateral vessel growth and improved
outcome in patients with critical limb ischaemia318. A different group, again in a very small
sample, showed angiographic evidence of improved collateralisation and perfusion scan
evidence of increased tissue perfusion when intra-coronary VEGF was given to patients with
ischaemic myocardium'19.
Preliminary phase II trials of VEGF protein administered by intra-coronary bolus followed
by intravenous infusions have had disappointing results in patients with coronary arterial
disease. No significant angiogenic effect was seen in the vascular endothelial growth factor
in ischemia for vascular angiogenesis (VIVA) trial'20. It has been suggested that the route of
administration, by intra-coronary bolus and subsequent i.v. infusion, meant a poor local
concentration of the drug was achieved. The amounts of drug administered were
significantly less than the doses per kilogram found to be effective in animal models.
It may be that small doses of VEGF are all that can safely be given into the coronary
circulation. When doses of 2mg were given as a bolus into the coronaries of pigs with
experimental ischaemia, half the animals died abruptly of severe hypotension '04.
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A human study used a local delivery of VEGF plasmid into angioplastied arteries. At six
months, no improvement in restenosis was seen130. This study was not in stented patients,
where the benefit of VEGF might be expected to be most noticeable. It also used a local
delivery balloon, which may cause intimal hyperplasia and so obscure any beneficial
response from the drug. An adenovirus vector to deliver VEGF-121 cDNA was administered
by direct intramyocardial injection during surgery in patients with severe coronary artery
disease. This Phase I trial suggested a subjective benefit for the treatment although no
statistically significant improvement in symptoms related to augmented angiogenesis
occurred121. A study using VEGF-165 plasmid delivery into the myocardium of inoperable
coronary disease patients showed objective improvements in perfusion as well as subjective
improvement in anginal symptoms in a small group of non-randomised patients '22. A
randomised, double-blind, placebo-controlled study has been reported, in a small group of
patients using percutaneous delivery to ischaemic myocardium of VEGF plasmid. This study
showed a reduction in anginal class in the VEGF group32'.
The Kuopio Angiogenesis Trial (KAT), a phase II clinical trial involving 103 patients, used
adenovirus gene transfer for VEGF, mainly in stented patients. At six months, no detectable
difference was seen in restenosis rates compared to controls, but there was a significant
improvement in myocardial perfusion'24.
1.8.13 The VEGF family of proteins.
1.8.13.1 VEGF-B
VEGF-B is also known as VEGF-related factor (VRF) and is co-expressed in tissues with
VEGF, especially in heart and skeletal muscle tissue. Structurally similar to VEGF, it forms
both homo-dimers and, with VEGF, hetero-dimers and may control the bioavailability of
VEGF. In contrast to VEGF-A, VEGF-B is expressed constitutively. No response to hypoxia
was seen in vitro'25. VEGF-B deficient mice develop normal cardiovascular systems, but
show atrial conduction abnormalities3"6.
1.8.13.2 VEGF-C
VEGF-C, or VEGF related protein (VRP), has 32% homology with VEGF28''. It binds to the
VEGFR-2 and -3 receptors. The VEGFR-3 receptor is largely restricted to the lymphatic
system'27 and it seems likely that VEGF-C is involved with the development and function of
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the lymphatic system. VEGF-C has been shown to have angiogenic effects in hindlimb
ischaemia models'128. There may not be a physiological function for VEGF-C in adult blood
vessels, but the protein may be useful for therapeutic angiogenesis.
1.8.13.3 VEGF-D
VEGF-D or c-fos-induced growth factor (FIGF) is structurally related to VEGF-C. It shows
mitogenic effects predominantly on fibroblasts and binds to VEGFR-2 and -31"9.
1.8.13.4 VEGF-E/ Orf virus.
Two sequences of DNA have been identified in the orf virus with some homology to VEGF.
This pathogen causes skin lesions in goats and humans characterised by extensive
microvascular proliferation. Members of this family of proteins have also been labelled
VEGF-E. They appear to bind to the VEGFR-2130.
1.8.13.5 Platelet Derived Growth factor (PDGF)
VEGF has striking homology with both PDGF A and B chains. All eight cysteine residues
are conserved suggesting a similar tertiary structure, along with about 15-20% identical
amino acid residues211. PDGF has angiogenic effects on the endothelial cell1'.
1.8.13.6 Placenta Growth Factor (P1GF)
P1GF is a protein with 53% homology to VEGF, isolated from placental tissue. P1GF is also
thought to be an angiogenic growth factor and binds to the VEGFR-1 receptor281. In
choriocarcinoma cells both proteins have been isolated as a P1GF/VEGF heterodimer332.
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1.9 Summary
The scale of the clinical problem posed by restenosis has been made clear. With increasing
numbers of patients undergoing PCI in the UK, this problem will only become more
pressing. Despite the reduction in restenosis derived from the increasing use of stents, the
problem still remains significant. Alternative therapies, including brachytherapy, have not
yet found widespread acceptance and carry their own associated problems. The importance
of understanding the restenotic process at a cellular level has been emphasised. The use of
pharmacological agents that interfere with the restenosis process has been discussed. Many
of these have seemed promising in initial trials only to disappoint in clinical use and the ideal
drug has not yet been identified. Local drug delivery, using a polymer-coated stent as the
delivery vehicle, holds promise as a means of reducing restenosis. This method allows the
use of expensive or systemically toxic agents as it delivers small amounts of an agent at the
site where it is needed most.
In summary, it has been demonstrated that in-stent restenosis is a significant clinical problem
with the potential to be prevented by local delivery of drugs using stents themselves as the
delivery vehicle. VEGF has been selected to test this hypothesis.
1.10 Original hypothesis
VEGF, acting on the endothelial cell, holds may speed the re-endothelialisation of a stent. By
loading it onto a polymer-coated stent, this re-endothelialisation process may reduce the
incidence of stent thrombosis and in-stent restenosis. This has not been tested before.
Chapter 2 deals with the pharmacokinetics of the absorption and release of VEGF from
polymer-coated stents. Chapter 3 examines the effects of VEGF and VEGF-eluting stents on
endothelial cell culture. Chapter 4 deals with the in vivo study of the effects of the VEGF-
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Chapter 2.
Absorption and elution studies of VEGF.
2.1 Background
VEGF was chosen for study since it has been demonstrated to accelerate the re-
endothelialisation process after PCI, when delivered locally. It has not however been
investigated as a stent-based therapy. The experiments detailed in this chapter are concerned
with the study of how VEGF is absorbed into and released from the polymer of the Cook
Supra G stent (West Lafayette, IN 47906). The absorption and elution kinetics in vitro were
studied to ascertain whether this combination of drug and stent was likely to prove useful in
further in vivo work.
2.1.1 Passive absorption
The absorption and release of drugs into the polymer coating of a stent depends on the
property of passive absorption. Passive absorption is the adhesion of peptides or other
molecules to artificial surfaces. This is a non-covalent interaction, i.e. without chemical
change of the agent used. It is a method that has been used to bind proteins onto polymeric or
other surfaces to facilitate drug delivery. This means that the molecules used for absorption
will remain intact during delivery, although some conformational change is possible
depending on how large the size of any pores in the polymer are. It is a very simple
technique to load an object, like a stent, with drug but is limited by the finite volume of the
coating on the stent. Furthermore, it is inevitable that a significant amount of the protein is
washed off very easily from the surface of the stent. Nevertheless, previous work has shown
that appreciable amounts of a protein will remain adherent to the polymer for longer periods
of time, up to many days1.
2.1.2 Experimental design
2.1.2.1 Stent structure
Since absorption and elution curves were dependent on the polymer present, it was decided
to examine the stent/polymer structure more closely using scanning electron microscopy.
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2.1.2.2 Absorption and elution experiments.
Preliminary assessment of the optimum conditions of VEGF loading onto polymer-coated
stents looked at: optimum concentration of VEGF solution; pH of buffer solution used to
dilute VEGF; length of immersion in VEGF. Next, stent sections were absorbed with VEGF
and then were immersed in buffer solution for various lengths of time. This system is
described as "simple" since stents were not actively perfused. Elution occurred by diffusion.
To try and mimic the in vivo situation, a perfusion circuit was built, a modification of
previously published work2. This placed the stents in tubing of internal diameter similar to
the coronary arteries and perfused them with a perfusate containing physiological
concentrations of protein at normal pH and temperatures. Finally, the elution of VEGF from
a polymer-coated stent was determined in an ex vivo model. This was to determine whether
the VEGF-coated stent would release the drug into the tissue or merely into the perfusion
fluid. The tissue, in this case internal mammary artery obtained from patients undergoing a
bypass operation, was stented with the VEGF-eluting stent and perfused for 24 hours.
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2.2 Methods and materials
2.2.1 Characteristics of the Supra G, polymer-coated stent.
This is a hoop and flex design stent (see fig. 2.1) which can easily be divided into hoop and
flex sections. The stent is coated with a 10-20 micron thickness polymer coating of a linear
chain of aromatic hydrocarbons. (Personal Communication Dr A Ragheb, Cook Inc. IN,
USA). The process by which this is bonded to the stent remains a commercial secret. The
volume of polymer on each hoop section is 0.31-0.62mnT or 0.22-0.44mm3 for the two sizes
available (fig.2.2).
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Figure 2.1. Diagram showing hoop and flex design of Supra G stent.
Stent size 4oop Sections Flex Sections
(mm) n Lumenal Total Area n Lumenal Total Area
Area (cm2> (cm2) Area (cm_) (cm2)
4.0x20 5 0.10 0.31 4 0.03 0.1
3.0x20 6 0.07 0.22 5 0.02 0.09
Figure 2.2. Table of areas of sections of Supra G stent. (Personal
communication from Dr Ragheb, Cook Inc.)
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2.2.2 Radiolabelling of VEGF - Iodogen method.
Radiolabelling was chosen as the means to quantify the absorption and subsequent rate of
release of the VEGF. The Iodogen method employs a gentle solid-phase oxidising agent and
is preferable to chloramine-T for proteins sensitive to chemical damage3. A small amount of
labelled agent was mixed with a known quantity of unlabelled agent. This "spiked" solution
was used to determine the amount of radioactivity associated with a known quantity of
unlabelled agent. This allowed the calculation of amounts of drug represented by samples of
a known radioactivity associated with the stents. The radiolabel used was Iodine-125, a
gamma emitting isotope.
VEGF was diluted to lmg/ml in borate-saline buffer (BBS) pH 8.5, ionic strength 0.1. 30
Eppendorf tubes and disposable test tubes were labelled. Iodogen (l,3,4,6-tetrachloro-3a,
6a-DI-phenylglycouril) was dissolved in chloroform to make a concentration of 0. lmg/ml
(e.g. 2mg Iodogen in 20ml chloroform). 0.2ml (20pg Iodogen) was added to ten Eppendorf
tubes. Chloroform was evaporated in a stream of nitrogen, rotating the tubes to leave a film
of residue on the inside of the tube. Tubes were removed onto ice and stored in fridge. A
Sephadex-G PD-10 (Pharmacia) column was equilibrated with PBS. Non-specific binding
was blocked with 0.25% gelatin in PBS. The column was washed through again with PBS
twice.
The iodination procedures were done in a shielded isotope room with the hood fan on. 200pl
of VEGF (i.e. 200pg of VEGF) was aliquotted into an Eppendorf tube on ice. 200pl of
VEGF was added to the reaction tube. The reaction was initiated with 4pl (0.25mCi) of
Nai:;,I and incubated for 20min. The resulting solution was decanted into a new tube and left
for another lOmin for reactive iodine to decay. Labelled protein and free iodine were
separated by running the reaction mixture through the gel column. PBS was added to the
column to produce elution. Eluent drops were collected into the numbered Eppendorf tubes,
the first ten drops into the first two tubes then five to seven drops in the rest.
5pl of each fraction from the numbered Eppendorf tubes was placed, with the pipette tip,
into the corresponding numbered disposable test tube. These were counted in the automated
gamma counter and the five tubes containing the maximum amount of labelled activity
selected for storage/use. Labelled VEGF was stored in lead containers in a 4°C fridge. An
example of the radiolabelling process is shown (fig 2.3).
Later experiments were done with previously labelled VEGF. This allowed the amount of
radiation used to be minimised.
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Radioloabeling with 1125 of VEGF
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Figure 2.3 "Spiking" of VEGF with radiolabelled Iodine. The first peak
represents labelled protein, the second is free Iodine, which is discarded.
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2.2.3 Absorption studies.
2.2.3.1 Absoiption Kinetics of VEGF (Variation with pH of solution).
Three buffer solutions were used:





(For composition of buffers see Appendix)
450pl of each buffer was placed into an Eppendorf. 50pl of 5mg/ml VEGF solution was
added to the Eppendorfs. This gave 500pl at a final concentration of 0.5mg/ml of VEGF in
each buffer solution. To each 500pl was added 5pl of radiolabeled VEGF as a "spike".
Sections of Supra G stents were obtained by cutting them with a scalpel blade at the junction
points where the thick hoop and thinner flex sections intersected {see fig 2.1). This was
partly to conserve limited supplies of stents and also because longer sections of stent had a
tendency to retain large droplets of VEGF solution within the lumen of the stent. Each thick
hoop section was weighed to allow for differences among them in the way they were cut.
Hoop sections (n=6) were placed into Eppendorfs again. To these Eppendorfs 80pl of
VEGF/buffer solution was added. A control was used for each buffer to allow for a
background radiation estimate to be made in the absence of a "spike". 5pl of the remaining
buffer solution were assayed for its radioactivity. This allowed for a correlation to be made
between the counts recorded and the amount of VEGF these represented. Each 5pl contained
2.5|ig of unlabelled VEGF. All samples were left at room temperature for two hours to allow
the VEGF to passively absorb onto the stents. After two hours, each stent section was
removed from the radiolabelled solutions and washed in PBS and then placed in a test tube.
All 24 test tubes (including controls) were measured in a gamma counter on two occasions.
The counts were adjusted to account for the small differences in the weights of the hoops (A
typical 3 x 20mm stent as used in clinical practice weighs about 55mg). An average of all the
values for each buffer solution was obtained.
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2.2.3.2 Absorption Kinetics of VEGF (Variation with concentration).
Concentrations of VEGF were made up in PBS (pH7.4) to give final concentrations of
0.5mg/ml, lmg/ml and 2mg/ml. These doses were chosen because previous published work
with absorbed proteins (e.g. urokinase and abciximab) into similar polymers had showed
maximal absorption at a concentration of lmg/ml1'4, (MD thesis of Dr. Rajesh Aggarwal).
Each 300ul of diluted VEGF was "spiked" as before with 10pl of radiolabeled VEGF. Nine
hoop sections were placed into Eppendorfs. To these Eppendorfs lOOpl of VEGF/buffer
solution was added to produce three samples for each VEGF concentration. A control was
used for each concentration to allow for a background radiation estimate to be made in the
absence of a "spike". Two 5pl aliquots of the remaining VEGF solution at each
concentration were assayed for their radioactivity. Stent hoops were removed from the
radiolabeled solutions and washed in PBS and then placed in test tubes. These were
measured in a gamma counter on two occasions. A second hoop was placed into the same
"spiked" solution of VEGF for each time point and concentration in each Eppendorf. The
counts were adjusted to account for the weights of the hoops and an average of all the
corrected values for each concentration/time point was obtained.
2.2.3.3 Absorption kinetics of VEGF (Variation with Time).
The radio-iodinated protein was diluted to 2mg/ml in PBS buffer, pH 7.4, maintained at
room temperature. Polymer-coated stent hoops of known weight were immersed in each
solution for 72, 48, 24 & 2 hours (n=3). All stent segments were then removed and counted
in a gamma well counter to quantify protein absorption. The readings were adjusted for
background and weight of stent sections to give a final reading of micrograms of VEGF per
stent.
2.2.4 Elution studies.
2.2.4.1 Simple elution of VEGF.
Four stent hoops of known weight were immersed in 2mg/ml VEGF solution in PBS for 24
hours at room temperature. The hoops were removed, excess VEGF solution shaken off and
surface VEGF solution removed by running the hoop section over filter paper until dry. The
hoops were counted in the gamma counter twice as before to give a baseline reading. The
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hoops were immersed in PBS, 2ml per hoop each. After 5 and 15 minutes and 1, 2, 24, 48,
72, 96, 120 and 192 hours, the hoops were removed from the solution, excess solution
shaken off and counted twice in the gamma counter. The readings were adjusted for
background and for the weight of the hoops.
2.2.4.2 Elution of VEGF in a perfusion circuit.
Stent hoops were immersed in 2mg/ml solutions of radiolabelled VEGF for 24 or 48 hours.
Hoops were rinsed with 5ml of PBS and gamma-counted. The hoops (n=3, with each
absorption time) were then perfused continuously at 20ml/min in a closed loop circuit (fig.
2.4) with PBS containing 4% bovine serum albumin. Pairs of stent hoops were placed into
circuits in polypropylene tubes with a total volume of perfusing solution in the circuit of
100ml. Circuits were maintained at 37°C by immersing the reservoirs containing PBS/BSA
in a water bath (Grant Instruments). Three separate circuits were set up for a total of six
hoops. The PBS was pumped through the circuit using a peristaltic pump (Watson-Marlow
302S, Falmouth, U.K.). Sterile silicone tubing (3mm bore, Fisons, Loughborough, U.K.) was
used to carry the perfusate to the stent hoops. After 5 and 15 minutes, and 1, 3, 8, and 24
hours all hoops were removed from the perfusion circuit and counted twice in a gamma well
counter to quantify the amount of VEGF remaining bound to each, and then returned to the
perfusion circuit. This was repeated for nine days. On each day the standards containing a
known amount of VEGF were also counted so that all the results could be adjusted to
account for radioactive decay of the Iodine label.
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Water Bath Peristaltic Pump Stent Y-Connector
Figure 2.4. Schematic of perfusion circuit used in elution experiments.
Figure 2.5. Scanning electron microscopy at 15kV of Supra G structure
cross section. Note variability in polymer thickness and large gap.
2.2.4.3 Ex vivo assessment of VEGF-elution in perfusion circuit.
Sections of polymer-coated stents were immersed in "spiked" 2mg/ml VEGF solution. These
were then left for 24-72 hours to absorb VEGF passively. Sections of stent were then air-
dried and gamma-counted. Sections of stent were then mounted onto an angioplasty balloon
catheter (Cook). Separately, sections of internal mammary artery were obtained, with verbal
prior consent, from patients undergoing coronary bypass grafting. The samples were the free
ends of the dissected artery, which is normally discarded as waste. These arterial sections
were typically l-2cm in length and 2-3mm in internal diameter. Internal size was estimated
visually. Samples were transported in DMEM and excess adventitia or adherent clots were
removed carefully. All clips used during the operation to seal side-branches of the vessel
were removed. Each arterial section was cut to a length equal to the stent segments. Using a
(Cook) angioplasty catheter, a single inflation to eight atmospheres for one minute was
performed in the tissue. This tissue then had the radiolabeled VEGF-soaked stent deployed
within it, inside a length of polypropylene tubing of appropriate internal diameter. The stent
was thus apposed to the tissue of the vessel wall. The short length of tubing, containing a
stented piece of vessel, was then placed in the perfusion circuit for 24hr. Sections were
removed and the tissue dissected free of the stent section. The tissue and the stent section
were then counted in the gamma-counter. Controls for background, and samples of known
VEGF content from the initial solution were also counted. Finally, 1ml aliquots of the
residual PBS/BSA solution were counted to assess how much VEGF had been washed off
into the total circulating volume. Proportions of radioactivity remaining in stent and vessel
were then calculated relative to the initial radioactivity on the stent.
2.2.4.4 Data analysis
Absorption data were summarised as means ± standard deviation. Significance was
established using Student's t-test. Elution kinetics were ascertained by nonlinear regression
(curve fitting) using a computerised scientific data analysis package (Prism, GraphPad
Software Inc., CA, USA). R2 values were determined for each fitted curve to assess the
overall goodness-of-fit and analysis of residuals performed to assess whether observed data
were consistent with the chosen regression equation. A p value of >0.05 for analysis of
residuals was considered to be consistent with non-significant deviation from the model.
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2.3 Results
2.3.1 Results of passive absorption of VEGF to polymer-coated stent sections.
2.3.1.1 pH studies.
No significant differences in the absorption rates of VEGF were seen amongst the three pH
conditions used (see fig. 2.6). Further work was all done on VEGF diluted with PBS. No
clear advantage to using this buffer was demonstrated over the others. It was used largely as
it has the same pH as blood and might therefore be less likely to denature or damage the
VEGF protein.
2.3.1.2 Concentration of VEGF.
This experiment established that an increase in the concentration did result in an increased
absorption of the drug. Higher concentrations of drug were not used in order to reduce
wastage. 2mg/ml was used in further experiments (seefig. 2.7).
2.3.1.3 Absorption of VEGF with variation of time of immersion.
Increasing the length of time that the stent sections were immersed in VEGF solution
showed an initial rapid rise in the amount of VEGF absorbed. After two hours, however, no
further significant immobilisation of protein to the stents was seen. Further work was done
with at least two hours of immersion time. A maximum of 21,7± 1.1 pg of VEGF was
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Figure 2. 8- VEGF absorption after differing immersion times.
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2.3.2 Results of VEGF elution experiments
2.3.2.1 Simple elution
This experiment showed that VEGF absorbed onto the Supra G stent was initially released
very quickly, with a second, slower elution phase (fig. 2.9).
2.3.2.2 Elution in the perfusion circuit
The results obtained in this experiment were very similar to those obtained in the simple
elution experiment. Again, an initial rapid decay was seen with an overall bi-exponential
decay. At five and nine days, 28% and 20% respectively of the initial dose still remained on
the stent sections (fig. 2.10 &2.11).
2.3.2.3 Elution in the internal mammary artery.
The results of this experiment are shown below (fig. 2.12). At 24 hours, 11±6.8% of the
initial VEGF loaded onto the stents was seen in the tissue. 12.3± 1.7% remained on the stents.
A large proportion of the initial VEGF-associated radioactivity was not detected in the stent,
the tissue or the perfusate. This was assumed to have become adherent to the plastic tubing
of the circuit or to small losses incurred when the stent or tissues were manipulated. The
length of the tubing was such that the relatively small amounts of radioactivity involved
would be very thinly dispersed.
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Figure 2.10. VEGF elution in perfusion circuit 1. These stents had been
dipped for 48 hours. R2=0.99. Analysis of residuals p= 0.11, not significant5.
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Figure 2.11. VEGF elution in perfusion circuit 2. These stents had been
dipped for 24 hours. Line fitted to bi-exponential curve, R2 =0.98, but p<0.05
for analysis of residuals.
Location % of initial value (mean) Standard deviation (%)
Stent section 12.3 1.7
Tissue specimen 11.0 6.8
"systemic" delivery 76.7 2.9
Figure 2.12. VEGF release in arterial tissue. Distribution of VEGF after 24
hours perfusion (initial loading 7.9+/-2.54mcgs of VEGF on a half-length,
i.e. 10mm, stent). "Systemic" delivery was the remaining VEGF deposited in
the glassware, tubing or in the perfusate5.
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2.4 Discussion
The radiolabelling experiments showed that about 20jUg of VEGF could be absorbed per
stent. This is within the same range that had been delivered with beneficial effects in similar
experiments. It did so in a manner independent of pH but influenced by both the initial
concentration of the solution and, to a lesser extent, the length of time that the polymer was
exposed to the solution. Absorption of VEGF was shown to reach a plateau over time, with a
lower absorption within the first 20min. This suggested that the drug was actually being
incorporated into the structure of the polymer (absorption), a process that would take some
time, rather than merely coating the exterior surface of the polymer (adsorption), which
would be expected to occur as soon as the stent section was immersed in the drug solution. A
large excess of protein was present in all the solutions compared to the small quantities
absorbed on the stent. However, at the lower concentration of VEGF solution a reduced
absorption of the protein was seen, despite long immersion times. This suggests that the
protein competes to be absorbed onto the stent with surrounding molecules, i.e. the
constituents of the buffer solution. Around 10% of the released protein was present in arterial
tissue, in an ex vivo circuit.
More importantly, the radiolabelling experiments showed that although a large quantity of
VEGF was eluted from the stent surface very quickly after it was placed in the perfusion
circuit, a more sustained release was also seen for more than a week. In a simple perfusion
circuit, retention of drug within the vessel was significantly higher than that seen commonly
after local drug delivery balloon use. The elution kinetics of VEGF from polymer-coated
stent sections were biphasic as evidenced by the R2 values (all >0.98) obtained by non-linear
regression to fit a two-phase exponential decay model. This pattern of elution may be
explained by an initial high rate of loss of VEGF from the stent, due to VEGF that was only
very superficially adsorbed to the surface of the polymer. The slower release of VEGF seen
over the later part of the curve would then be explained by a gradual release of VEGF that
had been fully absorbed within the polymer hydration space. The retention 19.7% of the
initial dose of the drug after nine days perfusion was an encouraging finding since re-
endothelialisation begins within this time frame. The release of protein was similar to results
seen in previous work1'2 with agents that then showed physiological benefit when tested in
vivo. It also favoured the concept of the stent as a local delivery device over local instillation
of solutions by balloon. These latter tend to deliver very small quantities of active drug to the
targeted tissue relative to the total amount infused, typically around 1%.
106
2.5 Study limitations
Great variability was seen in the total amount of VEGF that was shown to be absorbed in the
different experiments. Despite replicating the same absorption conditions, very variable
amounts of VEGF were detected in the gamma counter. These differences can be attributed
to relatively small amounts of VEGF-containing fluid adherent to the polymer surface. These
are difficult to remove, partly because the stent sections are complex three-dimensional
structures that hold droplets in the interstices of the structure. Various techniques were tried
to overcome this variability. Initially, stent sections were counted after having been merely
agitated to lose any residual droplets of VEGF solution. A second method was to rinse the
stent section after their absorption period in plain buffer. However, this resulted in dramatic
falls in the counted protein and it was felt that this step was really part of the elution process
and therefore did not accurately reflect the amount of VEGF absorbed. It also failed to
produce results with little variability. The final method settled on was to agitate the stents
and then to remove any residual droplets by rolling the wet hoops on filter paper. This
method produced reasonable reproducibility within each experiment.
Another explanation for the great variability in the amount of VEGF absorbed to any one
stent lies in the structure of the polymer coating itself. As can be seen from the electron
micrograph (fig. 2.5) of cross sections of the stent, large variability is seen in the thickness of
the polymer coating. Furthermore, gaps appear to be present between the metal of the stent
and the polymer coat. It is possible that these abnormalities are artefactual, occurring as a
result of a tangential cut through the stent strut, or as a result of the EM processing.
However, the findings are constant in several cross sections. These gaps will retain variable
quantities of dissolved drug above that absorbed into the substance of the polymer. The
release of drug from these gaps may be different from the release kinetics of the polymer.
Some assumptions have been made in conducting these experiments. It was assumed that
radiolabelled VEGF would absorb to, and elute from, a coated stent in the same way as
unlabelled VEGF. The size of the protein is, however, considerably larger than the added
iodine group and the process has been well established as a marker of proteins. Only three
concentrations of VEGF were tested and a plateau of VEGF absorption was not
demonstrated. It might be postulated that higher still concentrations of VEGF would result in
even higher absorption. Limited quantities of VEGF proved a practical constraint on
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exploring this possibility. Furthermore, higher concentrations of protein would tend to form
protein aggregates that would not behave in a comparable method to the isolated protein.
The favourable in vitro elution kinetics of the protein evaluated may be significantly
different in vivo when perfused by blood in physiological conditions, particularly given the
presence of plasma proteins and proteases. This limitation was overcome in part by using a
pH7.4 buffer containing 4% serum albumin to mimic the presence of plasma proteins.
Attempts to reproduce the cellular milieu into which stents are placed were made in the final
part of the experiment using IMA tissue. Plasma proteins in vivo would be absorbed onto any
artificial surface in the circulation potentially displacing any drugs already absorbed to that
surface6. Perfusion of the stent sections with blood would have some additional advantages,
most notably the potential to allow cellular and protein interactions with the immobilised
proteins. However, this option was impractical for the prolonged perfusion periods used in
the study. The ex vivo viability of cellular blood components is limited and unlikely to reflect
the in vivo situation. Some reassurance that the in vitro results may well be reproduced in
vivo can be found in the finding that the results seen in the simple elution experiment are not
altered by the introduction of the slightly more realistic conditions in the perfusion circuit.
108
Chapter 2 references
1 Aggarwal RK, Ireland DC, Azrin MA et al. Antithrombotic potential of polymer-coated stents
eluting platelet glycoprotein Ilb/IIIa receptor antibody. Circulation 1996:94:3311-
3317."
2 Foo R, Gershlick AH. Hogrefe K et al. Inhibition of platelet thrombosis using an activated
protein C loaded stent: in vitro and in vivo results. Thrombosis & Haemostasis
2000:83:496-502.
3 Woltanski KP, Besch W, Keilacker H et al. Radioiodination of peptide hormones and
immunoglobulin preparations: comparison of the chloramine T and iodogen method.
Experimental <& Clinical Endocrinology 1990;95:39-46.
4 Baron JH, Aggarwal RK, de Bono DP. Adsorption and elution of c7e3 Fab from polymer-
coated stents in vitro. Heart 1999;503-P2902(Abstract)
5 Swanson N, Hogrefe K. Javed Q, Gershlick AH. In vitro evaluation of Vascular Endothelial
Growth Factor (VEGF) eluting stents. International Journal of Cardiology 2003;In
Press:




VEGF-eluting stents - assessment in cell cultures.
3.1 Introduction
The experiments described in the previous chapter deal with the physical properties of VEGF-
eluting stents and demonstrated that it was technically possible to use polymer-coated stents
to absorb and then gradually elute VEGF. The following experiments were designed to
demonstrate whether or not the VEGF eluted from the stents was sufficient to significantly
affect the target cells, i.e. the endothelium. The tissue culture work done was performed on
two endothelial cell types, Bovine Aortic Endothelial Cells (BAECs) and Human Umbilical
Vein Endothelial Cells (HUVECs). BAECs are a cell type known to express VEGF
receptors'. BAECs are known to possess receptors for VEGF and stimulated growth of such
cells has been shown under the influence of VEGF1'2. However, such growth is less than that
seen with other cell types. HUVECs were used in further experiments to demonstrate the
efficacy of eluted VEGF in human, rather than bovine, tissue.
3.1.1 Experimental design
To establish that the cells used were endothelial cells rather than fibroblast overgrowths or
other cell types, they were stained for von Willebrand Factor using immunofluorescence
techniques. All endothelial cells express von Willebrand's Factor, which binds to the platelet
glycoprotein lb receptor on platelets, regulating the adherence of the platelets to the
endothelium. vWF is not expressed on any other cell types.
The growth of endothelial cells was determined in order to show the stimulatory effects of
VEGF either as an additive to the growth medium, or eluting from the polymer coated stent.
This was to demonstrate that the VEGF that had been obtained from Genentech was
physiologically active in endothelial cells. It also was to demonstrate that the principle of a
VEGF-eluting stent was capable of delivering a concentration of VEGF to nearby cells that
was sufficient to stimulate their growth.
As part of the varying of the conditions under which the experiment was performed, some
BAECs were grown under low serum conditions. This was initially done to minimise the
effects of any growth factors active within the growth medium so the effects of VEGF would
not be obscured..
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VEGF was then added to cell cultures using the polymer-coated stents as a vehicle. Cell
growth was determined using the PMS/MTS assay and cell counting with radiolabelled
thymidine.
3.1.1.1 Background to the PMS/MTS assay
MTS (3H,4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-
tetrazolium), or Owen's reagent, is bioreduced in the mitochondria of viable cells into a
formazan product that, when dissolved in culture medium, can be measured colorimetrically
at a wavelength of 490nm. This has been validated elsewhere1. The quantity of formazan
produced is directly proportional to the number of viable cells in each well. The stability of
MTS is enhanced in solution by the addition of the electron-coupling agent phenazine
methosulphate (PMS).
3.1.1.2 Background to thymidine labelling as a measure of cell growth.
Thymidine, one of the four bases essential for DNA synthesis, is incorporated into DNA as
cells undergo mitosis. Labelled thymidine can be a marker for cell growth. In a rapidly
dividing population of cells, such as the endothelial cells under study in vitro in this series of
experiments, thymidine incorporation will approximate to total cell numbers as all the cells
will undergo mitosis during the course of twenty four hours. Thymidine is typically labelled
with tritium in place of a normal hydrogen atom. This is a beta-emitting isotope that can
readily be detected in the laboratory.
3.1.1.3 Functional assay for the VEGF-eluting stent.
VEGF is known to stimulate the production of NO from cells at nanomolar concentrations. In
previous cell culture work this has been demonstrated, with maximal NO production
following exposure to NO after eight minutes4. Detection of Nitric Oxide production by
endothelial cells can be effected by the use of the Griess Reaction. This is a colorimetric assay
method where a azo-derivative is produced by the reaction of diazonium ions with N-(l-
naphthyl) ehtylendiamine. The diazonium ion is formed when acidified N02 ions react with
sulfanilic acid. To examine whether VEGF maintained these functional effects after delivery
using the VEGF-eluting stent, a further experiment was performed using HUVEC cell culture.
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3.2 Methods and materials.
3.2.1 Obtaining cells
BAECs were cultured from aortae of cows, freshly slaughtered at the local abattoir. Cells
were kept in liquid nitrogen until required. At this time they were thawed out and then grown
in sterile flasks to obtain enough cells for experimental use. Cells were divided when they
reached confluence using trypsin. These methods are set out in Appendix 2. HUVECs were
obtained from fresh human umbilical cords (Appendix 2). They were used directly, rather
than being frozen.
3.2.2 Positive staining for endothelial cells with vWF antibody.
Endothelial cells at a concentration of 2.5 x 104 cells/ml were plated out into eight well
chamber slides (Life Technologies Ltd.), 400|al in each well, i.e. 104cells per well. Cells were
left overnight in an incubator. Cells were washed three times with HBBS containing 1% BSA.
Wells were then incubated with 200pl of 2% paraformaldehyde in PBS and incubated at 4°C
for 16 hours, to fix the cells. The wells were washed three times with PBS/ 2%FCS/ 0.1%
saponin.
3.2.2.1 Primary antibody
A mouse monoclonal antibody was used. A 1:500 dilution in PBS/saponin/FCS was used,
because this proved to be the optimal concentration in previous titration experiments, and
1 OOjliI of this was added to the wells. Control wells had no primary antibody. Wells were left
on a rocker for half an hour to allow labelling of the antigen. The antibody solution was
washed off with a further three cycles of PBS/ 2%FCS/ 0.1% saponin. Saponin is a detergent
that permeates the cell membrane, allowing access to the nucleus.
3.2.2.2 Secondary antibody and nuclear stain.
The secondary antibody used was a Fi'l C (Fluorescein isothiocyanate) labelled rabbit anti-
mouse antibody. DNA in cell nuclei was stained with the fluorescent fluorochrome Hoescht
33258 stain at low concentration (lOOnmol). This nuclear stain allowed all cells to be
identified. Solutions of Hoescht and secondary antibody were made up in PBS/ 2%FCS/ 0.1%
112
saponin and 300pl added to the wells. Again they were left for half an hour during which they
were gently agitated to allow labelling to take place. After half an hour, slides were washed
with PBS/ 2%FCS/ 0.1 % saponin three times to remove the secondary antibody. The
chambers were removed carefully and the slides had coverslips fitted with an anti-fade
fluorescent mounting agent (DAKO). This was to reduce quenching of the fluorochrome.
Slides were left overnight in the fridge to allow the mountant to dry.
3.2.2.3 Imaging
Slides were visualised using oil immersion on a fluorescent microscope (Zeiss) fitted with a
digital video camera (Hamamatsu Photonics). This was connected to a computer with
"Motion Picture" software (ATM Ltd). Images were taken using separate filters for the
Hoechst and the FITC stains. These images were recorded separately for both positive and
control slides. The recorded images were then superimposed and processed using Adobe
Photoshop software. False colour was used.
3.2.3 Replication of ECs
Cells were seeded at an initial concentration of 106 cells per 75cm'1 flask and grown in
DMEM with 20% FCS. Flasks were observed daily until the cells appeared to be nearing
confluence (at which time normal growth might be expected to slow due to contact
inhibition). The cells were then trypsinised as before and then counted with the
haemocytometer. 106 cells per 75cm1 flask were then seeded once more and the cell numbers
counted again. Numbers of cell doublings were calculated using the formula Nc/Ns = 2x
where Nsis the number of cells seeded, Ncis the number of cells counted after tryspinisation
and x is the number of population doublings.
3.2.3.1 Cell counting - the PMS/MTS EC proliferation assay
Endothelial cells were cultured in a 96-well plate with 0.1ml of DMEM+20% FCS culture
medium at 37°C in an incubator under sterile conditions for 1 hour. 20pl of "One solution"
was then added to each well, taking care not to produce any bubbles. A final well containing
only culture medium and "One Solution" was used as a control or blank. The plate was
incubated for a further hour before being read twice in a spectrophotometer (Titertek
Multiskan Plus (ICN) Mkl 1). Any reading from a well containing a bubble gave a very high
absorbance and so any well with a visible bubble was eliminated from the analysis.
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3.2.4 Replication of ECs with VEGF
3.2.4.1 BAEC growth curves in six well plates.
ECs were grown until they reached confluence in a culture flask. The cells were then
trypsinised and re-suspended in fresh DMEM culture medium. The cells were well mixed and
then counted twice using an automated cell counter (Coulter 4C Plus 51). 100ml of culture
medium containing VEGF at lng/ml were prepared under sterile conditions. This
concentration was used as it was three times higher than the dose required to half maximally
stimulate foetal BAECs in previously published work5. To 50ml of this solution were added a
small quantity of the endothelial cell stock, with a final concentration of 1 x 104 cells/ml and
lng/ml VEGF.
An identical quantity of medium containing cells (1 x 104 cells/ml) was prepared. Sterile six
well plates were seeded with 3ml of cell-containing culture medium. Two plates were seeded
with medium containing VEGF and two without. At the same time every day after the cells
were seeded, one well from each plate was trypsinised by adding 1ml of warmed trypsin for
three minutes. The suspended cells were spun down to a pellet and re-suspended in 2ml of
fresh medium. These samples were counted in the cell counter and the results recorded. The
PMS/MTS assay and direct observation of cell numbers with a haemocytometer slide under a
light microscope were also used to quantify cell proliferation.
The results of the initial growth experiment proved difficult to replicate, due to fungal
contamination in the cell culture wells. This recurred despite using freshly made medium and
trypsin solutions. The high risk of contamination was felt to be a consequence of the
equipment used in the experiment. The plates used to grow the cells were not sealed with an
air filter. Furthermore, they were opened many times as each well in a plate was processed on
a different day.
Further experiments were done with a modified protocol. The main change was to use small
(25cm3) culture flasks with an air filter. Each day of the experiment led to the use of its own
specific flasks only. Flasks containing cells to be processed on other days were not affected.
A lOng/ml solution of VEGF was used, to see if higher concentrations continued to have the
same or any adverse effects effects on growth of cells. 5xl04 cells were seeded per flask,
because each flask was larger than the wells used in previous work. Similarly, 5ml of medium
was used per flask rather than 3ml. The automated cell counter was not used due to the
inaccuracy of its readings. Cell counting was performed as before.
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3.2.5 BAEC growth with VEGF after prolonged culture in low serum medium.
Cloned BAECs, which were at or around their 20th population doubling since primary culture,
were cultured for over two weeks in either 2% or 10% culture medium. After this time,
changes in the cell morphology (large, multinucleate or amorphous) microscopically began to
be seen and this was taken as an indication that the cells were approaching senescence (see
examples in fig. 3.1). Cells at this point were trypsinised and seeded in 25cm2 sterile flasks at
a density of 50000 cells per flask. To these flasks was added medium with either 2 or 10%
serum as before with or without lOng/ml VEGF. The flasks were cultured for up to four days
and then trypsinised, the cells were removed and then seeded into a 96 well plate, lOOpl per
well. To these wells, the PMS/MTS assay solution was added as before. The experiment was
repeated and the numbers of cells in each flask were also calculated by counting them using a
haemocytometer on day four. Examples of these flasks were formalin-fixed and
photographed.
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Figure 3.1. BAECs approaching senescence. Cells are large, with poorly
defined nuclei and have lost their typical morphology.
3.2.6 HUVEC growth with and without VEGF.
HUVEC cells were grown in 24 well plates. They were seeded at an initial density of 104 or 2
x 104 cells/well, in 1ml of medium. To this was added either a further 1ml of medium or 1ml
of medium containing VEGF (lOng/ml). 10 wells were used for each group and the growth of
cells was studied at three and four days. On the third day, the medium in the wells to be
studied was removed and 500pl of fresh medium was added. A further lOOpl of PMS/MTS
assay reagent was added to each well. This preserved the ratio used in previous 96 well plates
to ensure the reagent would react normally. The plates were then replaced in the incubator for
a further hour. After one hour, 120gl of the solution in each well was removed and added to a
96 well plate, taking care not to produce any bubbles in the wells. Any bubbles seen were
punctured with a needle to avoid artefact. The plate was counted twice in a spectrophotometer
at 492nm as before. The results were automatically adjusted with a control blank containing
120pl of culture medium incubated alongside the other wells with PMS/MTS reagent (i.e. no
cells).
The results were recorded and the ratio between the cells treated with and without VEGF
calculated to determine the % increase in growth due to the addition of VEGF. On the third
day the medium was changed for the wells to be studied in the same fashion at four days and
a further 2ml of medium was added to the wells again either with or without lOng.ml of
VEGF.
3.2.7 VEGF-eluting stents in BAEC culture - thymidine labelling.
BAECs were prepared at a concentration of 125000/ml in growth medium (DMEM
containing 20% FCS and gentamicin). The cells were then plated out onto 24-well plates
under sterile conditions, 1ml of cell-containing medium per well. Eight wells were left empty
to act as controls in the absence of cells. The cells were then incubated for 24 hours adhere to
the base of the wells. Sections of stents were cut and sterilised with ethylene oxide. 250pl of
2mg/ml VEGF solution in PBS was placed into two separate Eppendorfs. Into each
Eppendorf four hoop sections were placed. The containers were agitated to ensure the hoops
were fully covered by the VEGF solution. The hoops were left in this solution for 24 hours.
Eight control hoops were placed in two identical Eppendorfs containing 25()ul of PBS only.
At 24 hours, the hoops were taken out of the VEGF solution, excess solution shaken off them
and they were then left to dry in air. Control hoops were treated identically. The 24-well plate
was removed from the incubator and the remaining medium was removed, taking care not to
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touch the base of the plate where the cells were adhering. All hoops were placed into the 24-
well plate, one to a well. The hoops were then covered with 2ml of fresh medium. After 24
hours of incubation the plate was removed from the incubator and the medium removed,
together with any VEGF that had eluted from the stents into the medium. This corresponds to
the loss of VEGF that would occur in vivo as blood washed some VEGF away from the target
site into the general circulation. The medium was replaced with fresh medium. Every two to
three days thereafter, the medium was replaced. At five days the medium was removed and
replaced with medium containing tritiated thymidine. The cells were then cultured for a final
24 hours to allow for all growing cells to incorporate the thymidine. After this last 24 hours,
the radioactive medium was removed and discarded appropriately. The hoops were all taken
out of the wells and kept separately. The wells were then processed to assess thymidine
incorporation.
3.2.7.1 Protocol for radiolabeled thymidine use with endothelial cells.
ECs were incubated with culture medium containing 0.037MBq/ml H thymidine (adding lpl
of 37MBq/ml stock into 1ml of medium) for 24 - 72 hours, dependent on experimental need,
at 37 C. The amount of tritiated thymidine containing culture medium was 1 ml/well in 24
well plate. The isotope-containing medium was removed, cells washed with fresh medium
twice, and chased with fresh isotope-free medium for 60min at 37 C to reduce the
unincorporated tritiated thymidine in cytoplasm. Samples were then washed again with PBS,
and treated with 5% ice-cold trichloroacetic acid for 60min to precipitate DNA and
incorporated tritiated thymidine (1 ml/well in 24 well plate). After removal of trichloroacetic
acid the cells were washed with ethanol once, then a small amount of fresh ethanol added and
left to dry overnight to remove any remaining free isotope. The washed precipitate was re-
dissolved in 2N NaOH for 60min, 100pl/well in 24 well plate. The cell lysate was transferred
to a counting vial containing 5ml of "Hisafe" (Wallac) scintillant. After good mixing the
samples were left still for at least four hours to eliminate chemiluminance. The radioactivity
in the samples was counted by Tri-Carb 1500 liquid scintillation analyser (Packard) with
counting window set at tritium and a counting efficiency of about 65%. Each sample was
counted for 4min and all the samples were counted for two rounds to check variation. Control
samples containing 2N NaOH only were used to allow for background radiation.
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3.2.8 HUVEC growth under the influence of VEGF from stents
Fresh HUVEC cultures were prepared from umbilical cords. These were cultured in
Endothelial Growth Medium (see Appendix). The cells were confirmed to be endothelial cells
using vWF staining. Stent sections were immersed in VEGF 2mg/ml in PBS or BSA 2mg/ml
in PBS. These were left for 24hr. Stent sections were then removed and air-dried. All sections
were sterilised using ethylene oxide gas. Stent sections were placed in a 24 well plate with
lml of EGM for 24 hours. This was to allow the elution process to commence. A refinement
of the experiment was to investigate whether stents loaded with VEGF retained their
stimulatory effect on HUVECs even after a 24-hour period of passive elution into culture
medium. This medium, containing the VEGF which had already eluted from the stent in that
time, was removed, and fresh medium including HUVECs, was added to the stents. These
stents were then cultured for 72 hours and the growth of HUVECs measured using the same
assay techniques. The eluate was added to a separate group of cells and their growth
measured. A stock solution was prepared in EGM of HUVECs with a final concentration of
1.6 x 104cells/ml. lml of this stock solution was added to each of the wells containing a stent
and to the control wells.









Cells cultured without VEGF.
Cells cultured with stent sections dipped in BSA.
Cells cultured with stent sections dipped in VEGF, medium
unchanged.
Cells cultured with stent sections dipped in VEGF, medium changed
after first 24 hours passive elution.
Cells cultured with lOng/ml VEGF, as before.
Cells cultured with 500ng/ml VEGF - This was to exclude any
adverse effect of the relatively high dose of VEGF delivered by stent.
Cells cultured with the medium containing eluate from the group 4
stents.
Culture medium only, no cells.
The medium in each well was made up to 2ml by adding medium either with or without
VEGF. All wells were then cultured for 72 hours. The medium was not changed during this
time. After 72hr the medium in each well was removed and replaced in all cases with 500pl
of fresh EGM. To this was added lOOpl of PMS/MTS reagent. 120pl aliquots of each well
were drawn off and their absorption counted at 492nm. The results were adjusted for the
blank well. Two counts were made and averaged. The stents from each well were also placed
into fresh medium with PMS/MTS and this was cultured from up to four hours. Two positive
control groups were also studied. These cell cultures were those to which VEGF had been
added without stents. Two concentrations were used. The first was the same as in previous
cell growth experiments, i.e. lOng/ml. The second was a concentration of 500ng/ml, to test
the effects on cell growth of very large doses of VEGF and was calculated from the
absorption of VEGF seen in the radiolabelling experiments. It was assumed that the
maximum concentration the HUVECs might be exposed to would be the entire absorbed dose
of VEGF diluted in the 2ml medium in each well. As both these doses are at least an order of
magnitude above the ED50 from previously published work5, no further stimulation of EC
growth was expected. However, it remained possible that VEGF delivery by stent might have
adverse effects on EC growth.
3.2.9 NO production from HUVECs under the influence of VEGF.
Detection of NO was performed using the commercially available Total Nitric Oxide Assay
(R&D DEI600) according to the manufacturers recommended protocol.
2xl05 HUVECs were cultured to confluence, trypsinised and plated out in a 24 well plate. The
wells were left overnight to reach confluence, thus each well had an equal number of
confluent HUVECs. Stent sections were prepared with either BSA or VEGF.
Stents were added to each well of the 24 well plate. Negative control wells containing either
cells alone or just culture medium were also included in the study. After eight minutes lOOpl
of cell culture supernate was removed and stored at 4°C. The cells were exposed to the stent
section for a further 22 minutes, i.e. up to half an hour total exposure. At this point a further
lOOpl of cell culture supernate was removed and also stored. The cell supernate samples were
centrifuged for lOmins at 1500rpm to remove particulates. Each sample was diluted in an
equal volume of reaction buffer. The samples were then filtered through a 10000MW cutoff
filter using a Heraeus centrifuge at 13,000rpm for 15min (1 lOOOg) to remove proteins, as
these may interfere with the assay.
NADH was reconstituted in distilled water and kept on ice throughout the assay. It was
further diluted immediately prior to use. Nitrate reductase was reconstituted in buffer,
vortexed and kept on ice during the assay. It also was diluted immediately prior to use in
Reaction Buffer. To make the nitrate standard, doubling dilutions were made with reaction
buffer using the stock solution included in the kit,. A range of standard concentrations
between 3.12jimol/l and 100pmol/l were prepared.
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50pl of sample, standard solution or plain buffer (negative control) were added to wells in a
96 well plate. 25pl of NADH and 25pl were added to each well and the plate was incubated at
37°C for 30mins to allow the conversion of nitrate to nitrite. 50pl of the Griess I & II reagents
were added and the plate incubated for a further 10 minutes to allow the production of the
final coloured azo-derivative. The plate was then read in a microplate reader set at 540nm. All
samples were assayed in duplicate. Results were adjusted to account for background counts.
The whole assay was repeated with the samples obtained at 30min in an identical fashion. A
standard curve was derived from the known concentrations (fig. 3.2).
3.2.10 Statistical analysis used.
The results of the experiments were analysed to show that the data were compatible with a
normal distribution. The data were then subjected to a two-tailed t-test. Equality of variance
was calculated in each case and the results factored into the t-test. In almost all cases, equality
of variance was seen. Results are calculated as p values and displayed as means ± standard
deviation.
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Standard curve of nitrate
Absorbance at 540nm
Figure 3.2. Standard curve obtained with Nitric Oxide solutions of known
concentration. This was used to detect the amounts of NO produced from
HUVEC cultures with and without exposure to VEGF.
3.3 Results
3.3.1 von Willebrand staining of cells and cell morphology
The cells used stained uniformly with the anti-vWF antibody. No cells were seen that did not
express this antibody. The cells were therefore a pure culture of ECs. Furthermore, under
normal light microscopy, the cells demonstrated typical "cobblestone" morphology when they
reached confluence. An example of these findings is demonstrated below (fig. 3.3&4).
3.3.2 Endothelial cell growth curves
Steady exponential growth was seen in the cell cultures (fig. 3.5).
3.3.3 Effects of VEGF on BAECs and HUVECs
Two cell types were used. BAECs were used initially. However, the results obtained with
them proved variable and for this reason, the experiments were repeated with HUVECs. More
reproducible results were obtained with these (fig 3.7.a-d).
Slower growth was seen in low serum culture fig. 3.8). This variation to the experimental
design gave an unexpected result in cells grown in these conditions for over two weeks. These
cells seemed to be actually reduced in number compared to controls. As this was surprising,
the experiment was repeated twice under pre-set conditions VEGF stimulated the rate of
growth of normal endothelial cells in favourable growth conditions. However, senescent cells
cultured in adverse (low serum) conditions showed a significant decline in numbers compared
to similar cells grown in normal medium or without VEGF.
123
IBS R
Figure 3.3a Figure 3.3b
Figure 3.3&b. vWF staining of endothelial cells.
In figure 3.3a, cell nuclei are stained dark blue with Floechst stain. In figure
3.3b, cells are also stained for vWF factor, which is stained fluorescent green.
All cells have green staining, so all cells are ECs.
Figure 3.4 Light microscopy of endothelial cells. Photo of confluent BAECs
showing typical cobblestone morphology, confirming that the cells are
endothelial (x10 magnification).
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Doubling rate of BAECs
o
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Figure 3.5. Growth curve of BAECs. This used DMEM/FCS medium and
showed continuing cell doublings, i.e. cells had not reached senescence.
Growth curve for BAECs in DMEM









































































Days of exposure to VEGF
BAEC replication under influence of VEGF 10ng/ml
Figure 3.7c




















Day 3 Day 4
HUVEC growth with exposure to VEGF
Figure 3.7d
Figures 3.7a,b,c &d. Effects of VEGF on the replication of endothelial cells.
3.7a shows the results obtained when counted directly by light microscope.
3.7b shows the results obtained with a haemocytometer. 50000 cells were
initially seeded per flask. 3.7c shows the use of the PMS/MTS assay that was
used most commonly, because of its reproducibility (* = p<0.01). In each case
"control" was identical medium, lacking only the addition of VEGF.
3.7d. Shows the results for HUVEC replication, measured using the
PMS/MTS assay (* = p<0.001).
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Replication of BAECs after 2 weeks in 2%/10% Medium
followed by VEGF 10ng/ml
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Figure 3.8b
Figure 3.8&b. Replication of BAECs after prolonged culture followed by
exposure to VEGF-containing or normal medium. Direct counting used
microscope (3.8a) and the PMS/MTS assay (3.8b). In low serum conditions a
reduction in cell numbers was seen with VEGF exposure (Statistical
significance tested using 2-tailed t-test, variance not assumed to be equal).
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3.3.4 BAEC growth with VEGF-eluting stent sections.
An increase in endothelial growth in the groups treated with VEGF-eluting stents was seen,
but this was not reproducible. There was an absolute difference in cell numbers between
groups treated with bare stents and VEGF-eluting stents but this did not reach significance.
The results are described below (figs. 3.9a&b). The experiments with thymidine labelling
were repeated on three occasions. There was some variability in the radioactivity detected in
all cell groups. BAEC numbers in this experiment were significantly greater in the
populations exposed to the VEGF-eluting stent than to control groups of cells (22901 counts
+/- 5501 vs. 6576 +/- 2480 in controls (p<0.01)).
3.3.5 HUVEC growth with VEGF-eluting stents.
The results obtained showed an 11.3±4.9% (p<0.05) increase in cell growth over controls.
This was not significantly different to the effects seen when VEGF was added to the cell
cultures without a stent (figs3.10a,b&c).
3.3.6 Functional assay for the VEGF-eluting stent
Using a standard curve, the amounts of NO produced over either 8 or 30min. were calculated
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Figure 3.9a&b. The growth of BAECs when cultured with or without VEGF-
absorbed stent sections (hoops). After 48 hours, no differences were seen in
the different groups. However, by five days, a significant difference was seen
between VEGF hoops and the cells with no stent hoop. Although an absolute
difference was seen between the groups with VEGF hoops and bare hoops,




® 2 >< 100
£ $

















































Figures 3.10a,b&c. Replication of HUVECs after VEGF exposure, bound to a



















Treatment group of HUVECs
Figure 3.11. NO production from cells treated with or without VEGF. Results




3.4.1 Growth of ECs with VEGF
A variable response was seen to VEGF with the BAECs. This may be due to errors in
reproducibly plating out small numbers of endothelial cells at the outset. As these cells will
normally undergo exponential growth over the course of an experiment, any error in numbers
of cells seeded initially will be greatly magnified. Secondly, BAECs produce FGF, a non¬
specific endothelial cell mitogen6. This growth factor may exert a proliferative response in the
cells irrespective of the presence or absence of VEGF and thus obscure the effects of VEGF.
3.4.2 Serum-starved cells.
Prolonged serum starvation of cells adversely affects their growth and morphology, by
stimulating apoptosis7. Adding VEGF to such cells led to a decrease in the growth of BAECs.
A failure of VEGF to promote growth has been seen in BAECs treated with oxidised LDL,
which impairs the growth and function of ECs6. Oxidative stress can adversely affect the
growth of BAECs. This process was accelerated by the addition of VEGF8. It is postulated
that damaged cells exposed to VEGF will be driven into apoptosis.
The angioplasty site is an area covered normally by an endothelial layer of cells damaged by,
amongst others, oxidative stress and hyperlipidaemia. These cells are largely stripped away
during PCI. VEGF might complete this process by driving any remaining dysfunctional cells
to apoptose. Later, VEGF may promote the overgrowth of endothelium from nearby, less
atherosclerotic, parts of the artery. Such a hypothesis would be compatible with the results
seen in animal models, but cannot be substantiated without study in patients undergoing PCI,
where the endothelium is a mix of healthy and unhealthy subtypes.
3.4.3 Growth of HUVECs with VEGF - eluting stents.
VEGF-loaded stents were effective in promoting endothelial cell growth, albeit by only 11%
more than the control groups in the HUVEC study. The effect seen was comparable to the
stimulus seen when VEGF was added directly to the culture medium, so the delivered dose of
VEGF was higher than that necessary to produce maximal growth stimulation. The relative
increase in cell numbers was not large in the VEGF group. This may be because the cells in
the control group were already proliferating at a near maximal rate. Other studies have shown
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previously that the dose of VEGF needed to produce half-maximal growth stimulation was
less than lng/ml'\ The stents used in this work will release significantly more than this into
the surrounding medium. No toxic effect on cell growth of this dose was seen, nor did the
polymer of the stents themselves have any adverse effects on endothelial cell growth.
3.4.4 Functional effects of VEGF-eluting stents
Positive NO production was seen in all the wells equally, despite the absence of any ECs in
the negative control wells. This implies contamination at an early stage in the experiment with
a nitrate or nitrite-containing substance. It is possible that the growth medium used contained
substances, possibly peptides, which were small enough to pass through the 10000MW cut¬
off filter and contaminate all the readings.
No comment can be made about the effectiveness of VEGF released from stents in producing
any functional response in HUVECs.
In summary, VEGF has been shown to promote EC growth. Stent sections maximally
absorbed with VEGF released VEGF into the surrounding fluid, in this case cell culture
medium. Increased cell growth was seen in cells exposed to VEGF-coated stents. The effect
on growth was preserved beyond any very rapid loss of VEGF from the stent, since stent
sections that had been washed for 24 hours with medium and then added to the cell cultures
still significantly increased cell growth. VEGF-coated stents retained their effectiveness after
sterilisation of the stents.
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VEGF-eluting stents - In vivo assessment.
4.1 Introduction.
To test the apparent beneficial effects of VEGF-eluting stents on endothelium and neointima,
they were tested in vivo. A rabbit iliac artery model was chosen, after consideration of
alternative models available (see section 1.4.1).
Rabbits used underwent one of two different procedures. These were the acute and chronic
groups.
4.1.1 The acute model.
The aim of this model was to supply various data. Firstly, it provided control results of the
intima/media composition immediately after an angioplasty. Secondly, it showed the extent
of thrombus formation early on after stent implantation in this model. Finally, it assessed
whether the VEGF eluted from a stent might have some effect on the thrombosis process
early on. This effect would be independent of any mitogenic effects on the endothelium.
Rather, this would be due to the NO-stimulation known to occur with VEGF (see section
1.8.3). NO-donor coated stents have been shown to be anti-thrombotic in vivo1. VEGF
released early after implantation might protect a stent against thrombosis through its
stimulation of NO. Such an anti-thrombotic effect might also be related to the anti-restenotic
effects of VEGF, since thrombus formation is itself a stimulus for intimal hyperplasia (see
section 1.3.3.4).
4.1.2 The chronic model.
The chronic model was used to examine several reactions to the VEGF-eluting stent. Firstly,
endothelialisation at 7 days over the stented area of vessel was assessed. Secondly, stent
thrombosis at 7 days was observed. The animals studied at seven days were examined for the
amount of endothelialisation that had occurred over the stented vessels - either with or
without VEGF. This time point was chosen as it is known that in the rabbit endothelialisation
occurs quickly and is complete at 28 days2. Partial endothelialisation is of more interest, as it
is here that any differences between the groups might be seen. Seven days was used as the
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time point of studies by Van Belle and colleagues3 when administering VEGF through a
perfusion balloon to stented rabbit iliac vessels.
The extent of in-stent neointima formation at 28 days was measured using digital
morphometry. Digital morphometry was also used to ascertain whether the different stent
types had had any discernible effect on either the media, where the proliferating vascular
smooth muscle cells originate, or on the luminal area. This latter corresponds to the measure
most commonly used clinically to determine the success or otherwise of any new treatment,
i.e. quantitative coronary angiography.
4.1.3 Background to techniques used.
4.1.3.1 Indium labelling of platelets.
"'indium has a half-life of 67.2 hours and decays by emission of y radiation with two peaks
of energy, 171 and 245keV. Indium oxine complex is neutral and lipid soluble and thus
penetrates cell membranes. Within the cell. Indium becomes firmly attached to cytoplasmic
components and the liberated oxine is released by the cell. There is negligible release of
'"indium from cells4, "'indium is thus ideal for labelling platelets and quantifying platelet
accumulation at sites of arterial injury, "'indium labelling of autologous platelets is
commonly employed in both research and clinical practice for detection of venous and
arterial thrombi, determination of the thrombogenicity of prosthetic devices such as arterial
grafts and measurement of platelet survival5' 6.
4.1.3.2 Cyclic Flow Variations.
Cyclic flow variation (CFV) is the observation that flow down a damaged vessel varies.
Typically, flow gradually reduces and then is abruptly restored to normal, due to the gradual
accumulation of thrombus and its sudden dislodgement7'8. The stimuli to CFVs occurring
include adrenaline9. Clopidogrel can prevent adrenaline-enhanced cyclic flow variation in
canine coronary arteries9. In a canine study10, CFVs were produced in endothelial-injured
coronary arteries. Transient coronary occlusion during CFVs induced electrocardiographic
ST segment changes which returned to baseline after reflow. In those dogs which developed
persistent coronary occlusion, histologic examination showed thrombus formation at the
stenotic site and evidence of myocardial infarction. Eichhom and colleagues" found
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spontaneous variations in coronary blood flow velocity in 3 of 13 patients undergoing
angioplasty for severe angina. The authors concluded that flow variations were related to
platelet aggregation, vasoconstriction, or both at the site of angioplasty induced-injury.
Sunamara ct al12 showed that although CFV was rare in clinical practice (-5% of cases), it
was an important predictor of imminent, clinically significant thrombus formation or even
acute occlusion.
4.1.3.3 Evans' Blue dye.
Evans' Blue is an azo dye that binds to circulating albumin. This dye/protein complex cannot
cross a viable endothelium. Sections of vessel with an intact endothelium do not stain with
the dye, whilst segments with dysfunctional or absent endothelium will allow the dye to stain
the underlying surface of the vessel1'. This dye has no active effects on the vessel, but serves
as a marker of areas that are denuded of endothelium, such as occurs immediately after
angioplasty. The recovery of this endothelium has been traced using this dye in a rabbit
model14.
4.1.3.4 Silver staining.
Silver nitrate solution can be infused into vessels segments. The stain is taken up at the cell
boundary of ECs. Under scanning electron microscopy, this allows the cells to be more
easily differentiated from underlying tissues13.
4.1.3.5 Critical point drying.
Water has a relatively high surface tension at the liquid-gas phase and when wet tissues are
exposed to a vacuum excessive distortion and shrinkage of the tissues occur. Other
substances, including acetone, lose the liquid-vapour stage at certain temperatures and
pressures (the critical point). Tissue integrity may be better preserved by replacing the water
in them with acetone and then subjecting the samples to critical point drying. The process of
critical point drying replaces the dehydrating fluid, in this case acetone, with a transition
fluid such as liquid C02 at the critical point for the fluids. This transition fluid is then
removed at the critical point, leaving a dehydrated tissue sample. Despite the improvement in
tissue integrity that is seen by the use of these dehydrating and intermediate stages, it is
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recognised that some tissue distortion or shrinkage is inevitable. Nevertheless, critical point
drying is at least as good as other methods of drying animal specimens15.
4.1.3.6 Sputter coating.
Sputter coating is a method used to coat samples for SEM examination with an extremely
thin and even coating of atoms of a conducting metal, usually gold. The gold is bombarded
under a high voltage and atomises. This cloud of atomised gold will then thinly coat the
target sample. When the sample is then swept by the beam of electrons from the microscope
it becomes charged and will emit secondary electrons. These are detected and imaged by the
microscope.
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4.2 Methods and materials.
4.2.1 Loading of stents with VEGF for in vivo work.
3x1 Omm Supra G stents polymer-coated stents were gently removed from the delivery
balloon and immersed, unexpanded, in 2mg/ml VEGF in PBS solution. After twenty-four
hours, they were removed from the solution and allowed to dry. The stents were then
replaced on the delivery balloon with minimal handling of the stent itself. Stents were
removed from balloons to coat all surfaces of the stent and to prevent superficial VEGF
adhesion to the surface of the balloon. Delivery balloons and stents were then put through a
cold cycle (37°C) sterilisation program using ethylene oxide gas. This is the usual means for
sterilising stents and delivery balloons. Control stents without VEGF were treated
identically. Stents were stored, in sterile packs, at 4°C, for up to two months.
4.2.2 Angioplasty and stent model.
Male New Zealand White rabbits aged 4-8 months and weighing 3.0 - 4.5kg were used.
Animals were housed and cared for in the biomedical services unit, Leicester University and
all procedures were undertaken in accordance with the Animals (Scientific Procedures) Act
1986 under licence from the Home Office in London.
Clopidogrel and Aspirin (lmg/kg/day) were administered in drinking water for five days
before procedures and until sacrifice. General anaesthesia was induced 30 minutes after
premedication with Hypnorm 0.3ml/ kg (a combination of fentanyl citrate 0.315 mg/ml and
fluanisone lOmg/ml) (Janssen-Cilag, High Wycombe, Bucks). Inhaled halothane (2 - 3%)
was used for induction and a combination of halothane (0.5 - 3%) and oxygen (0.5 - 31/min)
for maintenance of anaesthesia. Animals were spontaneously ventilating for all studies; all
were placed on a heating pad (38°C) and had continuous intra-operative monitoring of heart
rate, respiratory rate and rectal temperature. All animals were given 1000IU unfractionated
heparin before angioplasty.
4.2.3 Acute Model.
The ventral aspects of both thighs, groin area and abdomen were shaved and cleaned
thoroughly with betadine and 2.5% chlorhexidine prior to sterile draping of the animal. The
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right and left neurovascular bundles, composed of femoral artery, nerve and vein, were
exposed by blunt dissection and the superficial femoral arteries carefully freed of
surrounding adventitial connective tissue. Next, a midline abdominal incision was used to
open the peritoneum; the abdominal contents were deflected to the right lateral position and
the iliac arteries exposed and dissected free of surrounding tissues to facilitate placement of a
perivascular flow-probe on each side.
An arteriotomy was fashioned between two ligatures placed loosely around the superficial
femoral artery distal to its lateral circumflex branch (fig.4.1)\ arterial bleeding was controlled
by tension on the proximal ligature. A 3x15mm diameter, non-compliant, coronary
angioplasty balloon catheter was advanced to the proximal part of the common iliac artery
0.5 - 1cm distal to the aortic bifurcation and inflated to eight atmospheres for 60 seconds
using a standard balloon inflation device. This was done three times, with a 30 second
recovery period between balloon inflations. The balloon catheter was then removed. A
3x10mm Cook Supra G stent was placed using a further delivery balloon into the iliac artery.
These were either a control or a VEGF-loaded stent, also mounted on a 3x10mm diameter
non-compliant balloon. Choice of stent was non-blinded, but determined before starting the
body of work. VEGF and control stents were spread evenly throughout the course of work to
avoid one group being influenced by any effects of a learning curve in performing the
procedures. The stent was introduced into the femoral artery, advanced to the proximal
common iliac artery under direct vision and deployed at the site of arterial injury by inflating
the balloon to eight atmospheres for 20 seconds.
Following stent deployment, the balloon catheter was removed and the superficial femoral





















Figure 4.1. Schematic illustration of operative anatomy, (illustration from MD
thesis by Rajesh Aggarwal).
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4.2.3.1.1 Cyclical flow measurements.
Baseline blood flow before any angioplasty or stent placement was recorded for 2-3 minutes
through each common iliac artery using perivascular transit time flow-probes (T206 small
animal blood flow meter with 2.5SB probes, Transonics Inc., Ithaca, NY, USA). Blood flow
through the vessels after they had been stented was recorded immediately after superficial
femoral artery ligation and continuously for two hours thereafter with the flow-probe placed
immediately distal to the stent.
4.2.3.1.2 Indium labelling of autologous platelets.
A minor modification of the method of Hawker et al was used to label rabbit platelets with
indium- 11116, as detailed below.
17ml of rabbit blood were obtained, by cannulating an ear artery, in a syringe containing 3ml
of acid citrate as anticoagulant (see appendix). A further 9ml was drawn up in a separate
syringe with 1ml of sodium citrate. A large bore needle was used to minimise platelet
activation or red cell haemolysis. The first sample was centrifuged at 180g (850rpm) in a
Wifug laboratory centrifuge (Eltex of Sweden) for 15 minutes. 5-7.5ml of supernatant,
containing platelet rich plasma (PRP), were then transferred using a "Kwill" into a 15ml tube
(tube A). The total amount of PRP was calculated by how much volume remained in the tube
that was not PRP. lOpl of PRP was removed, to be used to count the total platelet
concentration involved (see below). The blood from the other syringe was centrifuged at
640g (2100rpm, Wifug centrifuge) for lOmin. to obtain platelet poor plasma (PPP) for later
use. The PRP in tube A was mixed with Tyrode's buffer (appendix) to give a final volume of
10ml and then centrifuged at 640g for 10 minutes, leaving a platelet pellet in the bottom of
the tube. The supernatant (diluted plasma) was decanted and retained. The platelet pellet was
then thoroughly washed using 5ml of buffer.
Washed platelets were resuspended in 2.5ml Tyrode's buffer. lOMBq Indium (luIn) oxine
solution (Amersham Health Science, Bucks., UK) was added dropwise to the tube whilst
gently swirling it and the tube incubated for two minutes. Approximately 7.5ml of diluted
plasma were then added to the platelet suspension to give a final volume of 10ml and the
mixture centrifuged at 640g for ten minutes. The supernatant was then decanted and used to
measure labelling efficiency. The platelet pellet was re-suspended in 3ml of platelet poor
plasma. The total radioactivity present was measured by counting 10pl samples of labelled
platelets and supernatant in a gamma well counter using a 90keV symmetrical window
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around the 245keV peak (Cobra II auto-gamma counting system, Packard Instruments,
Meriden, CT).
Labelled platelets were re-injected into rabbits one hour before operation. At the end of the
procedure, stented vessels were dissected out and the radioactivity associated with the stents
calculated in the gamma counter.
To calculate the number of platelets represented by a single radioactive count, the platelets
per ml were counted. This used 10pl of PRP taken before the labelling process. This was
diluted with 990|tl PBS to make 1ml. A 50pl sample of this dilute sample was taken and
further diluted to lml in PBS again to dilute further. This solution was counted in a
haemocytometer and the initial number of platelets per ml of PRP calculated. Knowing the
total volume of PRP obtained, which contained all the platelets from that blood sample,
allowed calculation of the total platelet count per ml of blood. The total number of platelets
in each animal was estimated assuming 60ml blood per kilogram body weight (based on
Home Office (1991) Antibody production guidelines) and the number of platelets in the
suspension re-injected was estimated. From this a count per platelet was derived that allowed
the estimation of the amount of platelets adhering to the stents, based on their radioactivity.
4.2.3.1.3 Termination of animals and recovery of tissues.
Two hours after stent deployment, animals were sacrificed using an intravenous overdose of
pentobarbitone (140 mg/kg body weight). An intravascular cannula was then introduced into
the abdominal aorta, advanced distally and used to flush stented vessels with 0.9% sodium
chloride solution. Vessels were removed and formalin fixed.
4.2.4 Chronic model.
Animals that were allowed to recover after stent deployment for 7 or for 28 days were
anaesthetised and prepared as above. Operative dissection was restricted to left-sided groin
incisions for superficial femoral exposure. Particular care was taken to avoid trauma to
nerves during dissection of the neurovascular bundle since limb paralysis is associated with a
reduced likelihood of post-operative recovery. Animals were closely observed post¬
operatively for signs of limb ischaemia. Elective sacrifice was undertaken 7 or 28 days and
vessels dissected free as before.
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4.2.4.1 Method for study of endothelialisation and thrombus formation at 7 days.
The rabbits were sedated and anaesthetised under G.A. as before. Under G.A., 40mg
(i.e.approx. lOmg/kg) in 2ml normal saline Evans Blue dye was injected intravenously. This
was allowed to circulate freely for at least half an hour to stain any endothelium-denuded
vessels. An abdominal incision was made and the abdominal aorta and vena cava visualised.
Using blunt dissection, the aorta was dissected free of surrounding structures as far down as
lcm below the iliac artery stent site. The iliac artery on the contralateral side was also
dissected free. When these structures had all been identified, a small gauge catheter was
placed into the abdominal aorta. 10ml of normal saline was flushed through. This was
followed by 10ml of 0.25% silver nitrate solution over 20 seconds. Simultaneously an
overdose of sodium pentobarbitone was given intravenously. The silver nitrate was followed
by a further 10ml of normal saline to flush the vessels. The animal was exsanguinated post¬
mortem. This allowed more ease at dissecting out the iliac arteries and distal aorta. The
arterial block of tissue was placed in 10% formalin for fixation prior to further examination
for endothelialisation.
The extent of endothelialisation and thrombosis were assessed by:
a) Dividing the stents lengthwise and partly flattening them. The flattened stents, stained
with Evans Blue, were examined under light microscopy and scanned photographs were
examined by a blinded observer to evaluate the extent of endothelialisation.
b) Examining the tissues under scanning electron microscopy.
c) Wet and dry weights of any adherent thrombus in the stented section.
A macroscopic assessment of the stented arterial segment was made. Thrombus within this
segment was graded according to the following criteria:
Occlusive - completely occupying and occluding the arterial lumen
Luminal - visible encroachment into the lumen without complete occlusion
Minor - minimal thrombus visible on stent struts or endothelial surface.
None - no visible thrombus
Any thrombus visible was carefully removed from the stent structure and weighed. This
thrombus was re-weighed at a later date when completely dried. The semi-quantitative
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measure of stent thrombus formation in this model has been used in previously published
work (MD thesis, Dr. R. Aggarwal).
4.2.4.1.1 Endothelialisation - Light microscopy.
Stented vessels were cut open longitudinally, leaving the stent in situ. The stent struts were
cut carefully longitudinally and gently prised apart to reveal the luminal aspect of the stent,
still in contact with the vessel. It was not possible to completely flatten the stent without
detaching it from the vessel wall and so all studies were done on the portion of the stent
opposite the cut struts. The opened vessel and stent were pinned to cork and photographed
under a binocular light microscope (Olympus SZ). This was set at a magnification of x40 for
the maximum close-ups of the stented vessel. The vessels were lit from above with a cold-
light source (Schott KL1500). 800ASA colour film was used. Multiple photographs were
taken of each section, in particular of the stent stmts. Each photo was scanned into digital
format, focusing on the parts of the photo where the stented vessel was uninjured by the
process of opening the stent longitudinally, i.e. the part of the vessel opposite the incision
point. A blinded observer was asked to assess the amount of blue staining in each section
relative to undamaged tissue in the same samples. The staining was graded 1 to 5 in
increasing subjective impression of the amount or intensity of Evans' Blue staining.
4.2.4.1.2 Endothelialisation - scanning microscopy.
Samples of tissue were initially preserved in 4% formaldehyde in PBS. This was replaced
after three or four days with pure PBS. The tissue was dehydrated gradually in increasing
concentrations of alcohol and acetone (appendix 2). The dried tissues were then carefully
removed from their cork backing and the pins removed. The tissue was mounted on a
pedestal and sputter coated with a 15nm layer of gold in a Polaron sputter coating unit
E5150.
4.2.4.2 Method for study of restenosis at 28 days.
Each stented specimen was explanted with at least 1cm of artery either side of the stent.
Sections were formalin-fixed in 4% formalin for at least 48-72hours. Thereafter each
specimen was transferred into PBS and stored at 4°C. When all the samples were ready, they
were sent, still in PBS by courier to Sheffield Northern General Hospital for tissue
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processing in collaboration with Dr N. Malik. The technique used to resin-embed the
sections is described fully in published work17. The author of this work supervised the
processing of the tissues used in this work.
4.2.4.2.1 Resin embedding of tissue.
The technique allows the preservation of the arterial architecture with the stent in situ, while
still preserving the antigens that are used to identify the proliferative response on the smooth
muscle cells in the tissue. Stented tissue was dehydrated in 100% acetone and immersed in
infiltrating solution (50% benzoylperoxide with hydroxyethyl methacrylate) for 24 hours at
4°C. Blocks were then transferred into an embedding solution (infiltrating solution with
tetramethyl aniline) and orientated in polythene tubes. The tubes were hermetically sealed
and left at 4°C for 24hr. This allowed the formation of glycol methacrylate resin (T8100). A
high-speed precision saw (Isomet 2000) was used to cross-section the resin-embedded tissue
blocks. This produced 100pm thick sections which were then further thinned by use of a
Metaserv 200 grinder with increasing fineness of grinding paper used to produce sections
between 10-20pm in thickness. These sections were then affixed to Perspex slides with
Super-attak adhesive.
4.2.4.2.2 H&E staining of T8100-embedded sections.
Two slides from each stented vessel were used for H&E staining. Slides were stained using a
standard protocol (see appendix 2). Adaptations were made to the method, particularly with
regard to the length of time needed to clearly delineate histology by an initial stage with
varying length of time to produce the best results.
4.2.4.2.3 Digital morphometry of resin-embedded stent sections.
To assess qualitatively the extent of neointimal hyperplasia that had developed in the stented
iliac vessels, the resin-embedded cross-sections were examined under a microscope (Nikon
Eclipse E800) equipped with a digital video camera. This allowed the imaged stent sections
to be analysed using a digital morphometry package (Scion Image 1.62a) on an Apple Mac
computer. All the H&E stained slides had identifying marks concealed to ensure an unbiased
analysis. A single blinded observer made all the measurements. Two slides were chosen
from each stent. Thus 32 separate slides were examined (8 animals per group, two slides
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from each, control and VEGF coated stents). Day zero slides were examined to ascertain
whether there were baseline differences in the deployment of VEGF vs. bare stents. This was
determined by measuring the luminal area in both groups as a guide to whether the stents had
been deployed in an equal fashion.
The 28-day slides were examined and intimal growth quantified, using two different
techniques. At a low power magnification of the vessel cross-section the area of the lumen
was calculated. Then the total area of the neointima, the stent sections and lumen was
measured and the luminal area subtracted. At a higher magnification, further measurements
were made of each quarter of the vessel. This allowed more precise tracing of the boundary
between media and intima and gave a measure of the average intimal thickness within each
quarter. The results for each quarter were averaged to give the mean intimal depth in that
cross-section of the vessel. All measurements were performed by a single, blinded observer.
To ensure the results were reproducible, three randomly selected vessels were re-measured
and the various measurements plotted against the first reading. Intima:media ratios were also
calculated. Luminal area was measured in all the 28-day specimens and the results compared
both between the two treatment groups and against the day 0 (baseline) average luminal area
(i.e. an indication of late luminal loss).
4.2.4.2.4 Tissue fixation and staining.
H&E staining of tissue specimens was performed as described in Appendix 2.
4.2.4.2.5 Injury scoring.
The results at 28 days were observed to determine whether the original injury suffered by the
stented vessels were similar in the two groups. This injury scoring, which was done by a
single blinded observer, was done using the previously published and validated scoring
system of Schwartz et al1&. This work graded the injury seen in porcine stented arteries,
using wire stents. Stented vessels were cross-sectioned and stained. For each wire site, a
histopathologic score proportional to injury depth and the neointimal thicknesses at that site
were determined. A mean score for that vessel was calculated by dividing the total of all the
injury scores for that site by the number of wire sites seen.
The scoring system that was described in this paper and was used here is as follows. Two
slides (out of the 20+ from each specimen) from each stented vessel were examined. Each
vessel was examined microscopically and the number of stent/vessel contacts was counted.
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Each contact point was then scored as follows to indicate how much injury that stent section
had caused to the adjacent vessel wall:
Score Description of injury
IEL intact, media compressed slightly
IEL lacerated, media compressed
IEL lacerated, media compressed >50%, EEL
compressed but intact






(IEL = internal elastic lamina, EEL = external elastic lamina)
The value obtained for each stent section was added up and the total divided by the number
of stent struts visible in that cross-section. An average injury score for each slide was
calculated. The two slides for each stent were then averaged and the values obtained
compared between the VEGF-stent and plain-stent groups.
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Figures 4.2. Varying injuries to vessel wall. These pictures demonstrate the
different injuries seen in the rabbit iliac vessel after stent insertion. Variable
severity of injury is seen with damage progressively to the internal elastic
lamina (IEL), the media and the external elastic lamina (EEL). Rarely, the
injury can be so severe that the stent section breaks right through into the
adventitia.
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4.2.4.3 Method for study of systemic distribution of VEGF from in vivo studies.
Since the main reason for using stent-based delivery is to ensure a local delivery of VEGF at
the target site, it was decided that the extent, if any, of systemic delivery should be
evaluated. During the termination procedures of the various parts of the in vivo studies,
samples were taken of liver and kidney tissue, the most likely organs to eliminate any
excessive amounts of VEGF. The presence of above normal concentrations of VEGF in
either of these tissues would demonstrate the extent to which VEGF delivered locally was
being distributed systemically. The technique used to detect VEGF in these tissues was an
immunoassay (Quantikine DVEOO) using techniques suggested by the manufacturers (R&D
Systems Europe Ltd).
Liver and kidney tissue was stored at 4°C in 4% formalin solution. Tissues were then
vacuum-dried for at least eight hours using a FTS systems Flexi-dry MP machine. This gave
a desiccated sample. The dried samples were then powderised with a mortar and pestle in
liquid nitrogen, which aided the fragmentation of the samples. The powdered tissue was
added to 4ml HEPES buffer (see appendix). The resulting solution was then homogenised
and centrifuged at 3000g for lOmin at 2°C. The supernatant from this was collected and
centrifuged at 100,000g for 45min at 2°C for 45min. The resultant supernatant was collected
and labelled as the cytosol fraction. The pellet was washed with HEPES buffer and re-
suspended in TBS buffer using a small glass-glass homogeniser to yield the membrane
sample. Total protein content of each preparation was determined using the Pierce-Bradford
reagent (see below). The amount of VEGF was detected using the VEGF Quantikine kit
(DVEOO) from R&D systems. This involved diluting 25pg of the sample solution in RD5K
(buffered protein base and preservatives) diluent from the kit to a final volume of 200pl.
Where insufficient protein was in the samples, 200(itl was used directly and the amount of
protein this represented recorded. A VEGF dilution series was made using the stock solution
of 2pg/ml VEGF provided in the kit. Doubling dilutions were performed using RD5K as
before.
A micro-plate pre-coated with monoclonal antibody specific to VEGF was used. 50pl of
assay diluent was added to each well, followed by 200pl of either standard solution
(including zero blank) or sample. The samples were incubated at room temperature for two
hours. Each well was then aspirated dry and washed three times with wash buffer, taking
care to remove all fluid after each wash, to wash off any unbound substances. To each well
was then added 200pl of VEGF conjugate. This polyclonal antibody for VEGF had been
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conjugated with horseradish peroxidase (HRP). The conjugate was also left for two hours at
room temperature to adhere to all the VEGF present. Unbound conjugate was removed by
again washing each well three times. 200)il of substrate solution (hydrogen peroxide and
tetramethylbenzidine) was added to each well. This was metabolised by the HRP to form a
coloured product. The reaction was halted after 20min by the addition of an acidic stop
solution. The plate was then counted for the absorbance of each well at 450nm. Readings
were adjusted for optical imperfection in the plate by also reading the plate at 540nm and
subtracting these readings. All readings were also corrected by the subtraction of the reading
obtained in the zero standard well.
A standard curve was drawn of the absorption and a formula calculated that allowed the
absorption measurements to be correlated to a concentration of VEGF in each of the samples
examined. The readings were finally expressed as nanograms of VEGF per gram of total
protein.
4.2.4.3.1 Protein estimation.
Total protein in each sample was calculated using the BCA reaction19. The reagent is made
up using a 1:50 ratio of BCA Protein Assay reagent B: reagent A. (Pierce). 200|il of this mix
was put into each well of a 96-well plate with 50pl of diluted sample or diluted standard. The
BSA standard was serially diluted to provide data for a standard curve {see fig. 4.3). The
combined solution was gently agitated to mix the reagents and then incubated at 37°C for
30min. The plate was then counted in a colorimeter at 540nm.
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Figure 4.3. Standard curve obtained using the Pierce Bradford reagents.
This allowed the calculation ofprotein content of tissue samples.
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4.2.5 Statistical Analyses and power calculations.
Power calculations for sample sizes were calculated using MINITAB software as follows. In
designing the study sample sizes had to be compatible with Home Office guidelines about
reducing the number of animals in the study where possible. The paper by Van Belle et al
that had used similar methods with plasmid-derived VEGF was used as a guide to the likely
observed differences expected in work with a VEGF-eluting stent. 2-sample t-Tests were
used with a predicted power of 90% and a significance value of p<0.05.
a) Stent endothelialisation
In Van Belle's paper the actual difference in means of percentage was 54%, (SEM 7.4%,
n=7 SD=0.196). To reproduce these results, the sample size needed would be 5. To calculate
sample sizes in this work, a smaller reduction in endothelialisation was assumed. Alpha =
0.05, sigma = 0.196, mean difference of 0.35, target power of 0.9. This resulted in a sample
size required of 8 (actual power of 0.9127)
b) Restenosis
In Van Belle's work the actual difference in means of intimal hyperplasia areas was
0.83mm2, (SEM 0.11, n=8 SD=0.31). To reproduce these results sample size needed would
be 5. To calculate sample sizes in this work, a smaller reduction in restenosis was assumed.
Alpha = 0.05, sigma = 0.31, mean difference of 0.55, target power of 0.9. This resulted in a
sample size required of 8 (actual power of 0.9093)
The sample size for both endothelialisation and restenosis groups was eight animals. This
gave a highly powered probability of detecting substantial differences between plain and
VEGF coated stents. This number of animals was furthermore a practical proposition that
took into account ethical considerations without compromising scientific rigour.
Data are presented as means ± standard deviation unless otherwise stated. Differences
between means were compared using the two-tailed Student's T-Test, assuming unequal
variance. Differences between plain polymer and VEGF-coated stents were analysed using
the t test unless the data were non-normally distributed, in which case a non-parametric test




4.3.1.1 Flow following stent implantation/cyclic flow variations.
Flow measurements were obtained from six animals (i.e. 12 vessels), four control and two
given VEGF-coated stents. Two of the animals assigned to the VEGF-coated stent died
intraoperatively. This occurred before the stents were implanted and it was felt therefore that
the stent assigned was not related to the cause of death. Flow was measured before stent
implantation with and without occlusion of the distal vessel. This allowed calculation to be
made of the reduction in flow due to the tying off of the distal femoral artery. The results of
these measurements are shown below (fig. 4.4.), together with an example of the flow seen
during this procedure (fig.4.5).
In all the animals that survived long enough to have stent implantation, flow was preserved
at a rate similar to that seen after temporary femoral artery occlusion prior to stenting.
Changes suggestive of CFV was only seen in one vessel, one of the animals receiving a
normal, drug-free stent. The changes in flow that indicate CFV are shown below (fig. 4.6).
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Figure 4.4. Flow through iliac arteries prior to stent insertion. No significant
differences existed between the two groups prior to stenting. After ligation,
flow was still about 53% of that prior to tying the vessel (53.1+19.7 %).
n.b. Although results are given for both "VEGF" and "control" stents, this
differentiation is arbitrary because, at the time of flow recording, stents had
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4.3.1.2 Deposition of indium-labelled thrombus.
After the two-hour flow observation period had been completed, stented vessels were
dissected free. They were flushed gently with saline to remove blood, but not adherent,
formed thrombus and then fixed in formaldehyde. Any adherent fat or adventitia was
removed. The vessels were then counted in a gamma counter along with samples of the
labelled platelet solutions for each rabbit. Together with the known platelet counts per
animal these counts allowed a calculation to be made that related the radioactivity associated
with each stent to be converted into the number of platelets adhering to the stents and stented
vessel wall. These results are shown below (fig. 4.7).
Labeling efficiency was calculated each time the platelets were labeled. This was 86.2±6.6%,
in keeping with published efficiency in similar work and demonstrated that the labeling
technique itself was done effectively.
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Count
Stent Animal Stent per Platelets Mean platelets Standard
counts platelet per stent per stent in
each group
deviation
Control 1 57829 24.4 2369.7 19464.0 24497.2
60703 2487.5
2 43971 2.42 18163.7
47113 19461.6
3 84398 17.9 4709.5
97292 5429.0
4 48040 1.74 27613.0
131314 75478.3
VEGF 1 38605 6.50 5934.0 3377.9 2950.1
38586 5931.1
2 34037 39.5 861.7
30992 784.6
Figure 4.7. Results of Indium-labelled platelet deposition on stented iliac
vessels. Variability was seen, particularly in the platelet count per animal.
Two animals died perioperatively in the VEGF group, but before the stent had
been inserted. No data were obtained therefore from these animals. No
statistically significant difference in platelet adhesion was seen (p= 0.20; 95%
CI -3444,69544).
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4.3.2 Chronic model - day 7 results.
4.3.2.1 Thrombus formation.
2/8 stents in the control group were deployed too distally and were not deployed fully open.
They both were filled with occlusive thrombus. These stents were not included in the
analyses. 2/8 in the control group and 1/8 in the VEGF were deployed in the lower aorta
rather than the iliac artery as originally planned. These stents were deployed otherwise
normally and they were included in the analyses. Removing these results from the analysis
gave an even greater difference between the stent groups, so any bias due to the different
artery used if anything decreased the observed differences. The observed amounts of
thrombus are reproduced below (fig. 4.8).
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Treatment Stent Extent of Comments Thrombus Thrombus
number thrombosis (wet) (dry)
Control 1 Occlusive 92mg 17mg
2 Minor lOmg lmg





5 Luminal Stent in aorta 15mg 2mg
6 None Stent in aorta 0 0





VEGF 1 None 0 0
2 None 0 0
3 None Stent in aorta 0 0
4 None 0 0
5 None 0 0
6 None 0 0
7 None 0 0
8 Minor Stent detached
from vessel
<lmg <lmg
Figure 4.8. Table of results of stent thrombosis. Median clot demonstrated
was 12.5mg in control stents vs. Omg (p=0.0142; 95% CI 8.49,55.99) in
VEGF stents. The stented vessels were examined after seven days. Visual
inspection was made as to the extent of any adherent thrombus. This was
carefully removed from the vessel and weighed, both wet and dry. Where the
stent was deployed other than in the iliac artery this was also noted.
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4.3.2.2 Endothelialisation.
4.3.2.2.1 Light microscopic appearances.
Almost all the sections showed uniform Evans' Blue staining, suggesting that no significant
endothelialisation had occurred, or that any endothelial cells that were present were
completely dysfunctional (fig. 4.9). 2/7 control sections and 3/8 VEGF sections were not
stained at all, mainly due to blood clot adhering to the section preventing any staining.
In four of the control vessels endothelial recovery was absent because these were completely
occluded with thrombus. Of the remaining four vessels, three had macroscopically visible
thrombus that would have prevented some endothelialisation. In the remaining stent (CE6),
which had had no visible thrombus, the Evans' Blue staining was homogenous, suggesting
no significant endothelial recovery. Examples of all the light microscopy findings are shown
below (fig 4.10). The results of the Evans' Blue staining were inconclusive. No clear
demarcation was seen between newly endothelialised sections (or areas that had never had
any endothelial damage) and de-endothelialised areas. In both groups a very similar, diffuse
staining for Evans' Blue was seen in most of the stents, suggesting little or no
endothelialisation had occurred. The lack of clearly demarcated boundaries between stained
and unstained vessel wall meant computer morphometry measurements to quantify more
precisely the degree of staining were not possible. In two of the vessels (VE6 and VE7)
Evans' Blue staining appeared patchy, suggesting some re-endothelialisation had occurred.
These sections were studied in particular detail under scanning electron microscopy.
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Stent group Number Extent of re-endothelialisation Other comments






7 Unable to determine Dark Brown, clotted
VEGF 1 3
2 Unable to determine Yellow
3 1
4 Unable to determine Dark brown, clotted




Figure 4.9. Table showing the blinded assessment of Evans' Blue staining. A
score of 1 to 5 (increasing endothelialisation) was used to produce a semi¬
quantitative result.
A verage count in control =2.0
Average count in VEGF = 2.2 (p=0.74).
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Figure 4.10a Undamaged aorta (CE7) (x20 magnification).
Figure 4.10b. Control stent (CE7). Note superficial adherent thrombus (x20
magnification).
Figure 4.10c Control stent (CE5). Note transition from white (undamaged
endothelium) to blue (de-endotheliallsed tissue). Adherent thrombus visible
as orange (x10 magnification).
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Figure 4.10d. Control stent CE1. This stent was totally occluded and so took
up no Evans Blue dye at the stent site. Much adherent thrombus is visible
(x10 magnification).
Figure 4.10e. VEGF aorta (VE6). The black shadow is artefact from a pin in
the tissue (x20).
Figure 4.10f. VEGF stent (VE6). Although much of the specimen is blue,
there are patches of white vessel (arrowed), within the stent that suggest re-
endothelialisation (x10).
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De-endothelialised tissue Re-endothelialised tissue
(blue) (white)
Figure 4.1 Og.VEGF stent (VE6). Higher power picture of same vessel as in
4.10f, showing partial re-endothelialisation (x40).
De-endothelialised tissue Re-endothelialised tissue
(blue) (white)
Figure 4.10h. VEGF stent (VE7). This section also showed patches of white
vessel, suggestive of re-endothelialisation (x40).
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Figure 4.10i. VEGF stent (VE1) with little endothelialisation evident other than
at the extreme end of the stent. In the figure, a sheet of endothelium is seen
encroaching over the end of the stent struts (arrowed) (x40).
Figure 4.1 Oj. VEGF stent (VE2). In this section the stent has been removed
following staining to show the vessel wall underlying the stent struts (x40).
Figure 4.10a-j. Light micrographs of stented, Evans' Blue stained tissue. All
sections were taken from animals terminated seven days after stent insertion.
Evans Blue dye was administered systemically 30min before termination and
tissue retrieval. All photographs were taken using a cold light source from
above (giving occasional bright, white reflection artefacts). The film used was
800 ASA.
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4.3.2.2.2 Scanning electron microscopy.
Undamaged areas of perfusion-fixed aortae were examined under scanning electron
microscopy to provide negative controls where the endothelium had not been damaged. An
example of such a section is shown below (fig. 4.11). In many of the vessels with control
stents, extensive sheets of erythrocyte-rich thrombus had formed (fg. 4.12). Vessels with
VEGF stents had a similar picture. No significant re-endothelialisation was seen in the
stented segments. Less than 10% of the surface of the vessel wall was re-endothelialised.
Stents VE6 and VE7 appeared to show patches of endothelial recovery in between stent
struts, although the struts themselves remained completely devoid of endothelial coverage.
Examples of these endothelialised areas are shown below (fig. 4.13.a&b).
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15KU 26.6X 376b1 801
396X 25.3H 8012 UE5QS15KU 1.00KX 10.0H 8015 VE50S
Figure 4.11. SEM pictures of undamaged, perfusion-fixed, rabbit aorta. The
luminal aspect shows typical parallel ridges of endothelial cells. Top x26.6,
Bottom left x396, bottom right x1000.
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15KV 1.00KX 10.0f 7964 VE5ST
Figure 4.12 Scanning electron microscopy of stents in situ showing extensive
thrombus formation on the stent (dark arrows). Underlying these thrombus
sheets, de-endothelialised tissue is seen (white arrows). Increasing
magnifications up to 1000x.
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Figure 4.13a Stent VE6 at low and high SEM magnification. This shows
endothelialisation between stent struts (arrowed).
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1 5KU
Figure 4.13b Stent VE7 at low and high SEM magnification. This shows
endothelialisation between stent struts (arrowed).
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4.3.3 Chronic model - day 28 results.
4.3.3.1 Injury scores.
No differences were seen in the average injury scores for the restenosis specimens at 28 days
(Control 1.0+0.28 vs. VEGF 1.0±0.16, p=0.91).
4.3.3.2 Digital morphometry of media, intima and lumen.
Lumen measurements in the acute model samples obtained at day 0 are shown below
(fig.4.14). The internal control results are shown in graph form (fig.4.15). The results of the
measurements of neointimal and media areas and thicknesses are summarised below,
(fig.4.16). No significant difference was seen in neointimal thickness or area between the
two groups. Media area and media thickness also showed no statistically significant
differences between the two stent groups. A slight trend (p=0.07) towards a smaller media in
the VEGF group was detected. The reduction was 24% and 21 % for media thickness and
area respectively. Comparison of luminal size at 28 days, including comparison with luminal
area in the day 0 (acute model) stents was made. No significant difference was seen in
luminal area between the control and VEGF-coated stents. A trend towards decreased
luminal area was, as might be expected, seen between baseline measurements and those
obtained at 28 days (p=0.08 for both VEGF and control compared to day 0).
In the control group an average intima:media ratio of 1.99 ± 1.05 was seen vs. 2.19 ± 1.06
(p=0.73). No evidence of positive remodelling was seen.
4.3.4 Chronic model - systemic delivery of VEGF.
The amount of VEGF detected in liver and kidney tissues is shown below (fig. 4.17).
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Control VEGF
Figure 4.14. Comparison between day 0 (baseline) vessel lumens. No
significant difference was seen (p=0.32) between the two groups at day 0,
suggesting that the stents were equally deployed in the vessels. Values
quoted are means±SD.




Correlation between readings stent 11
count 1 (um2)
Figure 4.15b
Correlation between readings stent 24
count 1 (um2)
Figure 4.15c
Figures 4.15a-c. Internal controls of cross-sectional digital morphometry. A
high degree of correlation in measurements of areas was seen. Thus, the
readings can be confidently said to be reproducible (P=Perimeter (pm), M=
media, 1= intima, L=lumen, L+I=lumen plus intima, W=Whole vessel).
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Figure 4.16. Results of digital morphometry of stented cross-sections at 28
days. Results are mean+SD.
Treatment VEGF in ng/g total protein
Control stent day 7 kidney 807
Control stent day 7 liver 2455
Control stent day 28 kidney 5990
Control stent day 28 liver 255
VEGF stent day 7 kidney 312
VEGF stent day 7 liver 1572
VEGF stent day 28 kidney 1190
VEGF stent day 28 liver 255
Tissue with lOftg exogenous VEGF (positive control) 260974
Figure 4.17. Table showing the detected quantities of VEGF per gram of total
protein in various tissue samples from the experimental animals. The
average detected in the control animals was 2575±2390ng/g VEGF. Samples
from VEGF treated animals were 832±653ng/g VEGF, p=0.32 suggesting
that no detectable increase in VEGF was present as a consequence of the




The stent model used in these studies is a model known to have a high thrombosis rate. In
this work in the control groups three out of six vessels showed partial or complete
thrombotic occlusion. This was due to a combination of flow reduction and deep vessel
injury. Although deep vessel injury does occur after stent implantation in clinical practice,
use of flow reduction represents a divergence from the clinical situation.
The model allows for an evaluation of any effects of the therapy on thrombosis rates. In
clinical practice, with normal flow rates, this is a rare event. To study it in an animal model
without prohibitively large numbers of animals being sacrificed necessitates a model like this
one where thrombosis rates are higher. Flow reduction may allow longer persistence of
VEGF thereby exaggerating its benefit, although the in vitro elution studies discussed in
section 2.3.2. showed no significant change in elution rate of VEGF with a flow model
compared to a "simple elution" model. Some effects on restenosis may result from this low
flow model compared to a normal flow model, but this effect will not be more or less in one
group, so should not introduce bias into the results.
A bolus dose of 1000IU of heparin was given to all animals. Practical considerations limited
the ability to monitor coagulation parameters intra-operatively. It was impossible to
accurately size stents for implant as angiography was not available. Stents were all the same
size, but vessel diameter will have varied to some extent.
It is worth noting that local delivery studies performed in animals often, as in this case, use
vessels that do not closely resemble the coronary arteries in humans. Firstly, the coronary
arteries have a high number of small side branches. This means a great deal of the drug will
be lost down these branches where it is not needed. Secondly, in clinical practice, it is
patients with significantly atherosclerotic arteries who require these procedures. An
atherosclerotic plaque is highly vascular and in these lesions a considerable proportion of
drug delivered will pass down the vasa vasorum, away from the intended site of action20.
No direct measurement of VEGF delivery into the stented tissue (apart from the in vitro
work with IMA specimens).
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4.4.2 Flow changes.
CFVs are due to platelet adhesion within the vessel and occur more rarely in the presence of
antiplatelet medications. In the model used for this work two separate antiplatelet agents,
aspirin and clopidogrel, were used as well as the anti-thrombotic heparin and, in half the
cases, VEGF. High doses of aspirin given intravenously have been shown to abolish CFVs in
a canine model21. Clopidogrel, at a much higher dose than in this work, has also been shown
to abolish CFVs in a primate model of thrombosis22. The antiplatelet drugs given to the
animals in this work may have greatly reduced the chances of vessel thrombosis and
therefore CFVs. The flow recordings performed in the acute model animals show a large
drop in flow of around 50%. Despite this, flow was maintained in all the vessels throughout
the recording and no vessels occluded in the two-hour observation period prior to the animal
being killed. One vessel displayed the changes suggestive of CFV, but there are not enough
data to conclude any reduction in thrombosis due to the presence of VEGF on the stents
used.
4.4.3 Endothelialisation.
No evidence was obtained of accelerated endothelialisation using the VEGF-eluting stent in
this set of experiments. Light microscopy using Evans" Blue dye gave very dense staining of
the specimens with the dye. This suggests little or no functional endothelium. No discernible
differences were seen between the two groups. Under scanning electron microscopy, this
finding was confirmed. Stent struts remained either completely exposed or were covered
with sheets of organised, erythrocyte-rich thrombus. In isolated areas, re-endothelialisation
had commenced, but with no convincing evidence that this was occurring faster or more
comprehensively in the VEGF-treated group than the controls.
Therefore, at the time point chosen (seven days), in this particular rabbit model and using
this stent/polymer combination, re-endothelialisation was significantly less than had been the
case in similar studies at the same time point. In contrast to the published work of Van Belle
et al, where VEGF had produced 90% endothelial coverage by this time, less than 10% of
the stents structure was endothelialised in this work. There was, subjectively, more evidence
for re-endothelialisation between stents struts in two of the specimens studied that had had
VEGF-eluting stents implanted.
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Two main issues arise from these negative results - the slower endothelialisation than
expected in the control vessel and the lack of benefit in VEGF coated stents compared to
controls.
The slower endothelialisation may reflect differences between the model used in this work
and that used in the similar work by Van Belle et al. A different stent was used. The stent's
physical effects on the vessel may have been responsible for the delayed endothelialisation.
It is possible that it presents a more thrombogenic stimulus than the stent used in other work
or that the vessel wall injury is more severe, although this was not detected using the injury
scoring system. Apart from the structure of the stent, the polymer coating itself may have
had an adverse effect on the endothelialisation process. This polymer has not been tested
clinically and although designed to have little or no negative effects on inflammation,
thrombosis or restenosis, may have done so in this model. It is perhaps noteworthy that the
polymer coating was not completely smooth and even. Under SEM examination {see fig 2.5),
it was evident that the polymer was of varying thickness. SEM showed gaps between the
metal of the stent and the overlying polymer, i.e. faults in the coating process. The surface of
the polymer did not present an absolutely smooth surface and numerous minor imperfections
and irregularities were seen. The polymer may have had adverse effects on the vessel -
through thrombosis, inflammation or turbulent bloodflow - either from its physical structure
or from interactions with the blood and tissue. In this work, NZW rabbits were used
weighing between 3.0 and 4.4 kg, mean 3.6kg. In Van Belle's work, the rabbits were larger
(5-5.5kg). This difference may be important because a relatively greater injury, due to
smaller average iliac artery sizes, may have been induced in the smaller animals. This greater
injury from a relatively larger stent may have impeded endothelial recovery. As well as the
stent injury, the arteries were also injured by repeated (over)inflation of the angioplasty
catheter. This catheter was longer than the subsequent stent. At each end of the stent there
would have been, therefore, a balloon-injured, de-endothelialised area. If much of the re-
endothelialisation process occurred from the two ends of the stent, as appeared to be the case
in the stents examined for endothelialisation, then the balloon-injured area outside the stent
may have slowed down the ingrowth of endothelial cells, delaying stent re-endothelialisation
beyond the seven day period under study. The balloon was deliberately longer than the stents
used because of the technical difficulties in ensuring that the stent was implanted exactly
over the angioplastied site. With the larger balloon this could be done with some confidence,
as there was some margin for error. In clinical practice this is not necessary as the stent is
placed in the correct site under direct visualisation.
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Other small differences exist between the model described in this work and those previously
published. Most of these seem unlikely to have exerted any effects on endothelialisation.
One significant difference in this work compared to previous groups was the use of
clopidogrel as part of the standard treatment before and after stent implantation. This was
done partly to minimise the incidence of acute stent occlusion in a relatively pro-thrombotic
(reduced-flow) model. As importantly, it was used throughout since this is what is done in
clinical practice and brings the model closer to reproducing the effects seen in patients after
PCI. No obvious explanation exists for why clopidogrel might slow endothelialisation and so
this difference in technique is probably not a contributor to the delayed endothelialisation
seen. It is assumed that the lack of endothelialisation in the samples seen reflects accurately
what occurred in the animals during life. It is possible that the removal of the stented vessel
and subsequent processing may have dislodged any lightly adherent endothelium around the
stent struts. Great care was taken during handling of the specimens to prevent this
eventuality.
VEGF seemed to have no beneficial effects on the endothelialisation process, Several
possible explanations for this may be postulated. VEGF may have been washed off the stent
quicker than expected from the in vitro results. This may have occurred before the
implantation process, as the stent was passed through the femoral vessels. During this
passage, the stent was exposed to blood, which may have washed off some of the most
superficial VEGF. During implantation, great stress is placed on the structure of the stent and
polymer as the stent is expanded using high pressure. This distortion of the delivery vehicle
may have released VEGF into the bloodstream to be washed away ineffectually.
Calculated elution was that in an in vitro circuit. This may be different from the elution in
vivo in important ways. The stents in vivo are exposed to all the components of the blood,
including transport proteins that may absorb VEGF, enzymes that may degrade it and the
coagulation cascade that may have sealed VEGF within the polymer and prevented its
release. VEGF may have been released, but not where its effects could be exerted. No
endothelialisation was seen under stents. Here, where the VEGF-soaked polymer had been
pressed into the vessel wall, there was no room for endothelial cells to grow in from the
sides. Most of the absorbed VEGF from the stent may have been released into the vessel
wall, where there are no target cells for VEGF. This may be compared with balloon delivery
where VEGF is delivered to tissues (including any residual endothelium in the main vessel
or that in side branches with endothelial cells) where endothelial cells are still present.
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VEGF may have been washed off downstream and lost. Only that amount which was
released between the struts would potentially be exposed to the target endothelial cells. It
may be that not enough VEGF was delivered laterally along the vessel wall to have any
benefits - although enough did appear to have been released to reduce thrombosis.
Thrombosis occurs earlier than endothelialisation and so relatively small amounts of VEGF
released quickly after implantation may be enough to prevent thrombosis but not be
sufficient or sufficiently prolonged to stimulate re-endothelialisation. Insufficient VEGF may
have been delivered with this stent. In Van Belle's work lOOpg was delivered locally. The
VEGF stents in this work carried approximately 10|ig. Local delivery by balloon has been
shown to be a very inefficient means of delivering drug and the apparently low amount of
VEGF delivered by stent is likely to be delivering a higher amount of VEGF locally in
practice, once the inefficicency of balloon delivery is accounted for.
Endothelial cell proliferation may have been occurring at a maximal rate. VEGF may have
not been able to increase the rate of endothelial cell growth above that produced by the
vessel injury in the first place. VEGF may have been denatured or inactivated by the
storage/sterilisation process. Stents were kept, refrigerated for up to two months after initial
absorption with VEGF. In addition, VEGF-coated stents were sterilised using a cold ethylene
oxide sterilisation process. This treatment reflects the minimum level of sterilisation required
for products to be used in humans and the storage time is a realistic reflection of the storage
time of interventional products before their use. In order for the VEGF-coated stent to be
anything other than of research interest it must retain effectiveness through such treatment.
No loss of VEGF's effects was seen in the cell culture work where the VEGF-coated stent
sections were ethylene oxide sterilised, so it seems unlikely that this had any adverse effects
on the stents used in vivo. There seems to be no obvious reason for VEGF to degrade
spontaneously during a two-month storage period. VEGF is normally refrigerated for storage
and remains active for at least a year (according to manufacturer's literature). Finally, it may
be that VEGF remained active throughout the procedure and in adequate amounts but that it
is simply not a powerful enough mitogen to produce the desired effect. Despite its name,
VEGF's most pronounced effects are on vascular permeability and not cell proliferation. In
the cell culture experiments, only a modest increase in endothelial cell growth was seen;
about 10% higher than that seen with controls. The extent of endothelial loss in this model
was very great and any minor improvement in endothelial recovery may have been
undetectable. Such a small amount of accelerated re-endothelialisation would be clinically
insignificant. It interesting to note the poor results obtained in clinical trials of VEGF where
it has not led to any clinically significant proliferation of blood vessels (neoangiogenesis),
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despite its anticipated stimulation of endothelial (and so blood vessel) growth. Such a poor
proliferative effect of VEGF may explain its failure to stimulate re-endothelialisation in this
model, but would leave unexplained the strikingly positive results obtained by Van Belle et
al.
4.4.4 Thrombosis.
Previously published work where VEGF has been delivered has focused largely on the
effects of this agent as a promoter of endothelialisation, thus reducing intimal hyperplasia.
VEGF is responsible for the production, by endothelial cells, of a number of factors that act
on the coagulation and platelet activation systems (see 1.8.4).
In the rabbit iliac artery model, an apparent reduction in macroscopic thrombus accumulation
was seen at the seven-day time point, with a significant difference between the VEGF-coated
and the uncoated stents. At the earlier time point, no significant differences were seen in the
amounts of radio-labelled platelets measured as adhering to the stents, although this may be
due to the variations in the readings, which gave wide error bars.
The mechanism behind this apparent finding is unclear. VEGF may act as an inhibitor of
thrombus formation, through its stimulation of NO, PGE, tPA and urokinase. To exert such
effects however, VEGF must act through the medium of functioning endothelial cells, since
VEGF has no direct antiplatelet or anticoagulant effects. It has already been discussed that in
these studies, little or no endothelium was to be seen over or amongst the struts of the stents,
even those treated with VEGF. How then can VEGF be said to be responsible for the
apparent reduction in thrombus formation in the VEGF treated stents?
VEGF is released from the polymer of these stents quickly, and in a sustained fashion, as
reported in chapter 2. Inevitably, some of this VEGF is washed downstream from the site of
stent implantation, or down small side branches from the main artery near the stent site.
These downstream or side vessels remain endothelialised, since they were not injured by the
percutaneous intervention. These cells may be stimulated to produce significant quantities of
anticoagulant/antiplatelet factors that exert local effects, including around the nearby stent.
Some VEGF may permeate, through the vessel wall, to the endothelial cells that immediately
border the stent upstream.
As well as an effect on thrombus formation through platelets, VEGF may have other indirect
but equally important actions on clotting. In this reduced flow model, thrombus formation is
promoted. VEGF, acting through endothelium-derived NO, may produce vascular relaxation,
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increasing flow and inhibiting thrombus formation. No increase in flow was seen in the
arteries treated with VEGF-coated stents.
Any effects of stent-delivered VEGF on thrombosis must occur at low delivered doses, or
over much shorter time point, since no re-endothelialisation was seen over the same time
points. Further work would need to be performed, directed at the effects of VEGF on stent
thrombosis, for these results to be validated. Without a credible mechanism for a VEGF-
mediated reduction of thrombus independent of effects on the endothelium, the results in this
study have to be treated with caution, unless confirmed in any subsequent studies.
4.4.5 Restenosis.
No benefit in reducing restenosis was seen in these results. Any possible beneficial effects on
reduced thrombosis were not accompanied by a corresponding reduction in intimal
hyperplasia. The explanation for the lack of any reduction in intimal hyperplasia lies with the
observed failure of VEGF-eluting stents to promote re-endothelialisation. VEGF has no
direct effects on smooth muscle cell proliferation, requiring a functional endothelium to
passivate the underlying vessel wall. Since no endothelium was seen coating the VEGF-
eluting stents, intimal hyperplasia was likely to continue unchecked until much later than
hoped for.
4.4.6 Systemic delivery.
No increase in VEGF was seen in the distal tissue studied at the two study endpoints.
Although sustained VEGF release had been demonstrated from this stent polymer in the
earlier experimental work, this released VEGF was not seen in appreciable amounts distant
from the stent in the tissues where it was most likely to be metabolised or excreted from the
animal's body. The lack of VEGF detection in distant tissues suggests that significant
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In this chapter the results of the work with locally delivered VEGF will be summarised. The
scope for further study of VEGF-eluting will be discussed. The place of VEGF-eluting stents
in humans will be explored in particular, including the limitations on their use. Finally,
conclusions will be drawn from the whole body of experiments described thus far.
5.2 Radiolabelling experiments
The absorption of approximately 20gg VEGF per stent into the polymer is within the range
of delivered VEG that had been shown to exert a significant effect on the recovery of
endothelium over a stent in previous studies. In the elution experiments attempts were made
to recreate the physiological conditions the drug-coated stents would be exposed to in vivo -
flow, pH, temperature and plasma proteins. The sustained VEGF release over a week with
VEGF-eluting stents may be contrasted with other forms of local delivery, especially local
drug delivery balloons. In these forms of delivery, drug delivery can only occur for as long
as the delivery device is left in the target vessel. Furthermore, the internal mammary artery
tissue experiment showed that a much higher proportion of the VEGF was retained in the
tissue than is the case with delivery balloons.
5.3 Cell culture work.
5.3.1 VEGF-eluting stents in cell culture.
VEGF was released in sufficient quantities to exert a stimulatory effect on nearby endothelial
cells, in the same way as was hypothesised would need to be the case in vivo, when the
VEGF released from the stent would have to diffuse around the stent struts sufficiently to
stimulate the growth of residual endothelial cells within or near to the angioplastied area of
artery. The increased HUVEC proliferation was also seen in cell cultures, exposed to a
VEGF-absorbed stent that had been washed for 24 hours with culture medium beforehand.
This meant that the VEGF elution from the stent was sustained well beyond the initial
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immediate wash off of VEGF, and that this sustained release of VEGF was sufficient to exert
a beneficial effect.
The beneficial effect seen in all groups was modest, at around 10% more than that seen in
control groups of cell culture. In the light of the subsequent failure of such VEGF-eluting
stents to significantly improve the re-endothelialisation process, it may be that such a slight
improvement in endothelial cell growth is insignificant in vivo.
5.4 In vivo experiments.
The in vivo experiments did not show the expected improvement in endothelialisation or
reduction in intimal growth. There are many possible explanations for this finding, including
deficiencies in the techniques or model used. It seems likely however that the lack of
efficacy may well be a true finding as there did appear to be a detectable effect of the VEGF-
eluting stents, i.e. the reduction in measured thrombus formation on the stents. Such an effect
might make these stents less thrombogenic than current clinically used stents. This effect
requires ongoing in vivo evaluation. VEGF may be a suitable agent for local delivery by
stent in patients in whom a high risk of stent thrombosis may be anticipated, including
patients with small vessel stenoses.
5.5 Future studies of a VEGF-eluting stent.
The in vivo experiments leave doubt as to whether there is any place for a VEGF-delivering
stent. Three possible roles are now considered for the stent. These are:
> as an anti-restenosis device,
> to promote neoangiogenesis in ischaemic tissue,
> to inhibit stent thrombosis in high-risk situations.
5.5.1 VEGF-eluting stents to reduce restenosis.
VEGF has not been shown to speed re-endothelialisation or to reduce intimal growth in this
small animal model. It could be argued that there are important differences in the effects seen
in a peripheral artery, especially in abnormal flow conditions. To test the VEGF-eluting stent
in a coronary model would require the use of a larger animal, e.g. the porcine model.
VEGF has already been studied in a porcine model (see 1.8 and 1.9). However, no studies
have been performed in the pig that have given the VEGF in a sustained fashion.
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5.5.2 VEGF-eluting stents to promote neoangiogenesis
The VEGF-eluting stent could be tested for a neoangiogenic response in ischaemic tissues.
VEGF-eluting stents could be implanted in patients with critical limb ischaemia. Work
discussed in chapter 1 (1.8.9) used VEGF in patients with critical ischaemia to delay
amputation. A clinical trial would gather data on the safety/side-effect profile of the
stent/VEGF system and establish the efficacy of local VEGF delivery in humans.
Stents pre-absorbed with sterile VEGF could be placed percutaneously into the arterial tree
of the affected leg. The positioning of the stent would be immediately proximal to the
occluded section(s) of artery. The endpoints of such a study would be:
• Progression of disease sufficient to warrant amputation.
• Withdrawal due to side-effects/complications of VEGF or of stent implantation.
• At three months, angiographic reassessment of collateral density.
• Symptoms, ABPI, exercise tolerance and serum levels of VEGF would be assessed
at 7, 14 and 28 days and at three months.
If successful and safe, then a similar trial could be attempted in patients with severely
ischaemic myocardium who were judged to be unsuitable for traditional revascularisation
techniques.
5.5.3 VEGF-eluting stents to reduce stent thrombosis.
Stent thrombosis is, in general, a rare occurrence since the introduction of antiplatelet and
anticoagulant agents post-stenting. However, in certain situations, stent thrombosis remains a
relatively common, and potentially very serious, complication. One such high-risk group
would be patients undergoing vascular brachytherapy for restenosis (see 1.6.3.3). Late
thrombosis occurred in 9.1% of patients have suffered acute occlusion of the treated area,
40% of these with resultant myocardial infarction over a time period as long as nine months
post-treatment (see fig.5.1)1' .
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Figure 5.1. The incidence of late thrombosis in various brachytherapy trials.
These adverse findings may be due to the inhibitory effect that VBT has on the re-
endothelialisation process. Previous work has demonstrated that radiation slows re-
endothelialisation and degrades the morphology and function of endothelial cells in vivo3 1.
A VEGF-eluting stent may provide a reduced incidence of stent thrombosis in irradiated
vessels, either through a direct anti-thrombotic effect or by promoting re-endothelialisation
in a situation where it is particularly retarded by the effects of radiation on the endothelium.
To study the effects of the VEGF stent in such a situation the rabbit iliac artery model could
be adapted to include the use of a radioactive source (such as the BETACATH |3-emitting
train that is in current UK use) with either a plain stent or a VEGF-eluting stent inserted
after. Thrombosis would be assessed at various time points as has been done in the existing
animal work using the VEGF-eluting stent.
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5.6 Long-term future of locally-delivered VEGF.
VEGF may yet find a place as a locally delivered agent in human cardiological problems.
Three areas of research following on from the work of this MD thesis have been discussed
that would explore the potential of the VEGF-eluting stent. If these studies showed
encouraging results there are further obstacles to be overcome before the VEGF-eluting stent
could be used in mainstream clinical practice. These obstacles include concerns over the
safety of VEGF administration in humans.
• The aspect of most concern to any future use of VEGF in clinical trials is the risk of
death consequent to the therapy. Use of VEGF in clinical trials was temporarily
halted in 2000 after the death of a young man in an angiogenesis trial. In this case
large amounts of the adenoviral vector used to deliver DNA coding for VEGF was
accidentally injected into the patient's hepatic artery with fatal consequences8.
Ultimately it was felt that this case was not directly due to the use of VEGF, but
rather to the viral vector. No other deaths have yet been associated with VEGF use in
humans, but the total number of patient that have been treated with VEGF in any
form still is significantly less than 1000.
• VEGF is a potential carcinogen. Use of VEGF may have unwanted neoplastic effects
either in the heart or at distal sites, although this has not yet been demonstrated in
human subjects. Myoblasts genetically engineered to synthesise VEGF have been
implanted into the heart in a mouse model. Most animals treated with VEGF either
died or developed large tumours, usually of vascular origin9. In cell culture, VEGF
receptors have been demonstrated in uterine smooth muscle cells, which proliferate
in response to VEGF10. VEGF may therefore cause unwanted growth of uterine
tissue, e.g. fibroids. VEGF receptors have also been demonstrated in human cell
tumour lines including glioma, melanoma and squamous cell carcinoma of neck".
• Species differences in response to VEGF may be significant. VEGF has been shown
to reduce restenosis in a rabbit model (although not when delivered by stent).
However, in a porcine model, workers have not shown a reduction in restenosis.
Results in rats have been variable (see section 1.8.8). If interspecies differences can
be so great in the animal models, there is therefore no guarantee that VEGF will
exert an inhibitory effect on the in-stent restenosis process in humans, regardless of
any encouraging initial studies in animals. It is striking that, despite various positive
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studies in animals of locally delivered VEGF, there was no effect in the VIVA trial
(Vascular Endothelial Growth Factor in Ischaemia for Vascular Angiogenesis). In
this study, VEGF 165 was given to patients with untreatable severe ischaemia, most
of it by systemic delivery, with an intracoronary bolus. Despite some signs of
improved perfusion, no increase of exercise time or reduction of angina was seen
with VEGF compared to placebo. A strong, sustained placebo effect was seen12. In a
separate study, no ill-effects were seen in a series of ten patients who received
VEGF plasmid infusion into the coronaries after angioplasty13. This very small study
found no reduction in restenosis in the VEGF group. Finally, the KAT study failed
to demonstrate any reduction in restenosis using VEGF gene transfer (see section
1.8.12).
• VEGF is not purely an endothelial cell growth factor. One group has reported the
detection of KDR (VEGR-2) receptors on human smooth muscle cells in specimens
of atherosclerotic arteries14. The authors suggest that the atherosclerotic process
itself is the stimulus for the production of VEGF receptors in the smooth muscle
cells. It is not known whether these receptors have a significant effect in vivo.
Nevertheless, it is a disquieting finding that casts doubt over the appropriateness of
using VEGF as an agent to reduce restenosis in atherosclerotic vessels like the
diseased coronary. It is possible that in the presence of atherosclerosis, VEGF
promotes smooth muscle cell replication and might in fact exacerbate the growth of
neointima.
• The differences between healthy and atherosclerotic arteries may be of further
significance. VEGF may have the potential to accelerate atherosclerosis/destabilise
plaques. VEGF mRNA and VEGF receptors have been demonstrated in
atherosclerotic, but not normal, human coronary arteries15. VEGF may therefore be
an important promoter of the atherosclerotic process and exogenous delivery of
VEGF to diseased coronary vessels may accelerate the growth of these plaques. The
additional effects of VEGF (vascular permeability, chemoattraction for
macrophages) may destabilise existing plaques leading to increased risk of plaque
rupture and resulting acute coronary syndromes. This has not, as yet, been proven to
occur in the existing, small-scale, human trials of VEGF in ischaemic heart disease.
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5.7 Conclusions.
The work described in this MD thesis covers several new areas of investigation.
The potential for successful drug absorption and elution has been demonstrated for VEGF.
This was important, as one of the key advantages to the use of stents to deliver drug is that
the release of the drug is sustained. This has been demonstrated clearly and reproducibly
using radiolabeled markers. The effects of VEGF as a stent delivered agent have been
looked at in cell culture. To demonstrate the direct effect of a drug-coated stent on
endothelial cells is an original finding. Previous work records the effect of different drugs on
endothelial cell culture, but this work extends this by introducing the stent itself into the
culture dish. This may be important since in vivo the drug is released by passive diffusion
into nearby tissues, producing a gradient of concentration of drug that reduces the further
away the tissue is from the stent struts. Adding a drug in a solution to a cell culture dish
produces a uniform concentration across the dish. This model also allows for any direct
effect on cell growth of the stent or the polymer coating on the stent to be measured. In this
case there did not appear to be any such effect. The in vivo work is completely original since
VEGF protein has never been delivered bound onto a stent and so delivered in a sustained
fashion in such an animal model. Clear results have been obtained from this section of work.
No benefit to endothelialisation or restenosis was seen in the rabbit iliac model. The study
was powered sufficiently to detect any clinically meaningful result and so this negative result
may be confidently said to be a true conclusion. The result was obtained from soundly
designed experiments that predominantly used well-established methods that have been the
subject of published work in the past.
Although the ultimate results refuted the initial hypothesis under test, the methods used are
robust and will enable other research to be performed of a similar nature to test other
combinations of drug, polymer and stent. Some interesting results have been produced in the
course of the studies. VEGF appeared to inhibit endothelial cell growth in a particular subset
of cells, i.e. older passage cells in adverse culture conditions. Secondly, VEGF-eluting stents
appeared to reduce thrombus formation on the stents when assessed at seven days. These
results provide a starting point for further research into VEGF in the future. The possible
future usage of the VEGF-eluting stent have been discussed together with caveats regarding
the widespread use of VEGF in humans.
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The importance of the field of restenosis prevention has been emphasised, not least because
of the ever-increasing numbers of patients undergoing stenting. The work reported here is
part of a very dynamic research field. Ongoing and recently completed trials of various drug-
eluting stents have begun to produce very favourable looking results with substantial
reductions in restenosis and MACE, at least in the short to medium term after stent
implantation. It is not yet clear whether one agent will be superior to others. It seems more
likely that there will be a range of agents competing on the market. Some may have
particular benefits in different patient populations. VEGF-eluting stents may have a role in
preventing restenosis or thrombosis in particular situations where re-endothelialisation is
particularly likely to be poor.
The future of the drug-eluting stent appears to be very bright, with the promise of a therapy
that may spare many thousands of patients the morbidity and mortality associated with the
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Abbreviations
ABPI Ankle-Brachial pressure index
ADP Adenosine Diphosphate
BAEC Bovine aortic endothelial cells
BBS Borate Buffered Saline
BENESTENT Belgium Netherlands Stent study
BSA Bovine Serum Albumin
CFV Cyclic flow variation
DMEM Dulbecco's modified Eagle's medium
DMSO Di-methyl sulphoxide
EEL External elastic lamina
EGM Endothelial cell growth medium
EPIC Evaluation of 7E3 for the Prevention of Ischemic Complications
FCS Foetal Calf Serum
FGF Fibroblast growth factor
GAX growth-arrest specific homeobox
GRII Gianturco Roubin mark II stent.
H&E Haematoxylin and Eosin
HBSS Hanks Balance Saline Solution
HEPES N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
HUVEC Human umbilical Vein endothelial cell
IEL Internal elastic lamina
IHD Ischaemic Heart Disease.
IMA Internal mammary artery
IMS Industrial Methylated spirits.
IRIS Isostent Restenosis Intervention Study
ISR In-stent restenosis
IVUS Intravascular ultrasound
KAT Kuopio Angiogenesis Trial
LAD Left anterior descending artery
LDD Local drug delivery
LDL Low density lipoprotein
MACE Major adverse cardiac events.
MLD Mean luminal diameter
MMP Matrix metalloproteinase
NADH Nicotinamide adenine dinucleotide
NAME N(omega)-nitro-L-arginine-methylester
NO Nitric Oxide
NZW New Zealand White
PBS Phosphate Buffered Saline
PC Phosphorylcholine
PCI Percutaneous Coronary Intervention
PCNA Proliferating Cell Nuclear Antigen.
PCS Prostacyclin Synthase
PDGF Platelet Derived Growth factor
PDT Photodynamic therapy
PGL Prostaglandin I2
P1GF Placenta Growth Factor
PLLA Poly-l-Lactic Acid
PPP Platelet poor plasma
PRP Platelet rich plasma
PTCA Percutaneous Transluminal Coronary Angioplasty
RITA 2 Second randomised intervention treatment of angina trial.
RPB Randomised, Placebo-controlled, blinded study
SEM Scanning electron microscopy.
SMC Smooth muscle cell
STRESS Stent Restenosis Study
TGFp Transforming growth factor beta
TMR Trans myocardial revascularisation
TNFa Tumour necrosis factor alpha.
TVF Target vessel failure
VBT Vascular Brachytherapy Treatment
VEGF Vascular Endothelial Growth Factor
VIVA Vascular endothelial growth Factor in ischemia for vascular angiogenesis
trial
VSMC Vascular Smooth Muscle Cell
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Appendix 1.
Composition of buffers, and reagents.
1. Enzyme buffer - pH 4.5
Sodium Acetate (0.1 mol/L) 0.820g
Sodium Chloride (O.lmol/L) 5.84g
Adjust pH to 4.5 using conc. HC1 and dilute to 1 litre with deionised water




Dilute to 11 with deionised water - check pH 7.4 +/- 0.2




Dilute to 11 with deionised water - check pH 7.2 +/- 0.3
4 Borate Buffered Saline 0.1 mol/1 - pH8.3 (BBS)
Boric Acid (0.1mol/l)
Sodium tetraborate decahydrate (borax) 0.025mol/l 9.54g
Sodium Chloride (0.075 mol/1) 4.38g
Dilute to 11 with deionised water - check pH 8.4 +/- 0.1
5 Phosphate-buffered saline with 0.25% Gelatin
Phosphate-buffered saline pH 7.4 100ml
Gelatin 250mg




HEPES (free salt) lOmM =0.952g














lOpg/ml ovomucoid trypsin inhibitor (Sigma)
8 Acid-Citrate Solution
Trisodium citrate dihydrate 2.5g
Citric acid monohydrate 1.49g
Dilute to 100ml in deionised water. Dispense in 5ml aliquots into sterile
containers via a 0.22pm membrane filter.
9 Trisodium Citrate Solution
Trisodium citrate dihydrate 3.2g
Dilute to 100ml in deionised water. Dispense in 5ml aliquots into sterile
containers via a 0.22pm membrane filter.
10 Tyrode's Buffer







Prostaglandin Ei 0.15 mg
Adjust pH to 6.5 with 1M HC1; dilute to 500 ml total volume. Dispense in
25 ml aliquots into sterile universal containers via a 0.22 pm membrane
filter and store at -20° C.
Cell and organ culture media
11 BAEC Cell culture Medium - 20 % FCS in DMEM
500ml of DMEM, warmed to 37°C
Add 120ml of FCS
Add 15ml of Gentamicin
12 HUVEC culture medium




Endothelial Cell Growth Supplement (ECGS) 5ml of 5mg/ml solution
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Or
13 Endothelial Growth Medium (EGM)




Bovine brain extract 2.0ml
12% FCS
14 Composition of Organ Culture Medium (50ml)
RPMI 1640 Medium 33.5ml
Foetal Calf Serum 15ml
Penicillin.Streptomycin 0.5ml
Glutamic Acid 1.0ml






Endothelial cell culture techniques.
A.1 Primary culture of Bovine Aortic Endothelium.
BAECs were obtained using the methods described by Yang et all.
Bovine aortas were obtained from the local abattoir as soon as possible after slaughter.
Segments of descending thoracic aorta approximately 30cm in length were transferred to the
laboratory on ice and processed immediately under sterile conditions. The proximal end of
the aorta was ligated and the distal end clamped. Fat or connective tissue was carefully
dissected without damaging the root of any intercostals arteries near the aorta. All
intercostals arteries were ligated with suture. The clamped end of the vessel was cut off and a
kwill filling tube inserted in the distal end and the vessel tied off around it. The vessel was
washed thoroughly with saline and filled with 10ml of 0.1% collagenase in DMEM or
Hank's solution using a syringe. The syringe was left in place. The vessel was wrapped in
cling film and incubated at 37°C for 15 to 20 minutes. The vessel was gently massaged to aid
the release of loosened cells. The collagenase/cell solution was removed using the syringe
and the solution placed into a sterile universal tube. The lumen was rinsed with 10ml of
culture medium. The cell suspension was centrifuged at lOOOrpm for ten minutes and the cell
pellet rinsed once with culture medium. Finally the cells were resuspended in culture
medium and plated in an 80cm2 tissue culture flask.
Collagenase treatment removes the cells from the aorta wall in large sheets which make an
accurate cell count impossible, therefore the cells obtained from one such length of aorta are
initially cultured in 20ml of culture medium and plated in one 80cm2 tissue culture flask or
resuspended in 40ml of medium and plated in two flasks, depending on the yield, estimated
by eye under the microscope. Most of the endothelial cells should adhere to the culture flask
within two hours. Thereafter the cells are gently washed and replaced with fresh medium
after cell attachment. Generally the cells reach confluence after two to three days at a density
of about 8 x 10'780cm2 or 105/cm2.
A.2 Cloning of Bovine Aortic Endothelial Cells.
Cloned endothelial cells were used to avoid non-endothelial contamination.
Primary cultures of bovine aorta endothelial cells which had reached approximately 90%
confluence. Batches of cells with high quality and purity (i.e. typical endothelial cell
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morphology rather than the "troughs and valleys" appearance of fibroblast overgrowth) were
isolated (see fig.4.2). These batches were resuspended with 5ml of trypsin solution after
washing. This cell suspension was aspirated through a 25 gauge needle two or three times to
break up any cell clumps. The cells were diluted with 15ml of serum-containing growth
medium to inactivate the trypsin. The cells were recovered by centrifugation at lOOOrpm for
five minutes and washed with growth medium before finally resuspending in 20ml of
medium. The cell suspension was counted with a haemocytometer.
The cell suspension was diluted appropriately so as to achieve a final cell density of 10
cells/ml with growth medium. These cells were plated in a 96 well plate at lOOpl/well,
equivalent to one cell/well. After 24 hours, each well was visually scored for cell number
and individual wells examined for the following three days. Those wells containing a single
cell at 24 hours after plating were identified to be a possible clone.
After four days in culture, any wells containing a single colony consisting of 8 to 12 cells
were considered to be derived from one single progenitor cell. The culture medium was
changed every four to five days using a 50:50, fresh: conditioned medium mixture, until the
cells formed a monolayer. It takes about 12 to 18 days for the cells to reach confluence at a
density of about 4 x 104 cells/well. During this time the cells were estimated to have
undergone 13 to 15 cell doublings. The cells were transferred on a well-to-well basis to a 24
x 16mm well plate in normal growth medium. It takes about four to six days for the cells to
reach confluence at a density of about 2 x 105 cells/well (about 105/cm2), during which time
the cells can be estimated to have undergone another three to four cell doublings. Those
cells, which have retained the cobblestone morphology of normal endothelium on reaching
confluence and are free of contamination of other cells were expanded to 25cm2 flasks and
grown up for experiments or stored in liquid nitrogen for future use.
A.3 HUVEC preparation.
Human umbilical cords were collected in sealed plastic containers in HBSS and transported
in sealed heavy-duty polythene containers. All subsequent procedures were carried out in a
class II microbiological Safety Cabinet. Cords from patients known to be infected with HIV,
HepB, HSV2 or from patients suspected to be IV drug abusers were not used.
Cords were transferred to a foil-covered tray and cleaned. As much blood as possible was
removed from the vein. The ends of the cord were cut off and a plastic cannula inserted. A
syringe containing PBS/Albumin was attached at one end. Residual blood was Hushed out
with this syringe. Once the other end of the cord had been cannulated, collagenase solution
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(Gibco) was pushed into the vein until it was fully distended. The cord was then placed into
a pre-warmed, cling film-covered tray and then incubated at 37°C for 15min. The cords were
then massaged for two minutes gently to dislodge cells.
The collagenase solution was removed into the attached syringe. The vein was flushed again
with PBS/Albumin solution and this wash was added to the collagenase solution in a Falcon
50ml tube. This was centrifuged at lOOOrpm for five minutes. The resulting supernatant was
removed and the pellet of cells resuspended in 4ml HUVEC medium. The suspension was
added to a culture flask. This flask was coated with a 1% gelatin solution (made from 2%
gelatin mixed 1:1 with PBS). The remaining tissue was placed in disinfectant solution and
then disposed of safely.
A.4 Liquid Nitrogen Storage.
Confluent cloned cells in their second passage (in a 24 well plate) were trypsinised as
explained previously, washed thoroughly and resuspended in PBS. Cells were then
resuspended in 90% FCS: 10% DMSO (Dimethylsuphoxide) at a density of about 2 x 10^
cells/ml (approximately 1 ml/well). The DMSO prevents cell membrane rupture. 1ml aliquots
were dispensed into sterile cryotubes. The cells were stored at -70°C for 12 to 24 hours in a
well-insulated container to allow a slow drop in temperature, before transferring the cells to a
vapour phase in liquid nitrogen.
A.5 Removing cells from Liquid nitrogen storage.
Cells were frozen with liquid nitrogen in a 90% FCS/10 DMSO solution. The DMSO was
used to prevent ice crystals forming around the cellular membrane and thus prevents damage
to the membrane. The DMSO must be neutralised immediately after thawing.
Under sterile conditions, cell culture medium was made up as described in the Appendix. For
each tube of cells which is going to be thawed, 15ml of culture medium was aliquotted into a
universal container. The frozen cells were held in a 37°C water bath. Before the cells thawed
fully, they were removed from the water bath and the thawing process completed by
pipetting a small volume of warmed culture medium into the cell container. This was to
allow the cells to thaw surrounded by cell medium. The cells were spun down into a pellet
by centrifuging at lOOOrpm for five minutes and resuspended in 20ml of culture medium.
This cell suspension was pipetted into a tissue culture flask. After one hour's incubation, the
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cells were examined microscopically to confirm that they had adhered to the bottom surface
of the flask.
A.6 Procedure for trypsinising cells.
Cells used were trypsinised at several points. This is the process where cells adherent to the
plastic of the culture flasks and adherent to each other were treated so that they separated
into single cells that could be suspended freely. This allowed counting of the cells and also
dilution of the cells for further culture. Trypsin is a proteolytic enzyme that cleaves the
connections between cells and their surroundings. EDTA is a calcium-chelating agent.
Calcium is essential for the cells to adhere successfully. BAECs were cultured in 75ml flasks
with 5-10ml of trypsin/EDTA in HBSS (Life technologies) at a temperature of 37°C for five
minutes. The flasks were then examined under the light microscope to confirm that the cells
had dislodged from the wall of the flask and that the cells were not clumped together. If this
process was not completed, the cells were vigorously shaken. Finally, the fluid in the flasks
was aspirated up and down with a pipette. The cell-containing trypsin was drawn off from
the flask and 10ml of fresh, warmed culture medium was added. This was to inactivate the
trypsin to prevent damage to the endothelial cells. The mixture was then centrifuged at
lOOOrpm for three minutes. A small pellet of cells was seen at the bottom of the container.
All remaining fluid was drawn off and discarded. A further 20ml of culture medium was
added to the cells. These were then well mixed through the solution.
A.7 Cell counting - haemocytometer.
The number of cells in a well-mixed sample was calculated using a cell-counter slide.
Briefly, a few drops of the solution were dripped onto the slide, under a glass coverslip. The
slide was then examined under the light microscope. It is marked with counting squares. The
number of cells in four of these squares was counted, the result divided by four, to give the
number of cells in 0. lpl. This figure was multiplied by I04 to give an approximation of the
number of cells in every ml of medium.
206
Appendix 3.
Publications derived from experimental work
Papers
Drug-eluting stents: From lab bench to bedside
N. Swanson, A. Stephens-Lloyd & A.H. Gershlick
Cardiology News, Vol 4,5 June/July 2001
The stent as a local delivery device
N. Swanson, A.H. Gershlick
STENT Vol 2, 3 66-73 Jan 2000
The continuing challenge of coronary restenosis - is there a role for Vascular
Endothelial Growth Factor?
N. Swanson & A. Gershlick
(British Journal of Cardiology 2001; 8 (issue 5): 278-80)
Vascular endothelial growth factor (VEGF) eluting stents. In vivo effects on
thrombosis, endothelialisation and intimal hyperplasia.
N. Swanson, K. Hogrefe, Q. Javed, N. Malik & A.H. Gershlick
(Journal of Invasive Cardiology, 15 (12), 688-92)
In vitro evaluation of Vascular Endothelial Growth Factor (VEGF) - eluting stents.
N. Swanson, K. Hogrefe, Q. Javed, A.H. Gershlick
(.International Journal of Cardiology, 2003 Dec, VOL: 92 (2-3)
Book Chapters
Coronary artery stenting: A case-orientated approach
Chapter 15 Local drug delivery from coated stents (pp 179-189)
Gershlick J. Baron, J. Armstrong, N. Swanson, C. Newman & C. Holt
1st Edition Martin Dunitz Ltd. ISBN 1-85317-718-0
Editors N Curzen, MT Rothman (2001)
Handbook of local drug delivery
Chapter 65 VEGF-eluting stents.
N. Swanson & A.H. Gershlick.
Martin Dunitz Ltd
Editors Camenzind and De Scheerder (2001).
Abstracts, posters and presentations
Novel delivery of vascular endothelial growth factor using polymer-coated stents:
Loading and elution characteristics.
Oral presentation and moderated poster British Cardiac Society 2000, Glasgow.
N. Swanson, J. Baron, K. Hogrefe, Q. Javed, A.H. Gershlick
207
Heart 83 (Suppl 1 P28).
VEGF-eluting stents to reduce stent complications - pharmacokinetics of adsorption
and elution.
N. Swanson, K. Hogrefe, J. Baron, Q. Javed, A.H. Gershlick
6th International LDD&R Local Drug delivery meeting and cardiovascular course on
Radiation & molecular strategies - Abstract book (2000)
VEGF-eluting coronary stents stimulate endothelial growth in vitro
N. Swanson, K. Hogrefe, Q. Javed, A.H.Gershlick
Journal of Submicroscopic Cytology & Pathology 32 (3) 419 B087.
VEGF-Eluting Stents Stimulate Endothelial Cell Growth In Vitro
N. Swanson, K. Hogrefe, Q. Javed, M.A. Azrin, A.H. Gershlick.
Journal of the American College of Cardiology March 2001,Suppl 1038-12.
N. Swanson, K. Hogrefe, N. Malik, Q. Javed, AH.Gershlick Vascular endothelial
growth factor (VEGF) - eluting stents. In vivo assessment of effects on thrombosis,
endothleialisation and restenosis. Heart 2002;87:P38
VEGF-eluting stents reduce stent thrombosis, but not restenosis, in vivo
N. Swanson, K. Hogrefe, Q. Javed, N. Malik, A.H. Gershlick.
European Heart Journal abstract Suppl 2002.
Copies of these works are appended in the following pages.
208
In vitro evaluation of Vascular Endothelial Growth Factor (VEGF) -
eluting stents.
Authors
Neil Swanson MRCP* Kai Hogrefe MRCP Qamar Javed PhD Anthony H.
Gershliek FRCP
University ofLeicester, Cardiology Clinical Sciences, Leicester UK




Vascular Endothelial Growth Factor (VEGF) is a specific, endothelial cell mitogen. It
promotes re-endothelialisation ofthe damaged vessel surface seen after stenting. Stent
thrombosis and in-stent restenosis are partly related to endothelial denudation caused by
stent implantation. We propose using hydrocarbon polvmer-coated stents immersed in
VEGF to speed re-endothelialisation and reduce the risk ofstent thrombosis and
restenosis.
Methods
Stents (3x20mm) were immersed in VEGF solutions and maximal VEGF absorption
calculated. VEGF release from these stents was measured in a perfusion circuit. Delivery
of VEGF to arterial wall was measured. Sterile VEGF-loaded stents were cultured with
Human Umbilical Vein Endothelial Cells (HUVECs).
Results
18.5±4.1 pg VEGF was absorbed, 80% ofwhich was released over nine days. 11+/-6.8%
of initial VEGF loaded was delivered to the vessel wall. Cells exposed to VEGF-eluting
stents showed an 11% increase in growth relative to controls.
Conclusion










VEGF is a cytokine originally described in 1983 (1). It is involved in processes essential to
the growth, maintenance and repair ofvascular structures.
At tire time ofpercutaneous coronary intervention (PCI ), the endothelium covering the
stenotic area ofartery is severely disrupted or even destroyed. In animal models of stent
placement, re-endothelialisation begins to occur in the first 2-7 days post placement. Full
endothelialisation can take up to three or four weeks (2). It is thought that a similar or
longer time-course oeeurs in humans, although this has been difficult to quantify from the
rarity ofavailable autopsy specimens from patients post stent insertion (3). In animals,
endothelial dysfunction is seen up to three months post staffing (4). Over time the
endothelium grows back ova: tire PCI site and stent This process has bear called start
passivation.
Endothelial dysfunction may contribute to intimal hyperplasia, especially after stent use
(4). "Normal" endothelial cells produce heparin sulphate and Nitric Oxide which inhibit
cell proliferation (5-6).
Exogenous VEGF has been reported to show accelerated ie-endothelialisation ofdamaged
arteries in the rat carotid artery (7). Not only did tire group report superior re-
endothel ialisation in the treated group ofrats, but also intimal hypoplasia at the site had
been attenuated. Direct transfer ofrecombinant VEGF or VEGF plasmid in a rabbit hind-
limb model ofendothelial damage and stenting have been performed with delivery
balloons (8,9). A clear increase in the rate ofre-endolhelialisahon was shown in both with
reduced intimal hypoplasia and of thrombus formation on the stents.
A human study has been done using a local delivery of VEGF plasmid into angioplastied
artoies. At six months, no improvement in restenosis was seal (10). "Ibis study was not in
started patterns, whore the baiefit of VEGF might be expected to be most noticeable. It
also used a local delivery balloon, which is itself the cause ofsome intimal hyperplasia
that might obscure any baietieial response from the drug.
We suggest that a polymer-coated start, in this research tire Cook Supra G stent, will
deliver VEGF locally and for a sustained period, without the local trauma ofa delivery
balloon. To test this, the absorption and elution characteristics of VEGF on this stent was




The Cook Supra G is a stainless steel slotted tube design stent coated with an aromatic
hydrocarbon polymer surface (personal commimicaticn, Dr Ragheb, Medimt, IN, USA).
These stents were divided into sections and sterilized using Ethylene Oxide gas treatment.
This was done at low temperatures (<30°C) to avoid denaturing the protein or damage to
the polymer.
Human recombinant VEGF-165 was provided by Genentech California in a stock solution
of 5mg/ml. Iodine 125-radiolabelled VEGF was obtained from Amersham. Small amounts
of radiolabelled VEGF were added to each solution ofunlabelled VEGF used. The
solutions were now termed as "spiked solutions".
Radiolabeling experiments — stent absorption and eiution
Stents were immersed for two hours in three buffer solutions ofvarying pH- 4.5, 7.4 and
8.5 with I125-labelled VEGF (2mg/ml at 25°C). A second batch of stmts were immersed in
VEGF in different concentrations of I125-labelled VEGF (at 25"C. pH7.4), 0.5,1 and
2mg/ml for one hour. Further stents were immersed in VEGF (2mg/ml at 25°C) for 2Qmin,
2, 24,48 or 721ir and were gamma-counted at these times to calculate absorption.
Stent segments that had been absorbed with VEGF at the optimal conditions were then
perfused in a peristaltic-flow circuit, as in previous work (11), at 37°C with a phosphate
buffered saline (PBSyBovine serum albumin (BSA) solution representing plasma, for nine
day's. This had the same protein content as blood (40g/l ), was pfI7.4 and was perfused at a
rate of 20ml/min, approximately the rate at which the stents are perfused in a coronary
artery. At pre-determined times during perfusion the stent sections were gamma-counted
and replaced in the circuit.
Segments of internal mammary artery were obtained with consent from patients
undergoing coronary artery bypass grafting. Sections of artery were cut to be slightly
longer than the stents to be deployed. Ex vivo retention ofradiolabelled VEGF was
determined by deploying dipped balloon-mounted stmts, at eight atmospheres pressure,
into the arterial segments, which were placed within the lumen of the tubing constituting
the perfusion circuit previously described. Hie stented vessels were perfused in 100ml of
perfusate in the circuit for 24 hours. Longer perfusion times were not felt to be reliable
sources ofdata regarding retention in the tissue wall as the circuit was not sterile and the
tissue not viable in this circuit. After 24 hours, stent sections were separated from the
arterial segments. These were trimmed so only the slmted sections ofvessel were
examined further. Stents and vessel sections were gamma counted to estimate absorption
of VEGF.
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HUVEC cultures exposed to VEGF stents.
Cell culture was performed using Gibco Ml 99 with Earl Salts, glutamine (Ref31150-
022), 1 % Penicillin/streptomycin, heparin 2500iu/50Gml (Menoparin), Endothelial Cell
Growth Supplement (ECGS) and 20% fetal calf serum. Cells wane cultured at 37°C in 5%
co2.
Non-radiolabelled VEGF in PBS was used to coat sterile stents in the optimum fashion
determined previously. These stents were thai sterilised using ethylene oxide gas
treatment. Stents were then eo-eultured with lml of 1.6x 101 cells/ml Human Umbilical
Vein Endothelial Cells (HUVECs) solution. Hie HUVECs had been prepared from early
passage cultures obtained as described previously (II). The cells were confirmed to be
endothelial both by their Epical cobblestone microscopic appearance and by positive
staining tor von Willebrand Factor. One group ofstents was washed with culture medium
for 24 hours prior to HUVEC culture (washed stents). This was to determine whether
sufficient VEGF remained within the polymer to have continued physiological benefit after
any very superficially adherent VEGF had been washed oft* Hie effects of these stents
were compared to control stents. Hiese were immersed in 2mg/ml bovine serum albumin
(BSA) tor 24 hours, dried and sterilized as the VEGF stents. HUVEC growth was
detennined with a PMS/MTS assay depending on mitochondrial activity in the cells (12).
Alongside the wells containing HUVECs and loaded stents were cultured farther wells
that contained culture medium containing either 10 or StXlng/ml solutions of VEGF to
compare die effects of the VEGF delivered by strait to VEGF solution added directly to the
medium.
Statistical analysis.
Results are expressed as means +/- standard deviations. Elution kinetics w ere ascertained
by nonlinear regression (curve fitting) using a computerised scientific data analysis
package (Prism, GraphPad Software Inc., CA, USA); R2 values were determined for each
fitted curve to assess the overall goodness-ol-fit and analysis of residuals performed to
assess whether observed data were consistent with the chosen regression equation. A p
value of>0.05 for analysis ofresiduals was considered to be consistent with non¬
significant deviation from the model.
The results of the proliferation studies were analysed to determine that they were
compatible with a normal distribution (Kohnogorov-Smimov). Hie data were subjected to
a two-tailed t-test. Equality ofvariance was calculated (Levene's Test) and factored into




Buffer pH did not affect absorption to the stents {data not shown). All further work was
done using PBS, as this was ofphysiological pH7.4. An increase in the concentration did
result in an increased absorption of the drug at the concentrations used (see Figure I).
2mg/ml was used in further experiments.
Increasing the length of time that the stent sections were immersed in VEGF solution
showed an initial rapid rise in the amount ofVEGF absorbed (see Figure 2). 18.5±4.1gg
of VEGF was absorbed after two hours immersion onto a 3x20mm stent (total strait weight
= 55mg). After two hours, how ever, no further significant immobilisation ofprotein to the
stents was seen. Further work was done with at least two hours of immersion time.
Elution studies — in vitro, ex vivo and cell culture
In conditions replicating physiological conditions, the stents (n=8) in the perfusion circuit
retained significant amounts of VEGF for nine days. An initial rapid decay was seen with
an overall biexponential (t*=0.9% analysis ofresiduals p= 0.11) decay. At five and nine
days, 28% and 20% respectively of the initial dose still remained on the stent sections (see
Figure J). Ex vivo distribution ofVEGF eluted from a stent placed in a section of internal
mammary artery is demonstrated in Table I. At 24 hours, 1l+/-6.8% of the initial VEGF
loaded onto the stents was seen in the tissue and 12.3+/-1.7% remained bound to the
stents.
HUVECs cultured with VEGF-eoated stents showed an 11% increase in growth compared
to controls (p<0.001). Stents where the culture medium surrounding them was removed
after 24 hours and replaced afresh (washed stents) showed a 10% increase in growth over
controls (p=0.004Xs«?e Figure 4). Thus, the effect of the stents persisted, even after
washing.
Discussion
Tliis work shows that this polymer-coated stent can be used to cany significant quantities
of VEGF protein. This stent will then release the drug in a controlled fashion obeying
predictable kinetics into the surrounding tissue, as well as the local microcirculation. The
release is slow, over many days. The regrowth ofendothelial cells over the angioplasty site
takes many days or even w eeks to occur normally. This prolonged release ofVEGF is in
contrast to the bolus approach that is seen with balloon catheter delivery systems. Slow
release of VEGF has been serai where VEGF plasmid DNA has been delivered locally.
The transleetion efficiency ofthis technique is 0.12% ofcells (9) and the amount ofVEGF
released into the local tissue is difficult to quantify and seems likely to be different from
ease to case. Stent based delivery of the protein itselfwill release a known amount of
VEGF at a predetermined rate.
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This work has shown that 11 +6.8% of the initial dose of VEGF on the stent is to be found
in the vessel wall. This compares favourably with balloon delivery, where lower retention
rates tire the normal finding. Delivery of 1% or less ofthe delivered drug is typical (13).
The cellular work performed showed that VEGF loaded stents were effective in promoting
endothelial cell growth, by 11% more than the control groups. This modest increase in
growth was significant The effect seen was comparable to the stimulus seen when VEGF
was added direetly to the culture medium so the delivered dose of VEGF was higher than
that necessary to produce maximal growth stimulation.
Stent based delivery has been shown to be feasible in our laboratory with favourable in
vivo effects using the drugs abcixhnab (ReoPro) (15) and Activated Protein C (16).
Human studies of drug-eluting stents have now been performed. Sirolimus has been shown
to have a significant effect in reducing intimal hyperplasia in the RAVEL study [ 17],
which reported with a restenosis rate of0% incidence ofrestenosis in tire sirolimus group
vs. a 26% restenosis rate in the control arm (p<0.001 >. Three studies have reported benefits
of paclitaxel-eoated stents. ASPECT showed a reduction in binary restenosis (4% vs. 27%,
p<0.001). Taxus-I has reported a six month binary restenosis rate of0% vs. 11 %, p=0.011.
ELUTES showed a binary restenosis of3% vs. 21%. p=0.055. All these studies have
demonstrated the potential of stent-based therapies to reduce intimal proliferation in
humans. Although using different drugs, they share a common target cell, the vascular
smooth muscle cell.
VEGF-eluting stents, in contrast, target the endothelial cell selectively, since the receptors
for VEGF (Flt-1 and KDR) are found almost exclusively cm endothelial cells. Inhibition of
thrombosis and restenosis would therefore be mediated by a selective proliferation of
endothelial cells. Rapid re-endothelialisation oftire denuded vessel wall at the stented site
would reduce the time that the thrombogenic foreign body would presents a surface to the
coagulation system.
Furthermore, since an intact endothelium inhibits smooth muscle cell proliferation, VEGF-
eluting stents may indirectly reduce the extent ofneointima formation and resultant
restenosis
VEGF may be a candidate for stent-based delivery and may increase the rate of
endothelialisation in vivo.
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Figure Legends
Figure I — Absorption ofVEGF to Cook stent segments in differing concentrations of
IFGF in PBS (Phosphate buffered saline)far one hour. * = p 0.05 compared to
0.5mgfml value.
Figure 2 —Absorption of IFGF to Cook stent segments after differing immersion times.
Figure 3 IFGFelation in perfusion circuit. These datafita two-phase exponential decay
model (r2 =0.99, analysis ofresidualsp— 0.11).
Figure 4 HUVEC'growth with the 10 or 500ngml VEGFdidnot differ significantlyfrom
the response seen with the IFGFeluting stents (data not shown). BSA stents are those
coated with albumin as a control, washed stents were those VEGFloaded stents that had
been immersed in culture mediumfor 24 hours before the addition ofHUVECs infresh
medium. This was to slum' that the effect is notjust due to IFGFelutingfrom the stent
very early after immersion in culture medium.
Tables
Location % of initial value (mean) Standard deviation (%)
Stent section 12.3 1.7
Tissue specimen 11.0 6.8
"'systemic" delivery 76.7 2.9
Table 1 Distribution of IFGFafter 24 hours perfusion (initial loading 7.9+A2.54mcgs of
VEGFon a half-length, i.e. 10mm, stent, n=4). "Systemic "delivery was the remaining
































Vascular Endothelial Growth Factor (VEGF)-Eluting Stents: In Vivo
Effects on Thrombosis, Endothelialization and Intimal Hyperplasia
Neil Swanson, Kai Hogrefe, Qamar Javed, "Nadim Malik, Anthony H. Gershlick
ABSTRACT: Local drug delivery by stent can reduce in-stent
restenosis. Vascular endothelial growth factor (VEGF) is an endothelial
cell-specific mitogen. After stenting, the arterial wall is almost denuded of
endothelium. This loss of endothelium contributes to the smooth muscle
cell (SMC) proliferation seen in restenosis, since the endothelium actively
inhibits SMC hyperplasia. Over time, the endothelium recovers and
SMC hyperplasia is arrested. The capacity of VEGF-coated stents to
accelerate re-endothelialization, and to therefore reduce restenosis and
thrombosis, was tested in this study. Radiolabeled VEGF was absorbed
onto stents and released over nine days in an in vitro perfusion circuit.
VEGF-coated stents were deployed in arterial segments to study local tis¬
sue release. A New Zealand White rabbit iliac artery model for stent
implantation was used. Re-endothelialization and thrombosis were
assessed after seven days. Further animals were examined 28 days post¬
procedure for in-stent restenosis. Stented vessels were resin-embedded,
sectioned and stained. Intimal thickening was calculated using computer¬
ized morphometry. In vitro, the stents released 80% of the initial load
over nine days. At seven days, thrombus was significandy reduced (12.5
mg for controls versus 0 mg for VEGF; p = 0.014). No beneficial effect
was seen on endothelialization, nor on intimal hyperplasia. Neointimal
area was 2.2 ± 0.9 mm2 for controls versus 2.4 ± 1.8 mm2 for VEGF (p =
0.8). These VEGF-eluting stents do not accelerate re-endothelialization or
inhibit restenosis. Stent thrombosis appears to be reduced, which may
make these stents less thrombogenic and be valuable in higher-risk cases.
J INVAS CARDIOL 2003;15:688-692
Key words: endothelial function, growth factors, restenosis, stents
Several recent studies have reported favorable results in pre¬
venting restenosis using stent-delivered drugs. The antibiotic and
antiproliferative agent sirolimus has been shown to have a signif¬
icant effect in reducing intimal hyperplasia in the RAVEL study,
with a 0% incidence of restenosis.1 Three other studies
(ASPECT, TAXUS-I and ELUTES) have all reported benefits
of paclitaxel-coated stents. The STRIDE dexamethasone registry
reported a 3.3% occurrence of major adverse cardiac events
(MACE) at six months. However, other agents have proven less
effective. In the BRILLIANT trial, the MMP inhibitor batimas-
tat was tested but was abandoned because of poor restenosis
rates. Similarly, the ACTION trial of actinomycin-D was aban¬
doned due to poor results. All these drugs work by inhibiting the
cellular overgrowth, mainly aimed at the smooth muscle cells,
which is part of the healing process after percutaneous coronary
intervention (PCI). An adverse side effect of such drugs may be
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to also inhibit endothelial cell function and recovery. "Normal"
endothelial cells (EC) produce heparin sulphate and nitric oxide
(NO), which inhibit cell proliferation.2"' Endothelial dysfunction
contributes to intimal hyperplasia, and this dysfunction is pro¬
longed after stent use.5 In addition, the lack of an endothelium is
felt to increase the risk of thrombosis at the PCI site. This often
catastrophic condition is rare in most clinical situations, but has
been reported in 2—3% in small vessels' and in 9.1% of patients
in brachytherapy trials.
VEGF is a cytokine involved in processes essential to the
growth, maintenance and repair of vascular structures. At the
time of PCI, the endothelium covering the stenotic area of artery
is severely disrupted. In animal models of stent placement, re-
endothelialization begins to occur in the first 2—7 days post-
placement and can take up to 3^4 weeks to complete.7 It is
thought that a similar or longer time course occurs in humans."
Exogenous balloon-delivered VEGF or VEGF plasmid have
been reported to accelerate re-endothelialization, reduce throm¬
bus formation and reduce intimal hyperplasia in damaged rat
carotid arteries9 and rabbit iliac.10,11 Previous work has delivered
the VEGF with a variety of local delivery balloons. This study
assesses these apparent benefits using a polymer-coated stent as
the delivery device. Such a stent should release (elute) VEGF
gradually, thus prolonging the time during which it may act
upon the injured vessel. The effects were studied in a rabbit iliac
artery stent model. Elution characteristics of VEGF from the
polymer-coated stent were modeled in vitro, including the
amount retained in the wall of the stented mammary artery.
Methods
Stents and drug. Supra G, stainless-steel, slotted-tube stents
(Cook Cardiology, Miami, Florida) coated with an aromatic
hydrocarbon polymer surface were used. A previous generation
of these stents and polymer was successfully used to deliver the
protein abciximab in the animal model used in this work.
Human recombinant VEGF-165 was provided by Genentech
California in a stock solution of 5 mg/ml.
In vitro elution experiments. VEGF was radiolabeled with
the gamma-emitter Iodine 125 using the Iodogen method.
Stent segments that had absorbed VEGF at optimal conditions
(2 mg/ml stock solution in pH 7.4 PBS buffer for 24 hours at
room temperature) were perfused in a peristaltic-flow circuit at
37 °C with a PBS/BSA solution for nine days. This solution was
prepared such that it contained the same protein content as
blood (40 g/L), was pH 7.4 and was perfused in a pulsatile man¬
ner at a rate of 20 ml/minute. After 5 and 20 minutes, and at 1,
2, 4 and 24 hours and every 24 hours of perfusion thereafter,
stent sections were gamma-counted and replaced in the circuit.
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Radiolabeling experiments — Stent elution. VEGF solu-
ions were prepared containing Iodine 125 radiolabeled VEGF.
tent segments that had absorbed VEGF at optimal conditions
/ere perfused in a peristaltic-flow circuit. After 5 and 20 fnin-
ites, and at 1, 2, 4 and 24 hours and every 24 hours of perfusion
hereafter, stent sections were gamma-counted and replaced in
he circuit. A diagram of the flow circuit is shown in Figure 1.
In vitro retention of radiolabeled VEGF was determined by
leploying dipped stents in segments of internal mammary
.rtery, obtained with consent from patients undergoing coronary
.rtery bypass grafting. Artery sections were cut to the same
ength as the stents, i.e., 10 mm. The investigation conforms
vith the principles outlined in the Declaration of Helsinki (Car-
liovascular Research 1997;35:2-3). These sections of artery
vere again perfused in the circuit previously described for 24
lours. As the circuit was not sterile and the tissue was not likely
o remain viable in this circuit, longer perfusion times were not
elt to be reliable sources of data. After 24 hours, stent sections
ind arterial segments were separated and gamma counted to esti-
nate absorption ofVEGF.
Animal studies. The investigation conformed to the Guide
or the Care and Use ofLaboratory Animals published by the U.S.
slational Institutes of Health (NIH Publication No. 85-23,
evised 1996). All animal studies used male New Zealand White
abbits (3.0—4.6 kg). Animals were prepared for stent implanta-
ion with the addition of 1 mg/kg aspirin and 1 mg/kg clopido-
;rel in their daily drinking water for five days. These drugs were
:ontinued daily from the time the animals recovered from initial
inaesthesia throughout the study until termination.
Operative procedures for acute studies. General anaesthe-
;ia was induced 30 minutes after premedication with Hypnorm
).3 ml/kg (a combination of fentanyl citrate 0.315 mg/ml and
luanisone 10 mg/ml; Janssen-Cilag, High Wycombe, Bucks),
nhaled halothane (2-3%) was used for induction and a combi-
tation of halothane (0.5-3%) and oxygen (0.5-3 L/minute)
vas used for maintenance of anaesthesia. Under general anaes-
hesia, a midline abdominal incision was made and the iliac
irteries were exposed to facilitate placement of a perivascular
lowprobe on either side. The femoral arteries were also exposed
>n both sides through separate incisions. An arteriotomy was
•ashioned between two ligatures placed loosely around the
iuperficial femoral artery distal to its lateral circumflex branch.
3ne-thousand IU of unfractionated heparin were administered.
\ 3 x 15 mm angioplasty balloon catheter was inflated to 8
itmospheres three times in the iliac artery. A 3 x 10 mm stent
'either a control or a VEGF-loaded stent) was deployed at the
site of arterial injury. Following stent deployment, the superfi-
:ial femoral artery was ligated. Blood flow through stented ves¬
sels was recorded immediately after superficial femoral artery
igation (T206 small animal blood flow meter with 2.5SB
arobes, Transonics Inc., Ithaca, New York) and continuously
for two hours thereafter with the flowprobe placed immediately
distal to the stent. The flow was measured to record the inci¬
dence of cyclical flow variations in the stented vessels. These are
indicative of transient thrombus adhesion, causing variations in
flow rates. After termination, the vessels were dissected free and
water bath Peristaltic Stent Y-connector
pump
Figure 1. Diagram of the perfusion circuit used. Each circuit con¬
tained 2 stents in parallel, perfused with 4% albumen/buffer solution
at 37 °C. The pump generated peristaltic flow.
the stented arteries were fixed and then resin-embedded as
described below.
Operative procedures for endothelialization, thrombosis
and restenosis studies. Animals that were allowed to recover
after stent deployment for elective sacrifice after 7 or 28 days had
a single, left-sided groin incision for superficial femoral exposure.
No abdominal incision was made. Angioplasty and stenting of
the left iliac artery was performed as in the acute studies, again
with heparin as adjunctive therapy. The animals were recovered,
and aspirin and clopidogrel were continued (administered in
drinking water) until sacrifice at 7 or 28 days. Animals to be
examined for endothelialization (7 days) had 40 mg Evans Blue
dye12 injected intravenously. This was allowed to circulate freely
for at least half an hour to stain any endothelium-denuded ves¬
sels. At the time of sacrifice, a catheter was placed into the
abdominal aorta. Ten milliliters of 0.25% silver nitrate solution
were then instilled to improve the delineation of endothelial cells
under scanning electron microscopy.12 The animal was exsan¬
guinated post-mortem. The iliac arteries and distal aorta were
dissected free and fixed in 10% formalin.
The extent of endothelialization and thrombosis was assessed
as follows: 1) Stents were divided lengthwise and partly flat¬
tened. The flattened stents, stained with Evans Blue, were ana¬
lyzed by computerized morphometry as previously described.13 A
blinded observer was asked to assess the amount of blue staining
in each section relative to undamaged tissue in the same samples.
The staining was graded 1—5 in increasing subjective impression
of the amount or intensity of Evans Blue staining; 2) Tissues
were examined under scanning electron microscopy; 3) Throm¬
bus was estimated by removing adherent thrombus from the
interior aspect of the stented vessel and weighing it (wet and dry
weights). The extent to which the thrombus had occluded the
vessel lumen was also noted.
Restenosis studies. The 28-day rabbits were studied for
restenosis. Stented vessels were fixed and resin-embedded. Stent¬
ed vessels were also taken from the animals in the acute studies
for baseline measures to be made.
Resin embedding of tissue. The technique allows the preser¬
vation of the arterial architecture with the stent in situ, while
allowing staining to identify the proliferative response of the tis¬
sue.14 Stented tissue was dehydrated in 100% acetone and
immersed in infiltrating solution (50% benzoylperoxide with
hydroxyethyl methacrylate) for 24 hours at 4 °C. Blocks were
then transferred into an embedding solution (infiltrating solution
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with tetramethyl aniline) and orientated in polythene tubes. The
tubes were hermetically sealed and left at 4 °C for 24 hours. This
allowed the formation of glycol methacrylate resin (T8100). A
high-speed precision saw (Isomet 2000) was used to cross-section
the resin-embedded tissue blocks. This produced 100 pm thick
sections which were then further thinned by use of a Metaserv
200 grinder with increasing fineness of grinding paper used to
produce sections between 10-20 mm in thickness. These sections
were then affixed to Perspex slides with Super-attak adhesive.
Stent cross-sections were stained with hematoxylin and eosin.
Slides from the sections from die 28-day and day 0 animals
were examined and intimal growth quantified, using two differ¬
ent techniques. The area of the lumen was calculated at a low
power magnification of the vessel cross-section. Then the total
area of the neointima, the stent sections and lumen were mea¬
sured and the luminal area subtracted. At a higher magnification,
further measurements were made of each quarter of the vessel.
This allowed more precise tracing of the boundary between
media and intima and gave a measure of the average intimal
thickness within each quarter. The results for each quarter were
averaged to give the mean intimal depth in that cross-section of
the vessel. All measurements were performed by a single, blinded
observer. To ensure the results were reproducible, three random¬
ly selected vessels were remeasured and the various measure¬
ments were plotted against the first reading to demonstrate that
they were essentially the same.
Injury scoring. The results at 28 days were observed rn
determine whether the original injuries suffered by the stented
vessels were similar in the two groups. Injury scoring was done
using the previously published and validared scoring system of
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Systemic delivery samples. In addition to the above assays,
samples of liver and kidney were taken from randomly selected
animals that received the VEGF-loaded stents. These were
freeze-dried and powderized. Resulting solutions were then
assayed using a VEGF ELISA kit to detect any systemic delivery
of VEGF from the stents. Samples of tissue injected with VEGF
solution directly formed the positive controls.
Statistical analysis. Elution kinetics (Figure 2) were ascer¬
tained by nonlinear regression (curve fitting) using a computer¬
ized scientific data analysis package (Prism, GraphPad Software
Inc., California); R2 values were determined for each fitted
curve to assess the overall goodness-of-fit and analysis of residu¬
als performed. Power calculations were based on the findings in
similar work." The study was powered to detect a difference of
35% in mean area of endothelialized stent and a 0.55 mm2 dif¬
ference in mean area of intimal hyperplasia, both at a power of
greater than 90% at a significance level where p < 0.05. Differ¬
ences in thrombus weight between control and VEGF stents
were tested with a Mann-Whitney test. Differences in intimal
thickness/area were calculated with a two-tailed Student's t-test,
assuming unequal variance.
Results
Elution studies — In vitro. Radiolabeling data showed that
18.5 ±4.1 mg of VEGF could be absorbed after two hours of
Time (hours)
Figure 2. Vascular endothelial growth factor elution in a perfusion
circuit. These data fit a two-phase exponential decay model (ti=0.99;
analysis of residuals p = 0.11; n = 6).
immersion. The stents in the perfusion circuit retained signifi¬
cant amounts of VEGF for many days, with an initial rapid
decay and an overall biexponential decay pattern. At five and
nine days, 28% and 20% of the initial dose still remained on the
stent sections, respectively (Figure 2). In vitro distribution of
VEGF eluted from a stent showed that at 24 hours, 11 ± 6.8%
of the initial VEGF loaded onto the stent was seen in the tissue
and 12.3 ± 1.7% remained on the stent.
Acute studies. Two animals died perioperatively in the
VEGF group before the stent had been inserted. No data were
obtained from these animals. Cyclical flow variation was seen in
one animal, in the control group.
Endothelialization and thrombosis studies. Less thrombus
(measured by wet and dry weights of macroscopic thrombus) was
seen at seven days in the stents coated with VEGF than in the
controls. This was observed macroscopically and confirmed by
weighing the adherent thrombus, both when wet and after several
days of air drying to remove water and formalin (Figure 3).
Treatment Stent Extent of Thrombus Thrombus
number thrombosis (wet) (dry)
Control 1 Occlusive 92mg 17mg
2 Minor lOmg lmg
3 Minor 9mg 2mg
4 Luminal 15mg 2mg
5 None 0 0
6 Occlusive 56mg 7mg
VEGF 1 None 0 0
2 None 0 0
3 None 0 0
4 None 0 0
5 None 0 0
6 None 0 0
7 None 0 0
8 Minor <lmg <lmg
Figure 3. Results of thrombosis and endothelialization 7 days after stent
implantation. Thrombosis results arc median results of wet weight of
thrombus (p = 0.0142; 95% confidence interval, 8.49-55.99). Dry weight
results were 2 mg vs. 0 mg. The stcnted vessels were examined after 7 days.
Visual inspection was made as to the extent of any adherent thrombus. This
was carefully removed from the vessel and weighed, both wet and dry. Two
stents in the control group were maldcployed and as a consequence entirely
occluded with thrombus. These stents were not included in the final analy
sis. For the endothelialization at 7 days, a score of 1-5 (increasing endothe-
lialization) was used to produce a semi-quantitative result.
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\lmost all sections showed uniform Evans Blue staining, sug¬
gesting that no significant endothelialization occurred. No differ
;nce was seen between the groups with the Evans Blue staining.
Four of the control vessels were completely occluded with
:hrombus. Three had at least some macroscopically visible
Trombus that would have prevented some endothelialization.
No significant differences were seen in endothelialization scores
aetween control and VEGF-coated stents (Figure 3). Scanning
electron microscopy examination confirmed restricted re-
mdothelialization in both groups. Less than 10% of the surface
af the vessel wall was re-endothelialized.
Restenosis studies. Intimal hyperplasia was seen in all the
stents examined at 28 days to a variable degree (Figure 4). No
differences were seen in the average injury scores (1.00 versus
1.01; p - 0.91; n - 8), suggesting that equal vessel injuries had
been made at the outset. Average depth of neointima showed
no difference between the two groups (Figure 5). Neointimal
irea at 28 days again showed no statistically significant differ¬
ence between the control and VEGF treated stents (2.2 mm'
versus 2.4 mm7, p - 0.8). Intima (including stent siiuts) Lo
media ratios were 1.99 ± 1.05 for control versus 2.19 ± 1.06 for
VEGF (p = 0.73; n = 8).
The detected quantities of VEGF per gram of total protein
in liver or kidney samples from the experimental animals was
2,575 ± 2,390 ng/g VEGF (control group) and 832 ± 653 ng/g
VEGF (VEGF group) (p = 0.32), i.e., no detectable increase in
VEGF systemically as a consequence of the VEGF stent treat¬
ment in distal tissues.
Discussion
In vitro re«ult«
The initial in vitro experiments demonstrated that 18 mg of
VFGF protein, could be absorbed into the polymer coating of
the stents and that this VEGF was gradually released over a peri¬
od ofat least nine days. It was also shown that significant quanti
ties of the released VEGF were found in the vessel wall, where it
is likely to be effective. Ten percent of the initial dose of VEGF
loaded on the stent was detected in the tissue, which compares
favorably with the approximately 1% deliver}' efficiency in the
vessel wall of a local delivery balloon.16
In vivo results
Systemic delivery, cndothcliolization and restenosis. No
increase in VEGF was seen in the distal tissue studied at rhe two
study endpoinrs No evidence was obtained of accelerated
endothelialization using the VEGF-eluting stent. Stent struts
remained either completely exposed or were covered with sheets
of organized, erythrocyte-rich rhromhns In contrast to rhe pub¬
lished work of Van Belle et al., where VEGF had produced
90% endothelial coverage by this time, less than 10% of the
stent structure was endothelialized. This reduced re-endothelial-
izarion may reflect differences between models used. Different
stents were used and they (or the polymer coating) may have
contributed to the delayed cndothclialization. Smaller animals
were used (mean weight, 3.6 kg versus 5-5.5 kg in the Van
Belle study). A relatively greater injury may therefore have been
induced in the smaller iliac vessels.
There are various possible explanations for the failure of the
VEGF-eluting stent to improve re-endothelialization. VEGF
may have been inactivated by the storage and sterilization
process. VEGF may have been washed off the stent as the stent
was passed through the femoral vessels, or downstream after
implantation. The VEGF-soakcd polymer was pressed into the
vessel wall where there was no room for endothelial cells to grow
in from the sides. VEGF from the stent will largely have been
released into the vessel wall where there were no target cells for
the VEGF. Finally, VECF's most pronounced effects are on vas
cular permeability and not cell proliferation. In cell culture
experiments, only a modest increase in endothelial cell growth
was seen, about 10% higher than that seen with controls.17 In
clinical trials, VECF has not led to any clinically significant pro
liferation of blood vessels (ncoangiogencsis), despite anticipated
stimulation of endothelial growth."
No benefit in reducing restenosis was seen in these
results, presumably because of the lack of effect on the re-
250
Figure 4. Representative cross-section of stented vessel stained after
28 days in vivo with H&E to show extent of intimal hyperplasia. No
significant differences were seen between the vascular endothelial
growth factor and control treated specimens.
Control average . VEGF average
Figure 5. Comparison between the measured average depth of neointi¬
ma in the 2 groups. No significant reduction in neointimal depth was
seen (n = 8).
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endothelialization process. It would appear that any possible
beneficial effects on reduced thrombosis were not borne out
by a corresponding reduction in intimal hyperplasia.
Notably, a human study using local delivery of V'EGF plas-
mid into angioplastied arteries showed no improvement in
restenosis at six months."
Stent endothelialization to reduce restenosis has been tested
in several other studies. Some have examined the potential of
stents directly coated with endothelial cells (ECs).20 Several
agents other than VEGF have been delivered to the PCI site to
speed re-endothelialization. Prostacyclin synthase gene transfer,21
hepatocyte growth factor,22 blockade ofTNF,23 systemic estradiol
administration24 and locally-delivered antibody to throm-
bospondin25 have all increased re-endothelialization in animal
studies. None of these studies used the stent itself as the delivery
vehicle. Agents to promote endothelialization, such as VEGF,
may not be effective when delivered by stent, because the drug is
not delivered to the target cells at either end of the stent, whereas
delivery balloons release agent around the PCI site.
Thrombosis. A reduction in thrombus accumulation was
seen at seven days using VEGF-eluting stents. In other work,
reduced clot formation has been seen on stents implanted in
rabbit iliac arteries when washed with VEGF.11 The mechanism
for the observed reduction in thrombus formation in these
experiments is not known. VEGF increases the expression of
NO, PGI2, urokinase and tissue-type plasminogen activator,26
all of which antagonize thrombus formation. VEGF released
from the stents may have stimulated endothelial cells adjacent
to the PCI site, or in small sidebranches of the main vessel,
where the endothelium remained undamaged, to produce some
of these factors. Finally, VEGF may produce NO-mediated vas¬
cular relaxation upstream, increasing flow and inhibiting
thrombus formation.
Study limitations. This study has tested VEGF in a small
group of animals with only limited evidence of any benefit.
The study is limited by the model used, which is not a true
representation of the scenario in man. The vessel used,
although arterial, is not a coronary and is free of the mature
atherosclerotic plaques seen clinically. The mechanism under¬
lying the apparent anti-thrombotic effect of the VEGF-eluting
stent is not clear.
Conclusion. VEGF delivery by stent in this model does not
alter re-endothelialization. No beneficial results were seen on
restenosis. An apparent beneficial effect on thrombus forma¬
tion early after stent implantation was seen. Such an effect
would make these stents less thrombogenic than current clini¬
cally used stents. This effect requires ongoing in vivo evalua¬
tion. VEGF may be a suitable agent for local delivery by stent
in patients in whom a high risk of stent thrombosis may be
anticipated, including patients with small vessel stenoses.
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